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Abstract
Philanthotoxin-433 (PhTX-433) is an active component of the Egyptian
solitary digger wasp, Philanthus triangulum, venom which non-selectively inhibits
several excitatory ion channels. With the aim of improving potency and
selectivity, several synthetic analogues were developed based on the single or
multiple modifications in the hydrophilic polyamine tail and hydrophobic aromatic
head group of the PhTX.
In the first part of this study, we investigated the pharmacological actions
of two synthetic analogues, Philanthotoxin-343 (PhTX-343) and Philanthotoxin-
12 (PhTX-12), on mammalian hetero- and homooligomeric nicotinic acetylcholine
receptor (nAChR) subunit combinations expressed in Xenopus oocytes. Whole-
cell currents in response to application of acetylcholine alone or co-applied with
PhTX-analogue were studied electrophysiologically using two-electrode voltage-
clamp at three different membrane holding potentials (VH = -60 mV, -80 mV and
-100 mV). Concentration-inhibition curves were constructed and IC50 values
estimated for each holding potential. The IC50 (95% CI, n=oocytes) values for
3K7; LQKLELWLRQRI ĮǃĮǃĮǃĮǃĮĮǃ(F255V)Įǃ(V253F) and
ĮǃįǄSHDNFXUUHQWVDWP9ZHUHǴǴQ Ǵ
 Ǵ Q   Ǵ  Ǵ Q   Ǵ  Ǵ
Q   Ǵ  Ǵ Q    Ǵ  Ǵ Q   Ǵ
ǴQ DQGǴǴQ UHVSHFWLYHO\ IRU3K7;
WKH\ZHUHǴǴQ ǴǴQ Ǵ
 Ǵ Q   Ǵ  Ǵ Q   Ǵ  Ǵ Q
 ǴǴQ ǴǴQ DQGǴ
ǴQ UHVSHFWLYHO\LH LQFRQWUDVWWR0Q$&K53K7;ZDVPRUHSRWHQW
than PhTX-12 in all cases. All IC50s were lower when inhibition was measured
after 1 minute of application indicating use dependence. For inhibition of
heteromeric nAChRs, the peak potency of PhTX-343 was strongly augmented by
vii
holding the cell at more negative VH while this was not the case for PhTX-12
where only weak voltage-dependence was observed. The inhibition of homomeric
ĮUHFHSWRUVE\3K7;ZDVYROWDJHLQGHSHQGHQWZKHUHDVWKHEORFNE\3K7;
12 was voltage-dependent. In addition, these two synthetic analogues were
different in their recovery rates (PhTX-12 was generally faster than PhTX-343)
but they were similar in their mechanism of action, non-competitive inhibition.
In the second part of the project, I explored the structure-activity
relations of twenty one synthetic analogues, with a view to improving their
DFWLYLW\DQGVHOHFWLYLW\RQUDWQHXURQDOĮǃDQGĮǃQ$&K5VDW9H = -100 mV.
We showed that the presence of positive charge in the polyamine tail of PhTX
compounds is essential for nAChR subtype selectivity and its removal made the
molecule lose its selectivity. Also, it appears that adding a bulky group to the
terminal ammonium drastically reduced activity whereas a similar addition to the
head region it increased their potency. In addition, we identified the key regions
and substitutions responsible for increasing PhTX activity, cyclohexylalanine in
place of tyrosine, and selectivity, phenyl group. Analogues having
cyclohexylalanine and a phenolic group in the head region showed IC50 values in
the low nano-molar and pico-molar (160-400 pM) range. These data suggest
that PhTXs could serve as lead compounds for highly potent and selective
inhibitors of N-nAChRs.
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1CHAPTER ONE
GENERAL INTRODUCTION
Summary
Members of the neuronal nicotinic acetylcholine receptor (N-nAChR)
family are oligomeric ligand gated ion channel proteins and belong to the Cys-
loop receptor superfamily, which also includes 5-HT3 receptors, GABAA,
glutamate-gated chloride channels and glycine receptors. Five subunits of the
receptor are organized in a circular manner around a central water-filled ion
conducting pore. Each subunit is composed of four membrane-spanning
segments named M1-M4. The pore lumen is determined by the second of these
membrane segments, M2. Binding sites for non-competitive inhibitors (NCIs) are
located on the M2 trans-membrane segment of the pore. The nAChRs play a
critical role in many physiological and pathophysiological processes.
The venom of the Egyptian digger wasp, Philanthus triangulum, contains
a toxin, philanthotoxin-433 (PhTX-433), that interacts with ionotropic glutamate
receptors and nAChRs in their target prey. PhTX-433 or PhTX-343 has a
polyamine tail and aromatic head group that works as a strong non-competitive
inhibitor of cation selective ionotropic receptors.
This project aimed to investigate the action of several philanthotoxin
analogues such as PhTX-343 and PhTX-12 on the major wild-type and mutant N-
Q$&K5VLQ&16DQG316ĮǃĮǃĮǃĮǃĮDQG0Q$&K5VĮǃǄį
by their expression in Xenopus oocytes.
21.1. Overview
Ionotropic-receptor protein interactions with neurotransmitters, results in
activation or inhibition of cellular events. Modulation of this important signalling
event has become an important research area for the development of drugs and
understanding pharmacological properties of particular receptor proteins in the
cell. The origin of receptor theory goes back to Langley in 1905, who reported
the presence of a receptive substance in the end-plate of frog neuromuscular
junction (NMJ), which binds with nicotine and is stimulated by the chemical-
transmitter released from the presynaptic neuron. Research by scientists like
Dale and Otto Loewi showed that acetylcholine (ACh) was a chemical
neurotransmitter used for communication in autonomic ganglia and at the
neuromuscular junction (NMJ). ACh is synthesized in presynaptic nerve cytosol
by Choline-Acetyl-Transferase (Ch-A-Tr) from choline and acetyl-Co-enzyme-A
(Figure 1.1) and packaged into individual vesicles. ACh is released and exerts
its impacts on the peripheral and central nervous system (PNS, CNS) via two
separate groups of receptors: Metabotropic muscarinic ACh receptors (mAChRs),
respond slowly to ACh application due to their interaction with the second
messenger cascades, while ionotropic nicotinic ACh receptors (nAChRs) mediate
fast synaptic transmission and are the focus point of this work.
3Figure 1.1. Mechanisms of synthesis, degradation and synaptic transmission of
acetylcholine (ACh). ACoA = acetyl-Co-enzyme-A, Ch = choline, AChE =
acetylcholine esterase, ChTr = choline transferase, Ch-A-Tr = choline acetyl
transferase, VAChT = vesicle acetylcholine transporter.
Based on their major location of expression in the body, nAChRs can be
classified into two subtypes: Muscle-type nAChRs (M-nAChRs) are located on the
skeletal muscles where they mediate excitatory neuromuscular transmission,
while the neuronal-type nAChRs (N-nAChRs) generate fast electrical
transmission in the brain and autonomic ganglia. The N-nAChRs in the CNS form
one of the major excitatory group of receptors, which play critical roles in several
brain activities such as learning, consciousness, attention, reward and memory
(Steinlein and Bertrand, 2008; Taly et al., 2009). Also, their role in non-
SDWKRORJLFDOQRFLFHSWLYHSDLQKDVEHHQZHOOVWXGLHGIRULQVWDQFHNQRFNRXWRIĮ
DQGǃ LQDPRXVHPRGHO OHG WRD UHGXFWLRQ LQ WKHDQWLQRFLFHSWLYHUHVSRQVHRI
4nicotine on the hot plate test (Marubio et al., 1999). Alteration in the expression
level and function of this group of receptors might lead to the development of
many pathophysiological disorders; for example epilepsy, Tourettes syndrome,
Parkinsons disease, Alzheimers disease, anxiety, depression and schizophrenia
(Gotti and Clementi, 2004; Romanelli et al., 2007; Unwin, 2013).
As mentioned above, nAChRs participate in the control of signaling of much
of the CNS, PNS and skeletal muscle (Romanelli and Gualtieri, 2003). They have
become promising targets for several therapies such as drugs being developed
for smoking cessation, memory enhancement, pain relief and the treatment for
Parkinsons disease (Li et al., 2001). Thus, the study of N-nAChRs and the
development of selective agonists and antagonists could further our current
understanding of the functioning profile of different nAChR subtypes (Romanelli
and Gualtieri, 2003). Several useful ligands (agonists and antagonists) that have
been investigated on nAChRs have a natural source such as those obtained from
plants and animals, which include nicotine, conotoxins and philanthotoxin-433
(Romanelli and Gualtieri, 2003). For these reasons N-nAChRs have become a
novel therapeutic target for drug discovery and research.
1.2. Nicotinic acetylcholine receptors
1.2.1. Molecular structure and diversity
nAChRs are oligomeric excitatory ion channels, which have wide subtype
diversity due to the various possible subunit combinations (Figure 1.2). Each
subtype has particular pharmacological and functional characteristics and may be
confined to a specific region of the CNS or PNS (Millar and Gotti, 2009). This
family and other phylogenetically associated receptors including 5-HT3 serotonin
receptors, GABAA and GABAC gamma aminobutyric acid receptors, glutamate-
gated chloride channels and glycine receptors, are all members of a large
superfamily called the ligand gated ion channel (LGIC) superfamily and often
referred to as the Cys-loop receptors because of a highly conserved loop
5constrained by a disulphide bridge in the N-terminal part of the protein. In the
last decade, scientists identified homologues of LGIC in prokaryotic cells and
suggested that these may be the ancestral source of animal Cys-loop receptors
(Duret et al., 2011; Tasneem et al., 2005).
Figure 1.2. Schematic representation of the vertebrate nAChR phylogenetic tree
DQG VXEW\SH GLYHUVLW\ DV D UHVXOW RI YDULRXV VXEXQLW FRPELQDWLRQV 7KH Į
subunit is only present in avian vertebrates. The ACh binding site is shown as a
ZKLWH GRW SRVLWLRQHG DW WKH LQWHUIDFH RI WKH SULQFLSDO VXEXQLW Į DQG
FRPSOHPHQWDU\VXEXQLWĮRUǃLQQHXURQDOįǄDQGİRIPXVFOH,GHDGHULYHG
from Le Novere (2002).
All nAChR subunits share numerous homologous characteristics composed
of the following parts: (i) a large hydrophilic amino terminal region consisting
roughly of 200 amino acids and containing more than three glycosylation sites;
(ii) three hydrophobic transmembrane segments (M1-M3) of approximately 20
amino acids each connected together via small loops; (iii) an intracellular
6hydrophilic link, 110-270 residues long, between M3 and M4 and containing
phosphorylation sites; (iv) another hydrophobic transmembrane segment (M4);
(v) a small hydrophilic extracellular C-terminal region (Figure 1.3)
(Albuquerque et al., 2009; Bouzat, 2012; Paterson and Nordberg, 2000).
Figure 1.3 The topology of a single nAChR subunit. M1, M2, M3 and M4
represent transmembrane domains. The M2 domain (brown) forms the pore
region of the receptors. Both the long N-terminal, which contains the agonist
binding site, and the shorter C-terminal are projected towards the extracellular
space.
In total, seventeen subunits of nAChR have so far been described and
FORQHG LQ YHUWHEUDWHV ILYH QRQQHXURQDO Į į ǃ Ǆ DQG İ DQG WZHOYH
QHXURQDO Į DQG ǃ 0LOODU DQG *RWWL  7KH PXOWLSOH VHTXHQFH
alignment of nAChR subunits obtained from the Uniprot databank
(http://www.uniprot.org/) using the ClustalW software shows a vast subunit
similarity across the three species, rat, mouse and human; models that have
been used in this project (Table 1.1). Changeux and colleagues for the first
WLPHSXULILHGDQGGHVFULEHGĮǃįǄVXEXQLWVLQWKHPXVFOHOLNHHOHFWULFRUJDQ
of the fish, Torpedo californica (Changeux et al., 1970). These subunits have
7VWRLFKLRPHWU\ RI Į DQG ǃ į Ǆ LQ IRHWDO WLVVXH DQG ILVK HOHFWULF RUJDQ
5H\QROGVDQG.DUOLQZKLOHLQPDWXUHVNHOHWDOPXVFOHǄLVVXEVWLWXWHGE\
İ OHDGLQJ WR LQFUHDVHG RSHQ WLPH DQG LRQ FRQGXFWDQFH WKURXJK WKH FKDQQHO
(Imoto et al., 1991). Cloning of these subunits at the beginning of the 1980s
developed a new era of molecular analysis of nAChRs (Changeux, 2012). In
FRQWUDVWVXEXQLWVRI1Q$&K5VKDYHEHHQGLYLGHGLQWZRGLVWLQFWVXEIDPLOLHVĮ
QHXURQDO VXEXQLWV Į Į ZKLFK FDUU\ SDLUV RI DGMDFHQW F\VWHLQHV WKDW DUH
similar in location to C192 and C193 of their analogue subunit in muscle-nAChRs
Į ZKHUHDV ǃQHXURQDO VXEXQLWV ǃ WR ǃ ODFN WKHVH SDLUV RI LPSRUWDQW
UHVLGXHVOLNHLQWKHQRQQHXURQDOǃǄįDQGİVXEXQLWV*DLPDUULHWDO
Gotti and Clementi, 2004; Lindstrom, 2000). It has been suggested that both
W\SHV RI QHXURQDO VXEXQLWV Į DQG ǃ SDUWLFLSDWH LQ GHWHUPLQDWLRQ RI
pharmacological characteristics of diverse subtypes of N-nAChRs (Chavez-
Noriega et al., 1997; Luetje and Patrick, 1991).
8Table 1.1. Sequence alignment comparison of nAChR amino acids across three different vertebrate species. h = human, r = rat and m =
mouse. Values rounded to the nearest whole number and highlighted boxes show homology between rat/mouse subunits used in this
work, with the corresponding human equivalent.
KĮ KĮ  
KĮ 44 KĮ
KĮ 47 54 KĮ
KĮ 48 65 57 KĮ
KĮ 41 50 46 52 KĮ
KĮ 43 53 64 53 44 KĮ
KĮ 34 37 36 38 34 35 KĮ
KĮ 33 33 32 35 33 34 35 KĮ
KĮ 34 37 35 37 36 34 40 55 KĮ
Kǃ 37 37 36 39 34 36 30 28 31 Kǃ
Kǃ 39 47 44 51 38 45 34 29 34 41 Kǃ
Kǃ 42 53 47 51 64 46 34 33 33 38 41 Kǃ
Kǃ 40 45 45 48 41 42 35 30 34 40 61 43 Kǃ
Kį 33 34 34 34 35 36 29 29 32 40 42 36 38 Kį
KǄ 31 32 33 33 32 33 28 28 33 42 38 30 37 46 hǄ
Kİ 29 34 35 33 31 33 28 26 31 39 34 31 32 45 51 P
UĮ 46 55 92 57 46 63 36 33 36 36 45 47 45 36 33 33 rĮ
UĮ 48 62 57 85 51 53 38 35 36 40 50 52 49 34 35 35 57 rĮ
UĮ 35 38 37 39 34 35 93 35 40 30 33 34 34 29 29 29 36 38 rĮ
Uǃ 39 48 46 49 37 46 32 30 36 40 93 41 62 40 37 35 46 48 33 rǃ
Uǃ 37 44 44 49 41 42 36 31 34 40 61 41 80 37 35 32 44 48 36 61 rǃ
PĮ 94 47 50 51 43 46 37 35 34 30 42 43 42 35 32 32 49 37 37 42 39 mĮ
Pǃ 33 37 35 38 36 35 29 28 31 90 41 36 39 39 40 38 35 28 28 41 40 37 mǃ
Pį 33 35 36 34 34 36 30 29 30 41 41 34 38 88 45 45 36 29 29 40 36 35 40 mį
PǄ 25 29 29 30 27 28 24 26 27 34 33 24 31 42 89 46 29 25 25 33 31 26 34 42 mǄ
Pİ 28 32 33 33 30 32 28 27 32 37 36 31 35 46 50 89 32 29 29 35 32 30 37 46 46 Pİ
8
97ZR VXEW\SHV RI Q$&K5 KDYH EHHQ LGHQWLILHG LQ EUDLQ KHWHURPHULF Į
%JW[LQVHQVLWLYH DQG KRPRPHULF Į%JW[VHQVLWLYH /LQGVWURP  7KH
heteromeric subtype might be composed of as few as two homologous subunits
LQFOXGLQJĮVXEXQLWVĮĮRUĮDQGǃVXEXQLWVǃRUǃ'DQLDQG%HUWUDQG
 7ZR GLIIHUHQW VWRLFKLRPHWULHV Įǃ DQG Įǃ KDYH EHHQ IRXQG
IRU Įǃ SUREDEO\ VDPH IRU ĮǃQ$&K5V LQ HQGRJHQRXV FHOOV *UDG\ HW DO
2010) and heterologous expression systems (Moroni and Bermudez, 2006). The
VWRLFKLRPHWU\ FRQWDLQLQJ ǃVXEXQLWV KDV KLJKHU DJRQLVW VHQVLWLYLW\ DQG ORZHU
Ca2+ SHUPHDELOLW\ FRPSDUHG WR WKH ǃVXEXQLW VWRLFKLRPHWU\ $ULDV  ,Q
KXPDQĮǃ2ǃLVWKHPRVWFRPPRQW\SHLQWKH&16ZKLOHLQWKH316LWLV
Įǃ2ǃ ,Q KRPRPHULF UHFHSWRUV WKH ZKROH UHFHSWRU VWUXFWXUH LV IRUPHG E\
identical subunits. The most abundant homomeric receptor has been found in
PDPPDOVFRPSRVHGRIILYHĮVXEXQLWVZKLOHĮLQDYLDQVSHFLHVLVDOVRDEOHWR
SURGXFHDQDOODOSKDKHWHURPHULFUHFHSWRUZLWKĮ&RXWXULHUHWDO*RWWL
HWDO)XUWKHUPRUHĮKDVWKHDELOLW\WRSURGXFHIXQFWLRQDOKHWHURPHULF
UHFHSWRUVE\FRPELQDWLRQZLWKǃ.KLURXJHWDODQGQRQIXQFWLRQDOW\SH
ZLWK ǃ %URDGEHQW HW DO  E\ XVLQJ D KHWHURORJRXV H[SUHVVLRQ V\VWHP
6LPLODUO\ĮZKLFK LVPDLQO\ IRXQG LQFRFKOHDUKDLUFHOOVKDVWKHFDSDELOLW\WR
construct a homomeric protein complex when expressed in Xenopus oocytes
(OJR\KHQ HW DO  &RH[SUHVVLRQ RI Į ZLWK Į ZLOO JHQHUDWH D
heteromeric receptor, which shows faster and stronger agonist desensitization
DQGURXJKO\IROG LQFUHDVH LQFXUUHQW UHVSRQVHFRPSDUHG WRKRPRPHULFĮ
$FFRUGLQJ WR WKHVH ILQGLQJV WKHQDWLYHUHFHSWRURIĮ LVDKHWHURPHULFFRPSOH[
ZLWK Į (OJR\KHQ HW DO  9HWWHU HW DO  3OD]DV DQG FRZRUNHUV
KDYHGHPRQVWUDWHG WKDW WKHVWRLFKLRPHWU\RI WKHVH WZRVXEXQLWV LV Į2Į3
by their expression in Xenopus oocytes (Plazas et al., 2005).
 +HWHURORJRXV H[SUHVVLRQ RI 
RUSKDQ
 VXEXQLWV Į DQG ǃ DORQH RU LQ
SDLUVZLWKDQRWKHUĮRUǃVXEXQLWGRHVQRWSURGXFHDQ\IXQFWLRQDOFKDQQHOV7KH\
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can only generate active receptor channels when they participate as a third
subunit, so this group of receptors is more complex in their pharmacological
function compared to the previous ones due to the subunit variety (Conroy and
Berg, 1995; Lindstrom, 2000; Wang et al., 1996). These subunits cannot
contribute directly to the agonist-binding sites, so they possibly occupy the
SRVLWLRQ DV DX[LOLDU\ VXEXQLW OLNH WKHLU DQDORJXH ǃ VXEXQLW LQ PXVFOH W\SH
nAChR. They may play a role in other activity like agonist sensitivity,
conductance, receptor localisation and desensitization (Kuryatov et al., 2008).
The expression pattern of nAChR subunits may be highly restricted to certain
UHJLRQV LQ WKH EUDLQ IRU H[DPSOH WKH ĮVXEXQLW LV PDLQO\ SUHVHQW LQ
hippocampus, striatum, cerebral cortex, thalamus and superior colliculus (Mao et
DO:DGDHWDOZKLOHWKHĮVXEXQLWLVIRXQGLQVXEVWDQWLDQLJUD
and ventral tegmental area (Rasmussen et al., 2014). In addition, receptors
containing these subunits have unique pharmacological properties, for example
ĮFRQWDLQLQJUHFHSWRUVKDYHEHHQVWURQJO\FRQQHFWHGWRGUXJDGGLFWLRQ*DRHW
DODQGĮFRQWDLQLQJWRUHZDUGEHKDYLRXUDQGPRWRUFRQWURO'UHQDQHW
al., 2008). Thus this class of receptor becomes an attractive target for
pharmaceutical treatment for various CNS disorders such as smoking cessation
and Parkinsons disease.
N-nAChRs are found presynaptically and postsynaptically, while M-
nAChRs are only found postsynaptically. Pre-synaptic-types are involved in the
release of several neurotransmitters such as ACh, noradrenaline, 5-HT,
dopamine, glutamate and GABA, whereas postsynaptic types rapidly convert the
chemical signal into membrane depolarization of the postsynaptic neuron or
muscle (Arias, 2012; Jones et al., 1999; MacDermott et al., 1999). N-nAChRs
allow the inward passage of cations at hyperpolarized membrane potentials more
than outward current at positive potentials, otherwise known as inward
rectification; this is not the case in muscle (Francis and Papke, 1996). This
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phenomenon might be caused by inhibition of the channel by interacellular Mg2+
and spermine when there is a force pushing the outward passage of cations
(Haghighi and Cooper, 1998; Neuhaus and Cachelin, 1990). The phenomenon of
outward and inward current inhibition by Mg2+ has been observed and confirmed
previously for other ionotropic receptors such as NMDAR (Li-Smerin et al.,
2001).
In addition, the permeability of Ca2+ in brain nAChRs is higher compared
to their analogue in muscle. Roughly 2% of the whole current generated by ion
exchange through M-nAChRs is carried by Ca2+. This percentage approximately
LQFUHDVHGIROGDQGIROG LQKHWHURPHULFĮǃFRPELQDWLRQVDQGKRPRPHULF
Į1Q$&K5VUHVSHFWLYHO\9HUQLQRHWDO Lipovsek et al (2014) showed
WKDW PDPPDOLDQ KHWHURPHULF ĮĮ DUH DOVR KLJKO\ &D2+ permeable
FRPELQDWLRQVRIQ$&K5V7KLVVXJJHVWVWKHLPSRUWDQFHRIKRPRPHULFĮQ$&K5V
LQ QHXURQV DQG KHWHURPHULF ĮĮ LQ FRFKOHDU KDLU FHOOV IRU WKH FRQWURO RI
intracellular concentration of Ca2+ due to their role as one of the main pathways
of Ca2+ entry at holding potentials the same as or more negative than resting
potential (Lindstrom et al., 1995; Lipovsek et al., 2014).
Desensitization of nAChRs is strongly dependent on subunit combination
*LQLDWXOOLQHWDO9HUWHEUDWHQ$&K5VFDQEHGLYLGHG LQWRHLWKHUQRQǃ
containing nAChRs (homomeric) which have a rapid desensitization
PLOOLVHFRQGV RU ǃFRQWDLQLQJ Q$&K5V KHWHURPHULF WKDW KDYH ORZHU
desensitization rates (seconds) compared to homomeric (Corringer et al., 2000;
McGehee and Role, 1995; Quick and Lester, 2002).
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1.2.2. Architecture and functional state
Members of the nAChR family are complex integral membrane proteins of
roughly 290 kDa. Electron microscopic studies (EMS) show that the Torpedo
electric organ nAChR is approximately 80 Å in width and 120 Å in length, with 15
Å and 65 Å extending to the cytoplasmic and extracellular space, respectively,
and 40 Å embedded in the lipid bi-layer. This heteromeric receptor has two ACh-
orthosteric sites which are located at a distance of 40 Å above the cell
membrane surface (Unwin, 2005) (Figure 1.5). The pore has a tapering shape
for cation flow when viewed from the extracellular side of the receptor
(Miyazawa et al., 2003), with a diameter of 20 Å at the cytoplasmic side, 25 Å at
synaptic cleft and it is narrower in the membrane spanning region (Hucho et al.,
1996).
On the cytoplasmic side there is an interacting protein called rapsyn,
which has a 43 kDa molecular weight and was first purified with NMJ nAChRs.
This complex has a role in connecting the receptor with the cytoskeleton as well
as clustering them in the end plate of nerve-muscle synapses, which is essential
for active transmission (Gotti and Clementi, 2004; Millar and Harkness, 2008). It
KDVEHHQUHYHDOHGWKDWDODFNRIWKLVFRPSOH[LQQHXURQDOQ$&K5VVXFKDVĮǃ
DQG Įǃ ZLOO QRW DIIHFW WKHLU SDFNDJLQJ RQ WKH SODVPD PHPEUDQH RI WKH FHOO
(Millar and Harkness, 2008). However, Osman and co-works (2008) have
UHSRUWHG WKHSUHVHQFHRI UDSV\QZLWKĮDQGĮRI URGHQW LQWHUQDOHDU7KXV
rapsyn is possibly associated with certain subtypes of neuronal nAChR and
participates in particular functions.
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(A) (B)
Figure 1.5. Folding and construction of closed channel M-nAChRs (2BG9)
viewed from the synaptic cleft (A) and in the plane of the lipid bilayer (B). The
green colour shown in figure B represents the agonist binding site and grey
horizontal lines represent the position of the lipid bi-layer. Idea derived from
Unwin (2013) by using Pymol software.
Improvement in the understanding of the ACh orthosteric site stems from
the discovery and crystallization of the homologous acetylcholine binding protein
(AChBP) from Lymnaea stagnalis, Aplysia californica and Bulinus truncatus
snails. AChBP is synthesized and saved in glial nerve cells and modulates
synaptic transmission where it is released into the synapse (Brejc et al., 2001).
7KHQ$&K5OLJDQGELQGLQJVLWHVDUHORFDWHGDWWKHLQWHUIDFHEHWZHHQDQĮVXEXQLW
and a neighbouring subunit. Changeux and collaborators (1984) have
demonstrated that each muscle-type nAChR carries two allosteric ligand biding
sites. Similarly, heteromeric neuronal types are thought to carry two ligand
binding sites, whereas five sites per homomeric neuronal nAChR are proposed,
RQHDWHDFKVXEXQLW LQWHUIDFH ,QLWLDOO\ LWZDVH[SHFWHGWKDWRQO\WKHĮVXEXQLW
ACh-binding
site
Gate
Extracellular
domain
Intracellular
domain
Trans-membrane
domain
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was responsible for the construction of ligand-binding sites due to a high affinity
for the competitive antagonist, 4-(N-maleimido)benzyltrimethylammonium
LRGLGH 0%7$ WR UHVLGXHV LQ WKH ĮVXEXQLWV MXVW QHDU WR Į&\V DQG Į&\V
 DQG D UDWLR RI WZR ĮVXEXQLWV WR WZR DJRQLVWELQGLQJ VLWHV .DR HW DO
1984). Further evidence supporting the interface position of the ligand binding
VLWH LQQ$&K5V LQFOXGHVSDLUHGH[SUHVVLRQRIĮǄRUĮįVXEXQLWV OHDGLQJWRWKH
formation of active ACh-binding sites, whereas other combinations do not
%ORXQW DQG 0HUOLH  DQG WKH ĮǄ LQWHUIDFH ELQGLQJ VLWH GLVSOD\V
SKDUPDFRORJLFDO FKDUDFWHULVWLFV PDUNHGO\ GLIIHUHQW WR WKDW EHWZHHQ Įį WKH
ODWWHU FRPELQDWLRQ KDYLQJ KLJKHU DIILQLW\ IRU ĮFRQRWR[LQ 0, FRPSDUHG WR WKH
former in muscular nAChR in mouse, but the other way round for d-tubocurarine
(dTC) (Sine, 1993; Sine et al., 1995). Also, they are different in their affinity for
ACh (Sine et al., 1990). So, the ligand-activating site has two components:
SULQFLSDODQGFRPSOHPHQWDU\,QKHWHURPHULFUHFHSWRUVWKHĮVXEXQLWVFDUU\WKH
SULQFLSDOFRPSRQHQWDQGWKHįǄDQGİLQPXVFOHDQGǃVXEXQLWLQQHXURQDOKROG
the complementary component, whereas, each subunit of homomeric receptors
participate in both components.
The polypeptide chains of the receptors ligand binding domain are
DUUDQJHGDURXQGSDLUV RI ǃVKHHWVZKLFKFRPELQH LQWRǃORRSVYLDDGLVXOSKLGH
bridge and forming the Cys-loop (Unwin, 2005). Identification of aromatic
residues important for ACh binding led to the proposal of a binding pocket
consisting of six loops named A-F (Figure 1.6). The key photolabelled residues
from Torpedo marmorata SULQFLSDO VXEXQLW ĮVXEXQLW WKDW SDUWLFLSDWH LQ $&K
binding are Tyr93 (Loop A), Trp149 (Loop B) and Tyr190, Cys192 and Cys193
(Loop C) and three less labelled residues Trp86, Tyr151 and Tyr198 (Dennis et
al., 1988; Galzi et al., 1990). The main amino acids from the complementary
VXEXQLWVįRUǄVXEXQLWWKDWFRQWULEXWHWR$&KELQGLQJDUHǄ7USDQGį$VS
/RRS '  Ǆ7\U DQG į$UJ /RRS ( &KLDUD HW DO  &KLDUD HW DO
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 DQG  į$VS į$VS DQG į*OX /RRS ) &]DMNRZVNL DQG .DUOLQ
1995).
Figure 1.6. Schematic representation of the orthosteric ligand binding domain in
Torpedo nAChRs, (A) The location of the ACh binding site (B) Represents the
principle and complementary component with their loops, and the cysteine pair
LQORRS&RIWKHSULQFLSDOVXEXQLWIRXQGRQO\LQĮVXEXQLWV
The agonist-binding pocket is measured to be 33 Å from the ion channel;
binding of ligand to this site leads to a global conformational change (Herz et al.,
1989; Unwin, 2005). These changes are dependent on time of exposure to and
concentration of the ligand, and will lead to ion channel activation and
desensitization. According to the Monod-Wyman-Changeux (MWC) theory,
nAChR has the ability to change spontaneously between four functional states:
Resting state (B) in the absence of agonist, Active state (A) by short exposure to
agonist and low and high affinity desensitized states (I and D) from prolonged
exposure to agonist (Karlin, 1967). Unwin (2005) reported that the ligand-
binding site is the principle mediator for receptor conformation after binding with
agonist. This eventually will follow by reorganization of hydrophobic domains
inside the pore and opening the gate to allow penetration of small cations (
Figure 1.7), which can pass through the narrowest part of the ion channel with
diameter of 6.5 Å (Huang et al., 1978). A recent model has been published
based on the crystal structure of human GABAA5 ǃ KRPRSHQWDPHU DW  c
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resolution. This model suggests that the binding of benzamidine to the agonist
binding pocket and placed the channel into desensitized closed state (Miller and
Aricescu, 2014).
Figure 1.7. Illustrating the transduction mechanism of nAChR agonist binding to
channel gating. Top is swivel (Miyazawa et al., 2003) and bottom is twist model
(Corringer et al., 2010).
The location of the non-conducting gate in the channel of nAChRs has
been debated. Work by Unwin using high resolution electron microscopy
DVVXPHG WKDW ĮKHOLFHV DQG ǃVKHHW IURP WUDQVPHPEUDQH 0 DQG WKH
ammonium terminal of M1 from all subunits contribute in the construction of the
pore region of the receptor, while other transmembrane domains shield the pore
from the lipid bilayer (Unwin, 2005). Tikhonov and collaborators showed that in
human muscle-type nAChRs the channel lumen is formed by eight rings of
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residues with different chemical properties; each one is formed from
participation of identical or homologous residues from various subunits. The
rings arranged from extracellular to intracellular are outer glutamate, leucine,
valine, equatorial leucine, serine, threonine, intermediate glutamate and internal
aspartate ring, respectively (Tikhonov et al., 2004) (Figure 1.8). In the case of
neuronal receptors these rings have pretty similar properties to those of M-
nAChRs. The residues from M2 from each subunit that participate in the ion
channel pore are presented in Table 1.2. Unwin (2005) demonstrated that the
leucine ring at position 247 functions as a gate (position 11 in Table 1.2). In
contrast, Karlin and Wilson, using substituted-cysteine-accessibility-method
(SCAM), showed that 2-aminoethyl methanethiosulfonate (MTSEA) has
accessibility to bind amino acids in the intermediate ring at position 240 in the
closed state of the channel, which indicated that the location of the resting gate
was deeper in the channel pore and close to the selectivity filter (Wilson and
Karlin, 2001; 1998). According to Tikhonov et al. (2004) the closed channel is
the result of a hydrophobic ring (equatorial leucine) barrier to ions carrying
water in their stable shell, while MTSEA does not have these properties, so it can
penetrate the channel gate even when it is closed but hydrated cations cannot
pass through it.
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Figure 1.8. The ion channel of embryonic human M-nAChRs. The pore region is
generated by eight rings of homologous amino acids from the M2 domain and
00ORRSRIGLIIHUHQWVXEXQLWV7KHĮKHOLFDO0WUDQVPHPEUDQHUHJLRQPDLQO\
participates in the formation of the upper part of the pore which functions as a
water filled pathway, while the loop component is responsible for the pore
selectivity filter.
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Table 1.2. Aligned sequences for the nAChR second transmembrane domain,
M2, across three mammalian species. Blue and red amino acids are the single
GLIIHUHQFH EHWZHHQ 0 GRPDLQV RI ǃ DQG ǃVXEXQLWV 7KH EROG UHVLGXHV
participate in the ion channel pore lining rings.
Position
M2
Segment
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Rat
Į ( K V T L C I S V L L S L T V F L L V I
Į ( K V T L C I S V L L S L T V F L L L I
Į ( K I S L G I T V L L S L T V F M L L V
ǃ ( K M T L C I S V L L A L T V F L L L I
ǃ ( K M T L C I S V L L A L T F F L L L I
Mouse
Į ( K M T L S I S V L L S L T V F L L V I
ǃ ( K M G L S I F A L L T L T V F L L L L
į ( K T S V A I S V L L A Q S V F L L L L
Ǆ 4 K C T V A T N V L L A Q T V F L F L V
İ 4 K C T V S I N V L L A Q T V F L F L I
Human
Į ( K M T L S I S V L L S L T V F L L V I
Į ( K I T L C I S V L L S L T V F L L L I
Į ( K V T L C I S V L L S L T V F L L V I
Į ( K I T L C I S V L L S L T V F L L L I
Į ( K I C L C T S V L V S L T V F L L V I
Į ( K V T L C I S V L L S L T V F L L V I
Į ( K I S L G I T V L L S L T V F M L L V
Į ( K V S L G V T I L L A M T V F Q L M V
Į ( K V S L G V T V L L A L T V F Q L L L
ǃ ( K M G L S I F A L L T L T V F L L L L
ǃ ( K M T L C I S V L L A L T V F L L L L
ǃ ( K L S L S T S V L V S L T V F L L V I
ǃ ( K M T L C I S V L L A L T F F L L L I
į ( K T S V A I S V L L A Q S V F L L L I
Ǆ 4 K C T V A I N V L L A Q T V F L F L V
İ 4 K C T V S I N V L L A Q T V F L F L I
Experimental data from site directed mutagenesis techniques shows the
contribution of particular amino acid rings in determining Permeability
characteristics of the nAChR. For instance, the intermediate negatively charged
ring, glutamate, is mainly responsible for the permeability of divalent cations, so
PXWDWLRQ RI Į( WR $ HOLPLQDWHV &D2+ permeability of the channel, while it
does not affect sodium or potassium permeability (Bertrand et al., 1993).
)XUWKHUPRUHWKHPXWDWLRQVĮ9'DQGĮ($LQWKHK\GURSKRELFULQJDQG
intermediate ring of M1-M2 loop with an insertion of alanine or proline at the
intracellular end of M2 shows their role in charge selectivity by creating a
channel with anion selectivity (Corringer et al., 1999; Galzi et al., 1992).
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1.2.3. Role and distribution
nAChRs are found in various regions of organisms due to their important
function in many activities. To confirm the distribution pattern of these receptors
in CNS and PNS, different groups of probes including fluorescent and
radiolabelled ligands and antibodies have been used. These studies provide a
wealth of knowledge about the density and region specificity of nAChR gene
expression (Sargent, 1993). Understanding the role of particular nAChR subunits
in physiological and pathophysiological processes has been improved markedly
after using new knockout (Ko) and knockin (Kin) genetic techniques.
Peripheral nervous system
Muscle type nAChRs at neuromuscular junctions between motor neurons
and skeletal muscle are mainly localized postsynaptically, where they convert the
chemical signal from their binding with ACh to an electrical signal ultimately
generating muscle contraction (Jensen et al., 2005). Abnormality in the function
of this type of receptors will lead to pathological disorders such as myasthenia
gravis (Lindstrom, 2000). Therefore, it becomes a novel target for drug
discovery such as muscle relaxants (Lee, 2003).
The neuronal nAChRs in mammalian autonomic pathways that mediate
IDVWV\QDSWLFWUDQVPLVVLRQPDLQO\IRUPYDU\LQJVXEW\SHVIURPĮDQG
ǃ   VXEXQLWV ZKLFK DUH VLJQLILFDQWO\ GLIIHUHQW LQ WKHLU ORFDOL]DWLRQ DQG
PRGXODWRU\IXQFWLRQV6NRNHWDO7KHUDWLRRIFHOOVFRQWDLQLQJĮĮĮ
DQGĮ LQ V\PSDWKHWLFSDWKZD\VRI WKHJXLQHDSLJ LV URXJKO\ WKUHH IROGKLJKHU
than in the parasympathetic pathway (Glushakov et al., 2004), therefore, the
SKDUPDFRORJ\RIERWKSDWKZD\VDUHPDUNHGO\GLIIHUHQW7KHPRVWSUHGRPLQDQWĮ
VXEXQLWV LQ DXWRQRPLF JDQJOLD DUH Į IRUPLQJ KHWHURPHULF UHFHSWRUV VXFK DV
Įǃ 

JDQJOLRQLFW\SH Q$&K5V

 3DSNH DQG +HLQHPDQQ  DQG Į DV
KRPRPHULFUHFHSWRUVLQUDW+HUUHURHWDO.QRFNRXWRIWKHĮVXEXQLWLQ
mice has led to wide failure in autonomic pathways mainly causing intestinal,
21
bladder and pupillary of eye disorders (Xu et al., 1999). Also, it has a major role
in autoimmune autonomic ganglionopathy (Vernino et al., 2009).
Central nervous system
To further understand nAChRs and map their expression in the CNS,
researchers have used various techniques such as ligand binding and gene
expression.
Clarke et al. (Clarke et al., 1985) used three radioligands; 125,Į%JW[
(antagonistic ), 3H-nicotine and 3H-ACh (agonistic) on rat brain tissue to identify
the distribution of high-affinity binding sites. This study shows identical regional
distribution of both agonists binding sites which are distinct from that of the
antagonist. Binding sites of 125,Į%JW[DUHREVHUYHGPDLQO\LQWKHKLSSRFDPSXV
hypothalamus, inferior colliculus and particularly layers I and IV of the cerebral
cortex. Binding sites of 3H-nicotine and 3H-ACh were seen in high density in
interpeduncular nucleus, numerous thalamic nuclei, medial habenula and
superior colliculus. Moderate density was seen in ventral tegmental, cerebral
cortex (especially in layer III and IV), presubiculum and substantia nigra pars
compact. Low density was noticed in the cerebellum and no labelling was seen in
either the hippocampus or the hypothalamus region.
Given that N-nAChR genes differ in their expression patterns in different
areas of the brain (Table 1.3); it is likely that unique neuronal subsets express
different nAChRs genes. To assess the gene expression of N-nAChRs in the CNS,
different methods have been used such as in situ hybridization, RNAse protection
and Northern blots (Sargent, 1993). In situ hybridization studies show that
several areas of rat brain express at least a single gene of N-nAChR with a
XQLTXHSDWWHUQLQHDFKUHJLRQ:DGDHWDO)RUH[DPSOHĮVXEXQLWVDUH
widely expressed in a high concentration in many areas of the rat brain, whereas
Į VXEXQLW H[SUHVVLRQ LV KLJKO\ OLPLWHG LQ LWV UHJLRQDO GLVWULEXWLRQ 7KH Į
H[SUHVVLRQ SDWWHUQ ZDV LQWHUPHGLDWH EHWZHHQ Į DQG Į ,Q WKH FDVH RI ǃ
22
VXEXQLWV ǃ H[SUHVVLRQ LV REVHUYHG LQ WKH PDMRULW\ RI WKH UDW EUDLQ SDUWV
ZKHUHDVǃH[SUHVVLRQZDVUHVWULFWHGWRSDUWLFXODUUHJLRQV'HQHULVHWDO
ǃH[SUHVVLRQZDVREVHUYHG VWURQJO\RQO\ LQPHGLDOKDEHQXOD 'XYRLVLQ HW DO
EXWDODWHUVWXG\QRWLFHGPRUHEURDGH[SUHVVLRQRIǃLQUDW&16'LQHOH\
Miller and Patrick, 1992).
The native subtypes of nAChRs expressed in CNS have been suggested to
participate in many brain activities and behaviour. For example, it has been
SURSRVHGWKDWSUREDEO\ERWKĮǃDQGĮǃDUHLQYROYHGLQQHXURGHJHQHUDWLRQ
FRJQLWLRQ DQ[LHW\ GHSUHVVLRQ DQG SDLQ ZKHUHDV Įǃ Q$&K5V DUH OLQNHG WR
DGGLFWLRQ DQG UHOHDVH RI GRSDPLQH DQG Į FRQQHFWHG WR WKH UHOHDVH RI *$%$
(Lloyd and Williams, 2000).
There are several lines of evidence that propose a role for nAChRs in
neuroprotection (Arneric and Brioni, 1999). Firstly, a reduction in the nAChR
population was observed in the cortex and hippocampus of Alzheimers disease
patients. Secondly, Smokers appear to be less likely to develop early onset
Alzheimers disease(van Duijn et al., 1995), suggesting that nAChRs could play a
potential role for finding a pharmaceutical treatment for this disease. Thirdly, a
IHZVXEW\SHVRIPDPPDOLDQQ$&K5VVXFKDVĮDQGĮĮDUHKLJKO\SHUPHDEOH
to Ca2+, indicating a critical role in controlling intracellular signaling, synaptic
transmission and modulation of nerve growth factor (Albuquerque et al., 1997;
Lipovsek et al., 2014; Role and Berg, 1996). Finally, some nAChR modulators
are neuroprotective in both in vitro and in vivo studies. A few of these ligands
have a huge side effect due to non-selective action over different subtypes of
nAChRs. This problem could be solved by identifying ligands that interact
selectively with one particular subtype over other combinations of nAChR
subunits.
23
Table 1.3. The regional distribution of the various subunit combinations of
nAChRs in the CNS. Modified from (Taly et al., 2009)
CNS regions Expressed combinations of N-nAChRs
6SLQDOFRUG ĮǃĮǃĮ
5DSKHQXFOHL Įǃ
2FXVDHUXOHXV ĮǃĮǃǃ
,QWHUSHGXQFXODUQXFOHXV ĮǃĮǃĮǃǃĮ
Substantia nigra
Ventral tegmental area
ĮǃĮĮǃĮǃ ĮǃǃĮ
7KDODPXV Įǃ
+\SRWKDODPXV ĮǃĮ
$P\JGDOD ĮǃĮ
6WULDWXP ĮǃĮĮǃĮǃǃĮĮǃǃ
2OIDFWRU\EXOE ĮǃĮ
&RUWH[ ĮǃĮĮǃĮ
+LSSRFDPSXV ĮǃĮĮǃ ĮǃĮ
0HGLDOKDEHQXOH ĮǃĮǃ ĮǃǃĮ
3LQHDOJODQG ĮĮǃ
&HUHEHOOXP ĮǃĮǃĮĮǃ
Non-neuronal location of neuronal nAChRs
 ,Q WKH LPPXQHV\VWHP WKUHHĮ DQG WZRǃ VXEXQLWVDUH
found on T-cells (Kuo et al., 2002); also functional nicotinic receptors containing
ĮRUVXEXQLWVDUHIRXQGRQ%O\PSKRF\WHVZKHUHWKH\GHFUHDVHDQWLERG\
production and stimulate growth (Skok et al., 2003). Moreover, both human
PDFURSKDJH DQG EUDLQ PLFURJOLD KDYH Į Q$&K5V *RWWL DQG &OHPHQWL 
7KHĮQ$&K5DOVRKDVDFULWLFDOUROHLQWKHLPPXQHV\VWHPDQGKDVEHFRPHD
potential therapeutic target for anti-inflammatory drugs (Pohanka, 2012).
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In the human skin, epidermal keratinocytes synthesize ACh (Lindstrom,
2010) and express receptors which have pharmacological and biophysical
FKDUDFWHULVWLFV RI WKH JDQJOLRQLF Į VXEXQLW *UDQGR HW DO  7KHVH
receptors perform numerous skin functions such as proliferation, differentiation,
adhesion, motility and apoptosis, via controlling Ca2+ influx into keratinocytes
(Gotti and Clementi, 2004; Grando et al., 1995). The vascular system
endothelial cells and smooth muscle express different types of nicotinic subunits,
also some subunits have been found in bronchial cells of lung (Lindstrom, 2010).
Invertebrate and insect nAChRs
The complete genomic sequence of the nematode worm Caenorhabditis
elegans was a great achievement; it gives researchers the opportunity to use
this animal as a model for the investigation of many human diseases which
might lead to the development of new treatments. One important target for drug
discovery is nAChRs; it appears from analysis of this small worms genome
sequence that it has at least 27 distinct nAChR subunits (Jones and Sattelle,
2003). So far, Levamisole, which acts as an agonist of invertebrate nAChRs, has
been used in humans and other animals as a drug to control the intestinal
disease cause by helminthes such as tapeworms, roundworm and blood flukes
(Fleming et al., 1997; Martin, 1997; Millar and Denholm, 2007).
Insect nAChRs are the major excitatory neurotransmitter gated ion
channels, which are present in huge abundance in excitatory post-synaptic
membrane (Sattelle, 1980). Therefore, due to the critical role of these receptors
as fast excitatory channels, they present an effective target for the development
RIVHOHFWLYHLQVHFWLFLGHV0DWVXGDHWDO6RIDUWKHSUHVHQFHRIVHYHQĮ
VXEXQLWV'ĮWRĮDQGWKUHHǃVXEXQLWV'ǃWRǃRIQ$&K5VKDYHEHHQ
confirmed by molecular cloning studies in the fruit fly Drosophila melanogaster
(Millar, 2003; Tomizawa and Casida, 2001). The data reported from insect
genomic sequence projects suggested a comparable level of nAChR subunit
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diversity found in the fruit fly to other insect species (Jones et al., 2006). Insect
nAChRs are difficult to express alone to investigate their characteristics,
therefore to understand the pharmacological properties of each insect subunit
and their possibility to co-assemble with others to generate functional channels,
researchers have used native tissue and heterologous expression systems
(Millar, 1999; 2003). Several techniques and approaches have been used to
investigate the profile of insect nAChRs such as their expression with the
YHUWHEUDWH DX[LOLDU\ VXEXQLW ǃ %HUWUDQG HW DO  /DQVGHOO HW DO 
developing a chimeric subunit (Lansdell and Millar, 2004) and using insect cells
as a native source of receptors (Lansdell et al., 1997).
1.3. Pharmacology
Pharmacologically various groups of synthetic and natural compounds
have been examined and their effects on the activity of nAChRs explained
(Figure 1.9). These drugs can be divided in to three main categories based on
binding sites and consequent events after interacting with receptors (Figure
1.10): agonists (stimulation), antagonists (inhibition), and allosteric ligands
(molecules that stimulate or inhibit agonist activity by binding to allosteric sites
other than the agonist binding-site).
Agonists are drugs that lack subtype selectivity between different
combinations of nAChR subunits (Gotti et al., 1997), with few exceptions. A
diverse range of agonists has been tested; some of them are full agonists with
strong potency such as ACh and carbacol (CCh), while others are partial agonists
with weak potency like suberylcholine (SubCh). However, a few agonists have
been identified as selective for N-nAChRs such as dimethylphenylpiprazinum
'033IRUĮǃ3UDGRDQG6HJDOODDQGYDUHQLFOLQHDVDIXOODJRQLVWRQ
ĮDQGSDUWLDODJRQLVWRQĮǃKDVEHHQSHUPLWWHGUHFHQWO\E\)'$)RRGDQG
Drug Administration) to use as an aid drug for smoking cessation (Mihalak et al.,
2006).
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Figure 1.9. Structures of established nAChR ligands.
Antagonists are compounds that diminish the action of any agonist. These
drugs have shown a high subtype specificity among nAChRs and can be divided
into classes based on their site of action: Competitive antagonists compete with
agonist for their binding sites, whereas non-competitive antagonists have two
possible sites of action, some at the subunit-lipid interface and others in the pore
lumen of nAChRs. Changeux et al. (1984) called the substances with binding
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sites in the lumen as non-competitive inhibitors (NCIs), which classically have
been identified as blockers of the open ion channel, inhibiting passage of ions
(Neher and Steinbach, 1978). It seems to be that open channel blockers are
mostly cationic and interact within the membrane electrical field so their activity
is usually voltage-dependent (i.e. their effect increases at more hyperpolarizing
membrane potentials).
A well-studied example of a competitive muscle-type nAChR selective
antagonist is the snake toxin derived from Bungarus multicinctus, Malayan
%DQGHG )RUPRVDQ .UDLW FDOOHG ĮEXQJDURWR[LQ Į%JW[ ZKLFK ZDV XVHG YLD
various types of experiments to determine the pharmacological properties of
muscle-type nAChRs. Also it was used in the original affinity purification of
nAChRs from electric organ (Lindstrom and Patrick, 1974) that led to the first
nAChR protein partially sequenced (Raftery et al., 1980) from which the whole
cDNA sequence was obtained (Ballivet et al., 1982). Further works show that
QHXURQDOĮWRĮKRPRPHULFUHFHSWRUVDUHDOVRLQKLELWHGE\Į%JW[ZKHUHDV
heteromeric neuronal receptors are not blocked by the toxin. Research on this
toxin has lead scientists to understand the properties and distribution of
KRPRPHULFUHFHSWRUV OLNHĮDQGWKHLUSRVVLEOHUROH LQQHXURWUDQVPLVVLRQ,WLHU
and Bertrand, 2001). d-Tubocurarine (d-TC), the active chemical compound of
curare, also acts as a specific M-nAChR selective competitive antagonist.
Competitive antagonists of N-nAChRs include k-bungarotoxins (k-BgTX),
tetraethylammonium and trimetaphan; the latter one is used during surgery
causing local hypotension. Other competitive antagonists of nAChRs include
trimethylammonium diazonium fluoroborate (TDF), p-N,N-
(dimethylamino)phenyldiazonium fluoroborate (DDF) and
maleimidobenzyltrimethylammonium (MBTA) that all interact with agonist-
binding sites through covalent binding and are widely used in nAChR labelling
studies (Arias, 2000).
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Non-competitive nAChR antagonists such as chlorpromazine (CPZ) and
QX-222 were used to characterize the ion channel/M2 domain. Works by
Giraudat et al. (1989) and Revah et al. (1990) show the ability of CPZ to label
UHVLGXHVLQWKHĮKHOLFDOSRUWLRQRIWKH0UHJLRQ7KLVEORFNHUKDVDKLJKDIILQLW\
for its binding sites in the ion channel; therefore a number of homologous
residues (Ser240, Thr244 and Leu247) in different nAChR subunits were
identified. Its antagonistic action on nAChRs as an open-channel blocker is
voltage-dependent, while its effect as closed channel blocker by reducing
frequency of channel opening and role in enhanced desensitization is voltage-
independent (Benoit and Changeux, 1993; Wang and Sun, 2005).
Figure1.10. schematic drawing of nAChRs showing various binding sites: (A)
Agonist and competitive antagonist (B) Allosteric modulators (C) non-luminal (D)
luminal binding sites of non-competitive antagonist.
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Further work characterizing different residues of the pore region was
done by using a wide range of compounds which have binding sites in the
channel such as QX-222, the local anaesthetic, found to mostly interact with the
same rings that CPZ binds to (serine, threonine and leucine) (Arias, 1998).
Spermine is a ubiquitous polyamine that participates in cellular
PHWDEROLVPLQDOOHXNDU\RWLFFHOOV,WVQRQFRPSHWLWLYHDFWLRQRQĮǃDQGĮǃ
neuronal nAChRs was investigated by Haghighi and Cooper (1998). They showed
that this compound displayed a high affinity to block neuronal nAChRs at
depolarized potential when applied from the cytoplasmic side of the pore. The
spermine concentration in a neurone such as rat superior cervical ganglion (SCG)
cells, is high and their voltage-dependent mode of blocking explains the inward
neuronal rectification of nAChRs. As explained by the Woodhull model of voltage-
dependent block (Woodhull, 1973), the mode of channel blocking by spermine
occurs after entering the open channel and interacting with its binding sites in
the membrane electrical field where it can impede the penetration of small
cations through the channel. In contrast it acts as a voltage-independent
LQKLELWRURIPXVFOH7(FHOO OLQHQ$&K5VLQWKHSUHVHQFHRIǴDUFDLQHD
potent antagonist at the polyamine site of the NMDA receptor) and can
potentiate the receptors in the absence of arcaine when applied extracellularly
(Shao et al., 1998).
Also a number of natural active antagonists for nAChRs have been
LGHQWLILHG IRU LQVWDQFH ĮFRQRWR[LQ DQG SKLODQWKRWR[LQ 3K7;
6\QWKHWLFGHULYDWLYHVRIWKHODWWHUIRUPWKHEDVLVRIWKLVSURMHFWĮ&RQRWR[LQLVD
small neurotoxic peptide of 12-20 amino acids, which is derived from the venom
of cone snails (genus Conus) (Jensen et al., 2005). In addition, different types
RIFRQRWR[LQDFWRQWKH10-W\SHRIQ$&K5V7KHIDPLO\RIĮFRQRWR[LQVFDQEH
IXUWKHUGLYLGHG LQWRIRXUVXEIDPLOLHVĮĮĮDQGĮGHSHQGLQJRQ
the number of amino acid residues separating the cysteine residues in loop I and
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II (Dutton and Craik, 2001). The last three types of conotoxin are selective
LQKLELWRUV RI 1Q$&K5V ZKLOH Į DUH VHOHFWLYH IRU 0Q$&K5V 1LFNH HW DO
2004).
Ethidium is an irreversible non-competitive nAChR antagonist with higher
affinity for the open channel state. It has a deep binding site in the ion channel
(Bixel et al., 2000). Ethidium has been used as a tool in a number of
experiments to describe the activity of compounds as antagonists or agonists as
well as receptor characterization.
Extensive studies show that a diverse group of structurally related
molecules can modulate signalling pathways of nAChRs via allosteric binding
sites at the receptor complex. Zinc as an endogenous ligand mainly impacts on
heteromeric neuronal nAChRs. Zn2+ enhances the strength of the agonist
response at concentrations up to 100 µM and higher concentrations impede the
nAChRs functional state (Jensen et al., 2005).
1.4. Polyamines and Philanthotoxin
Polyamines are compounds carrying more than one amino group in their
structure and are synthesized in all eukaryotic cells. Putrescine, spermine and
spermidine are the main biological polyamines that have so far been found in
living cells which play a critical role in many physiological activities such as
modulation of ion channel function, including nAChR. These organic compounds
have also been found and identified in the venom of predatory spiders and
wasps. Eldefrawi and his colleges (1988) for the first time characterized the
active component of the Egyptian solitary digger wasp, Philanthus triangulum,
venom, which causes paralysis to honeybees, and named it philanthotoxin-433
(PhTX-433). It has molecular weight of 435 (Figure 1.11) and 4-3-3 denotes
the methylene groups separating nitrogens in the tail region (Nakanishi et al.,
1997).
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Figure 1.11. Philanthus triangulum with paralysed honeybee and chemical
structure of the venom active component, PhTX-433. (Red) region I=
ammonium group, (blue) region II= thermospermine, (green) region III=
butyryl and (brown) region IV= tyrosine. (Photograph courtesy of Warren
Photographic).
The structure of natural PhTX-433 is composed of a long polyamine
(thermospermine 4-3-3) chain, which carries a primary amino group at the
terminal end, and a head-group containing an aliphatic butyryl group and an
aromatic tyrosyl group at the other end. These moieties are linked together via
amide bonds (Stromgaard et al., 2005) and form a molecule with hydrophobic
properties at the head and hydrophilic at the tail region. It acts as a non-
competitive antagonist targeting several important cation-permeable ion
channels such as ionotropic glutamate receptors and nAChRs (Stromgaard et al.,
2000A). The inhibitory potency of PhTX-433 has been reported previously on
qGluR naturally expressed in locust leg muscle, where its IC50 was 18 µM (Bruce
et al., 1990). This potency was in agreement also with binding assay studies on
rat NMDA receptors but was higher (IC50 = 1 µM) in nAChRs (Anis et al., 1990).
The antagonistic actions of PhTX-433 and the many analogues that have been
synthesized is mainly related to the number of nitrogen atoms in the polyamine
chain and their probable interactions with negatively charged or polar amino
acids of the channels cation-selective lumen (Mellor et al., 2003; Stromgaard et
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al., 2002) and to a lesser extent on the head group which anchors the toxin to
the extracellular entrance of the channel (Stromgaard et al., 2005).
The main obstacle facing use of the natural toxin (PhTX-433) as a
candidate for drug development and understanding pharmacological
characteristics of ionotropic receptors is the lack of subtype selectivity.
Therefore, modifying the toxins structural moieties by adding, removing or
substituting groups of atoms might lead to changes in their inhibitory potency
toward particular categories of targeted receptors. This selectivity makes the
philanthotoxins important tools for examining functional activity of specific
ionotropic receptors (Stromgaard et al., 2005).
The existence of four different sections in the structure of PhTX-433
makes it suitable for developing a wide range of analogues by using solid-phase
synthesis (SPS). The action of these analogues has been investigated on
different types of receptors, and it appears that some analogues have specific
inhibitory properties on particular receptor categories. The pharmacologically
standard analogue that mostly has similar properties to PhTX-433 is PhTX-343
where the polyamine chain is spermine rather than thermospermine. Replacing
one or both secondary amino groups in the long-polyamine tail of PhTX-343 with
a methylene group will lead to PhTX-83 and PhTX-12, respectively (Figure
1.12).
Converting PhTX-343 to PhTX-12 markedly altered the inhibitory potency
of the toxin on different receptors. PhTX-343 non-selectively antagonizes
different types of ionotropic receptor including nAChRs and iGluRs and their
potency level is mostly similar on all of them. However, PhTX-12 exhibits strong
inhibitory activity on M-nAChRs in Torpedo electric organ and human, whilst it
does not affect several types of iGluRs (Stromgaard et al., 2000B). A further
modification of the PhTX-12 polyamine tail led to the development of a series of
analogues, PhTX-7 to PhTX-11. PhTX-11 was found to be the only sy
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compound to have a considerable increase in potency compared to PhTX-12,
whereas, all others did not (Stromgaard et al., 2002). Moreover, PhTX-83 has
EHHQNQRZQWRKDYHVWURQJDQWDJRQLVPVHOHFWLYLW\WRZDUGĮDPLQRK\GUR[\
methyl-4-isoxazolepropionic acid receptors (AMPAR) (Mellor et al., 2003).
Figure 1.12. Shows the structure of philantotoxin-343 and its abasic analogues
PhTX-83 and PhTX-12.
However, ambiguous effects have been reported from the modification of
the aromatic head group of philanthotoxins with few exceptions that lead to
strong subtype selectivity. For instance, replacing the amino acid moiety (tyrosyl
group) in PhTX-343 derivatives with N-cyclohexyl-L-alanine (Cha) led to the
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synthesis of six analogues. All these analogues show selectivity towards human
muscle nAChRs and their potency at negative holding potential was significantly
higher than PhTX-343, while mostly similar potencies were recorded on AMPA
receptors (Olsen et al., 2006). In contrast to this, the antagonism potency of
PhTX-343 derivatives on both NMDAR and nAChR was increased markedly by
substituting the butyryl group with 2-phenylacetyl (Stromgaard et al., 2000B).
Philanthotoxin head-group modification has proposed the orientation
mode of this toxin inside the receptor channel. In a photo-labelling study, Choi
et al (1995) found that in Torpedo HOHFWULF RUJDQ Q$&K5V WKH ĮVXEXQLW LV
probably the main subunit responsible for the action of philanthotoxins due to
their high crosslinking to approximately 20,000 Dalton between Ser173 to
Glu338 and 12,000 Dalton from Asn339 to Gly437, with N3-Ph-
125I2-PhTX-343-
Lys. They suggested a head-down orientation mode for philanthotoxin in the
lumen of nAChR channel. However, a tail-down interaction mode for N3-Ph-
125I2-PhTX-343-Lys has been suggested in the channel pore by Bixel et al (2000)
when N3-Ph-
125I2-PhTX-343-Lys was applied from the extracellular side, while
intracellular application of this compound and PhTX-343 did not show any effect
on nAChRs of the BC(3)HI muscle cell line (Jayaraman et al., 1999). In addition,
the latter mode of philanthotoxin receptor interaction has been supported by
structure-activity relationships (SAR) using toxin analogues having a huge
aromatic head group (Bixel et al., 2000; Nakanishi et al., 1997).
Interestingly, modification of the terminal amino group in philanthotoxin
structures, which is mainly responsible for toxin inhibition activity (Jaroszewski
et al., 1996), dramatically affects their potency. It has been shown by previous
studies that the polyamine tail might bind to residues near the serine ring
(Tikhonov et al., 2004). Therefore, adding positive charge to this region such as
arginine or lysine will decrease half maximal inhibitory concentration, IC50,
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whereas adding a bulky group or neutralizing the charge will increase
philanthotoxin IC50 value.
Most investigations on the action of philanthotoxins on nAChRs have used
muscle-type receptors. An early patch clamp study by Rozental and colleagues
suggested that PhTX-433, at micro-molar concentrations (1-20 µM), inhibited
frog muscle responses and reduced channel opening rate and channel open and
burst time. Binding of [125I]-alpha-Bgtx to honeybee brain membrane was
inhibited by PhTX-433, as was [3H]-perhydrohistrionicotoxin a synthetic
derivative of a natural alkaloid NCI extracted from the skin of the Colombian
frog, Dendrobates histrionicus. Moreover, low and high concentrations of PhTX-
433 caused potentiation and inhibition of the binding affinity of [3H]-ACh to
Torpedo electric organ, respectively (Rozental et al., 1989). Brackley et al
(1990) showed that the ACh response of Xenopus oocytes injected with rat brain
RNA was potentiated at low concentration of PhTX-343. Therefore, Rozental and
co-workers concluded that the main inhibitory action of natural philanthotoxin on
nAChRs is due to a non-competitive mode of antagonism, open-channel block,
but also it has a competitive mode of inhibition at high concentrations (Rozental
et al., 1989).
Initially, a closed channel mode of inhibition was suggested for PhTX-343
due to its higher affinity for the closed channel state of nAChRs than the open
channel conformation in BC(3)H1 cell line by using a laser pulse photolysis
method. This work concluded that the rate constant of channel opening was
decreased by PhTX-343, while channel closing was not affected; also channel
opening was affected by using PhTX-343 at different holding potentials indicating
voltage-dependence of toxin action (Jayaraman et al., 1999).
Data from electrophysiological studies proved the idea of voltage-
dependent and independent inhibition of muscle (Mellor et al., 2003; Shao et al.,
1998) and neuronal (Liu et al., 1997) nAChRs by philanthotoxins. The antagonist
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action of PhTX-343 is time-dependent, which indicates that its inhibition mode is
slow and requires gate opening following receptor activation (Brier et al., 2003).
Mellor et al (2003) found that nAChRs in the TE671 cell line were antagonized by
PhTX-12 even at depolarized membrane potential, while this was not the case for
analogues like PhTX-343 and 9-oxa-PhTX-38. Furthermore, the impacts of PhTX-
343 on neuronal nAChRs in rat phaeochromocytoma, PC12, cells using whole cell
SDWFKFODPSPHDVXUHPHQWVZDVLQYHVWLJDWHG,WDSSHDUHGWKDWWKHǴ$&K
HYRNHGLQZDUGFXUUHQWZDVLQKLELWHGE\DQGǴRI3K7;DWKROGLQJ
SRWHQWLDO$OVRWKHLQZDUGFXUUHQWRIǴ$&KDQGǋ0RI3K7;ZDV
gradually reduced during membrane hyperpolarization pulse application starting
from -40 mV to -120 mV; such reduction was not found with application of ACh
alone (Liu et al., 1997).
The position and organization of both shallow and deep non-competitive
binding sites in the pore region of nAChRs was suggested by Tikhonov and his
co-workers. The inhibition mode of blockers such as PhTX-343 results in binding
to the deep site in a mostly voltage- and state-dependent manner in the open
channel conformation, because this site is located beyond the gate (at the
equatorial leucine ring). In contrast, compounds like PhTX-12 antagonize via
shallow sites with a voltage-independent or weak voltage-dependent action
because they do not have to penetrate through the narrowest portion of channel
(Tikhonov et al., 2004).
The likely reason behind these two different modes of inhibition by PhTX-
343 and PhTX-12 is their shape (Figure 1.13). PhTX-12 has a distance of
twelve methylene groups between the single ammonium in the tail region and
the aromatic head, so the molecule can adopt a folded shape in vacuo due to H-
bond formation, whereas in the case of PhTX-343 these bonds form between two
carbonyl groups of the head region and hydrogen atoms of the nearest
ammonium group in the polyamine tail, which give a distinct head and tail
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conformation to PhTX-343 (Tikhonov et al., 2004). Consequently, the diameter
of PhTX-12 is roughly 12 Å, which prevents their penetration in the deep pore
region of nAChRs and binds to the outer pore region, while the roughly 5 Å
diameter of PhTX-343 gives it the ability to penetrate deep in the pore and
interact with the hydrophilic and charged rings.
Figure 1.13. Schematic representation of the proposed mode of orientation and
interaction for PhTX-343 A. head-down B. head-up C. PhTX-12.
1.5. Xenopus oocytes as a system for investigating ion channels
Xenopus laevis oocytes from the South African clawed frog have so far
been used as a versatile expression system for various biological studies. This
system is widely used to express functional ion transport proteins (Sigel, 2010)
due to the low numbers of endogenous transport proteins in their surface
membrane (Dascal, 1987); functional nAChRs have not been detected
(Sumikawa et al., 1981). Gurdon and his colleagues for the first time confirmed
that injection of Xenopus laevis oocyte nuclei with deoxyribonucleic acid (DNA)
or of cytoplasm with ribonucleic acid (RNA) (Figure 1.15) will allow its
processing to produce functional protein (Gurdon et al., 1971; Mertz and
Gurdon, 1977). The electrical properties of newly synthesised ion channels can
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be measured by two-electrode voltage clamp (TEVC) or patch clamp recording
techniques such as inside-out or outside-out (Stuhmer, 1998).
Figure 1.14. Genetic processing of foreign nAChR subunit encoding DNA or RNA
in a Xenopus oocyte.
The first transmembrane ionotropic receptor expressed in Xenopus
oocytes was the nAChR. It appeared that pharmacological properties of
expressed nAChR was mostly similar to the native subtypes, which indicate the
efficiency of this artificial system in assembling different receptor subunits and
their localization in membrane (Sumikawa et al., 1981). Further investigation
about the functional activity of the receptor was done by Barnards group. They
showed that nAChR subunit messenger-RNA injected into the oocyte could
translate and post-translate then insert into their correct location in the
membrane, where they function as a receptor (Barnard et al., 1982).
Xenopus oocytes have many advantages as an experimental tool in the
biology laboratory. They are large, roughly 1 mm in diameter, and easily
obtained (Moeller and Fenton, 2010). An oocyte has the ability to be injected
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with more than 50nl of diluted nucleic acid. Moreover, the hard oocyte plasma
membrane gives more benefits to cells such as surviving during defoliculation,
removal of connective tissues, and easier penetration of the microinjection
pipette (Sigel, 2010). The main advantage of using this artificial system in terms
of nAChR studies is that most of the electrophysiological techniques can be
simply performed on the oocyte. So, after membrane clamping, the effects of a
wide range of natural and synthetic substances (agonist and antagonist) can be
measured on the cell response. These data will help the further understanding of
the receptor-chemical characterization.
1.6. Aims of the project
While philanthotoxin analogues have been well studied at ionotropic
glutamate receptors and M-nAChRs the information of their actions on N-nAChRs
is sparse, restricted mainly to a single study on PC12 cells (Liu et al., 1997). This
suggests that they may be selective for certain neuronal subtypes and this may
reveal more about the binding requirements for philanthotoxins. To address this
gap in our knowledge, we aimed to characterise the effects of PhTX-343 and
numerous analogues on a range of N-nAChR subtypes found in the mammalian
nervous system and compared them to the muscle type receptor.
The first objective was to investigate the action PhTX-343 and PhTX-12
RQ WKH PDMRU ZLOGW\SH DQG PXWDQW 1Q$&K5V LQ &16 DQG 316 Įǃ Įǃ
ĮǃĮǃĮDQG0Q$&K5VĮǃǄįE\WKHLUH[SUHVVLRQLQXenopus oocytes.
The peak and decay current IC50 values for both analogues obtained at -80 mV
by using the two-electrode voltage-clamp technique to generate concentration-
inhibition relationships. Their IC50 values on different investigated subtypes of
nAChRs were compared to evaluate whether there is any subunit-specific
sensitivity difference for inhibition by PhTX-343 or PhTX-12.
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The second objective was to examine the mode of inhibitory action of
PhTX-343 and PhTX-12 on the various nAChR subtypes. Again two-electrode
voltage-clamp was employed to evaluate whether the action of PhTX-343 and
PhTX-12 is dependent or independent on the membrane holding potential.
Furthermore, I investigated whether PhTX-343 or PhTX-12 competed with ACh
for its binding site or not.
The final objective was to conduct a structure-activity study of twenty one
synthetic analogues of PhTX-343, to investigate whether their potency and
VHOHFWLYLW\FRXOGEHLPSURYHGRQUDWQHXURQDOĮǃDQGĮǃQ$&K5V
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CHAPTER TWO
MATERIAL AND METHODS
Summary
We used several molecular biology techniques for nAChR DNA
manipulation and RNA transcription. The heat shock technique was used to insert
the plasmid into E. coli strain XL-1 or X10-gold. DNA was extracted by using a
maxi prep kit from sigma. Agarose gel electrophoresis and DNA sequencing were
used to confirm each subunit. RNA transcription was achieved through two main
steps: linerazion and transcription.
Electrophysiological recordings were taken from microinjected oocytes by
using two-electrode voltage clamp using a Geneclamp 500 voltage and patch
clamp amplifier (Axon instrument). A range of experimental protocols were
applied such as ACh concentration-response relationships, PhTX concentration-
inhibition relationships and voltage-dependence of inhibition.
Data were recorded by using WinEDR computer software and analysed by
using Graphpad prism 6 to calculate different variables such as IC50, EC50DQGį
value.
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2.1. Molecular biology
2.1.1. Chemicals and Plasmids
Restriction enzymes were obtained from New England Biolabs and
Promega. Markers for determination of DNA band size were obtained from Bio-
Rad. E. coli bacteria strain XL-1 and X10-gold were used for DNA manipulation.
All other chemicals were purchased from Sigma. Kits for RNA synthesis were
obtained from Ambion.
Each nAChR subunit gene from rat, mouse and human was provided in a
particular plasmid. The characteristics of all subunits and plasmids are shown in
(Table 2.1). All plasmids have resistance to ampicillin. All plasmids were
REWDLQHG IURP WKH 6DON 5HVHDUFK ,QVWLWXWH H[FHSW KXPDQ Į WKDW ZDV NLQGO\
provided by Prof. David B. Sattelle formerly at the University of Manchester now
DW 8QLYHUVLW\ &ROOHJH /RQGRQ DQG PXWDWHG UDW ǃ(V253F) DQG ǃ(F255V) from Dr.
Cecilia Borghese at the University of Texas at Austin.
Table 2.1. Characteristics of different plasmids used for DNA manipulation.
Subunit Subunit
size (bp)
Plasmid Plasmid
size (bp)
Restriction
enzyme
Linearization
enzyme
Promoter
Rat
Į 2094 pSP64 2999 HindIII EcoRI SP6
Į 1858 pSP64 2999 SmaI(5-)
EcoRI(3-)
EcoRI SP6
ǃ 2522 pBSSK(+) 2958 EcoRI(5-)
XhoI(3-)
XhoI T3
ǃ 2197 pSP65 3005 EcoRI HindIII SP6
Mouse
Į1 1860 pSP65 3005 EcoRI SmaI SP6
ǃ1 2100 pSP65 3005 EcoRI HindIII SP6
Ǆ 1844 pSP64 2999 BamHI(5-)
EcoR1(3)
EcoRI SP6
į 1961 pSP65 3005 EcoRI SmaI SP6
Human
Į7 XbaI T7
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2.1.2. DNA manipulation
Transformation
 7KH SURFHVVHV RI WUDQVIRUPDWLRQ ZDV VWDUWHG E\ DGGLQJ  ǋO RI 
GLOXWHGSF'1$aQJOWRDQ(SSHQGRUIFRQWDLQLQJǋORIFRPSHWHQWFHOOV
and incubated for 20 minutes on ice. The heat shock technique was then used to
insert the plasmid into E. coli strain XL-1 or X10-gold. This was achieved by
putting the sample in a water bath at 42 °C for one minute then placing it on ice
IRUDQRWKHUPLQXWHV$IWHU WKLV WLPHǋORI /%EURWKJ7U\SWRQHJ
yeast extract, and 10 g NaCl in one litre of deionized water) was added to the
sample and left at 37 °C for half an hour. Then cells were gently spread on a
petri dish that contained agar and 50 µg/ml ampicillin (the antibiotic important
for the selection step) and left for 24 hours, after which, colonies had developed.
A single colony was then selected under sterile conditions and transferred to a
tube containing 5 ml of LB broth with 50 µg/ml ampicillin. The sample was
incubated in a shaking bath at 37 °C at 221 rpm, overnight.
Crude DNA extraction
1.5 ml from the above culture was added to a fresh tube and the cells
were centrifuged using an Eppendorf 5417R centrifuge at maximum speed,
14000 rpm, for 1 minute. The supernatant was removed and the pellet was re-
VXVSHQGHGLQǋORIVROXWLRQ,P0JOXFRVHP07ULV&OP0('7$
S+ ǋORIVROXWLRQ,,01D2+IUHVKO\GLOXWHGIURPD0VWRFNDQG
6'6DQGǋORIVROXWLRQ,,,PORI0SRWDVVLXPDFHWDWHPORI
glacial acetic acid, 28.5 ml water; the resulting solution was 3 M with respect to
potassium and 5 M with respect to acetate) were then added. The samples were
mixed gently by inverting the tubes 6 times after adding each of the solutions.
The mixture was next centrifuged for 10 minutes at 14000 rpm, and the
VXSHUQDWDQWZDV WUDQVIHUUHG LQWR D QHZ WXEH1H[W ǋO RI LVRSURSDQROZDV
added to the supernatant and the mixture was again spun at maximum speed,
44
USPIRUPLQXWHV7KHOLTXLGZDVUHPRYHGDQGǋORIHWKDQRO
was added to the pellet without vortexing and the tube was centrifuged, at
 USP IRUPLQXWH 7KH VXSHUQDWDQWZDV UHPRYHGDQGǋO RI GLVWLOOHG
ZDWHUZDVDGGHGWRWKHUHPDLQLQJ'1$SHOOHW7RVWDUW'1$DQDO\VLVǋORIHDFK
SF'1$WKHVDPSOHZDVDGGHGWRǋORIUHVWULFWLRQHQ]\PHWRWDOUHDFWLRQ
YROXPHDQGǋORIHDFKVSHFLILFHQ]\PHEXIIHUDQG%6$PJPODQG WKH
YROXPHZDVPDGHXSWRǋOE\DGGLQJGLVWLOOHGZDWHU
Agarose gel electrophoresis and sequencing
Agar gels were prepared by adding 50 ml of 1x Tris-acetate-EDTA (TAE)
buffer to 0.5 g of agarose and mixing them gently. The mixture was melted in a
PLFURZDYHIRUPLQXWHVDQGWKHQOHIWWRFRROGRZQWR&$IWHUWKDWǋORI
HWKLGLXPEURPLGHǋJPOZDVDGGHGWRYLVXDOL]HSF'1$EDQGVXQGHU89
light. The gel was cast by pouring the agar into the gel holder after the comb
had been placed in the appropriate position. The gel was then left to set and
then put in the electrophoresis tank. 3 µl loading buffer (methylene blue 0.2
mg/ml) and 3 µl pcDNA was mixed on clean parafilm and loaded into the wells
with the first well loaded with 10 µl 1kb ladder only. The cover was gently
placed on and the voltage adjusted to 100 V. This was left to run for 45 minutes.
Upon completion, the bands were visualised using UV light. For further
confirmation, the samples were sent for sequencing by using primers directed at
the specific promoters as shown in Table 2.1 and the result was in a full
agreement with published sequence of each subunit.
DNA maxi preparation
 7KHSURFHVVRI'1$PD[LSUHSDUDWLRQEHJDQE\DGGLQJǋORIFRPSHWHQW
cells that contained plasmids to a conical flask containing 400 ml of LB broth
VROXWLRQ DQG  ǋO RI  JPO DPSLFLOOLQ 7KH PL[WXUH ZDV OHIW VKDNLQJ
overnight. Following this, the solution was centrifuged at 13,000 rpm for 30
minutes. The supernatant was removed and the bacterial pellet was re-
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suspended homogenously in 10 ml of buffer P1. 10 ml of buffer 2 was then
added and the solution was mixed by inverting the tube 4 to 6 times. This was
left to incubate at room temperature for 5 minutes. Then 10 ml of buffer P3 was
added to the solution and mixed thoroughly by inverting the tube 4 to 6 times.
This was left to incubate on ice for 20 minutes. The mixture was then centrifuged
at 13,000 rpm, for 30 minutes.
A QIAGEN-tip was equilibrated by adding 10 ml Buffer QBT and allowing
the column to empty by gravitational flow. After this, the supernatant from the
centrifuge step was added to the QIAGEN-tip and washed twice by adding 30 ml
Buffer QC. DNA was eluted using 15 ml Buffer QF into a clean vessel and
precipitated by adding 10.5 ml isopropanol at room temperature, 25 °C, and
centrifuging at 11,000 rpm, for 30 minutes, at 4 °C. The supernatant was
removed and the DNA pellet was washed with 5 ml of 70% ethanol and
centrifuged again at 11,000 rpm for 10 minutes. Finally, the supernatant was
once again removed and the pellet left to air-dry for 5-10 minutes. The pellet
was then re-suspended in a suitable volume of buffer or distilled water. Following
this, the concentration could be determined by using the nano-drop technique.
2.1.3. In vitro RNA transcription
Linearization of pcDNA
Linearization of pcDNA was achieved by using different restriction
enzymes depending on the plasmid; for more details about plasmids and
enzymes see Table 2.1  J RI SF'1$ DQG  ǋO HDFK RI UHVWULFWLRQ HQ]\PH
buffer (according to type of plasmid) and BSA (0.1 mg/ml) were combined and
WKHWRWDOYROXPHZDVPDGHXSWRǋOE\DGGLQJQXFOHDVHIUHHZDWHU7KLVZDV
mixed gently and left to incubate for 1 hour in a 37 °C water bath. The
HQ]\PDWLFDFWLRQZDV WHUPLQDWHGE\DGGLQJǋORI0('7$ǋORI0
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DPPRQLXP DFHWDWH DQG  ǋO RI  HWKDQRO DQG IUHH]LQJ DW  & IRU 
hour. The mixture was then centrifuged at 14000 rpm, for 15 minutes at 4 °C
DQGWKHSHOOHWVOHIWWRGU\IRUWRPLQXWHVǋORIGLVWLOOHGZDWHUZDVDGGHG
to the DNA pellet and their concentration was determined using a nano-drop.
Transcription
 7RV\QWKHVLVHP51$LQYLWURWRǋJRI OLQHDUL]HG'1$ZLWKǋORI
173&$3DQGǋOHDFKRIHQ]\PH637RU7GHSHQGLQJRQWKHSODVPLGDQG
its reaction buffer were combined. The tube was flicked gently to collect the
mixture in the bottom and then placed in a water bath at 37 °C for 2 hours. The
UHDFWLRQ ZDV WHUPLQDWHG E\ DGGLQJ  ǋO RI QXFOHDVH IUHH ZDWHU DQG OLWKLXP
chloride to precipitate the RNA and placed in the freezer for 1 hour. The mixture
was centrifuged at maximum speed for 15 minutes at 4 °C. The supernatant was
removed and the pellets were washed with 1 ml of 70% ethanol. Finally, these
were centrifuged again at 14000 rpm for 15 minutes at 4 °C. The supernatant
ZDV RQFH DJDLQ UHPRYHG DQG WKH SHOOHW ZDV UHVXVSHQGHG XVLQJ  ǋO RI
nuclease free water. The sample concentrations were determined by nano-drop.
All RNA was stored at -80 °C.
2.2. Electrophysiology procedure
2.2.1. Oocyte preparation
Oocytes isolated from mature female Xenopus laevis were supplied by the
European Xenopus Resource Centre, University of Portsmouth, UK. Oocytes were
treated with collagenase (0.5 mg/ml, Sigma type 1A) in Ca2+-free solution (96
mM NaCl, 2 mM KCl, 1 mM MgCl2, 5 mM HEPES, 2.5 mM Na-pyruvate, 100 U/ml
penicillin, 0.1 mg/ml streptomycin, pH 7.5) with shaking at 19 °C to defolliculate
and remove the connective tissue surrounding the cells. A spherical shape of the
cells remains because it is still surrounded by the vitelline layer. After the
separation of oocytes, they were washed 4-7 times with modified Barths
solution (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, 2.5
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mM Na-pyruvate, 0.5 mM theophylline, 50 mg/ml gentamicin, pH 7.5) and kept
at 19 °C in the same solution.
2.2.2. Selection of oocytes for microinjection
Oocytes were examined under the microscope to select those cells which
looked healthy and had reached stage VI of development. Healthy oocytes
should not damage easily when injected. The selected oocytes were kept in clean
modified Barths solution (MBS) in the 19 °C incubator.
Injection pipettes were prepared from glass capillaries (model 4878,
World Precision Instruments Inc, USA) by using a vertical pipette puller (model
700C, David Kopf Instruments, USA). The end of the capillary was broken
roughly to 15 µm gently under the microscope, filled with paraffin and mounted
onto the nano-liter injector (World Precision Instruments Inc, USA). A mixture of
nAChR subunit RNAs was loaded into the pipette to be ready for injection; for
KHWHURPHULFQHXURQDOUHFHSWRUVDUDWLRRIĮǃ51$DWQJOIRUPRXVH
HPEU\RQLFPXVFOHDUDWLRRIĮǃǊįDWQJOKXPDQĮDWQJO
was mixed with RIC-3 at 30 ng/µl. Each oocyte was injected with 50 nl of RNA
solution. Injected oocytes were saved in Barths solution at 19 °C for two to
three days until mRNA expressed and gave the target protein. During this time
oocytes were regularly checked to remove unhealthy oocytes from the solution.
2.2.3. Assaying oocytes for gene expression
Electrophysiological recordings were taken from injected oocytes by using
two-electrode voltage clamp using a Geneclamp 500 voltage and patch clamp
amplifier (Axon instrument) (Figure 2).
Microelectrodes were prepared from borosilicate glass capillaries (Harvard model
1.5 mm O.D. and 1.17mm I.D.) using a programmable micropipette puller
(model p-97, Sutter instrument company, USA) and had resistances of 0.5-2.5
0ƻZKHQILOOHGZLWK0.&OZKLFKZRUNVDVDJRRGFRQGXFWRUWRPLQLPL]HWKH
series resistance).
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Figure 2. Diagrammatic representation of the main equipment set up used for
current recording in this project. I = current electrode and V= voltage electrode.
Oocytes were placed in the perfusion bath and voltage-clamped with a Gene
clamp 500 amplifier. Perfusion of either ACh alone or co-applied with PhTX
analogue was controlled by an automate 8-valve perfusion system. Data were
recorded to a PC with WinEDR software.
An injected oocyte was put in the perfusion chamber by using a plastic
pasture pipette. The bath was perfused with fresh Frog Ringer solution (96 mM
NaCl, 2 mM KCl, 1.8 mM CaCl2 and 5 mM HEPES, pH 7.5). After lowering the
electrode carefully into the bath, the junction potentials were zeroed and the
electrode resistance was checked. The resistance should be between 0.5 to 2.5
0 LI LW ZDV QRW WKH HOHFWURGH ZDV FKDQJHG 9ROWDJH DQG FXUUHQW HOHFWURGHV
were inserted into the cell. The resting membrane potential was observed on the
Geneclamp 500; there should be agreement between both electrodes and
normally it should be between -20 and -50 mV. The oocyte was voltage clamped
and the holding potential (VH) was altered to the required voltage depending on
the experiment. Agonists and antagonists were applied by an 8-channel
perfusion system (Automate) and agonist evoked currents were recorded to a PC
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via a digidata 1200 analog-to-digital converter (Axon Instuments) using WinEDR
v3.2.6 Software (John Dempster, University of Strathclyde).
A wide range of experiments and solutions were used on the oocyte:
ACh concentration-response relationships  Each nAChR combination was
activated repeatedly by applying a range of ACh concentration (from 10 nM to 1
mM) with one minute application and 6 minutes washing interval depending on
the receptors sensitivity. EC50 values were calculated for the peak current, decay
current and net charge by normalizing all responses as a percentage of the
maximum response.
PhTX-343 concentration-inhibition relationships  A constant
FRQFHQWUDWLRQRIǴWRǴ$&KZDVXVHGLQWKHH[SHULPHQWVGHSHQGLQJ
on the subunit combination and their sensitivity to ACh (EC50). These ACh
concentrations were prepared from a 10 mM stock solution with Frog Ringer.
Experiments examining the impacts of philanthotoxins used PhTX-343 at (10-9 M
- 10-5 M). A 1 mM concentration of PhTX-343 was prepared by adding 0.64 ml of
Frog Ringer to a 0.5 mg aliquot of toxin. Serial dilutions were then carried out in
ACh test solution to create the different concentrations required for testing, i.e.
PhTX-343 was co-applied with a fixed concentration of ACh. The same protocol
was used for all other analogues but adjusting the PhTX concentration range for
increased or decreased potency.
Voltage-dependence of inhibition  The above concentration-inhibition
relationship procedure was repeated for PhTX-343 and PhTX-12 at three
different holding potentials: -60 mV, -80 mV and -100 mV. The IC50 value on
each combination was compared statically at different VH by using student t-test.
The p value was used as an indicator for voltage dependence level of each PhTX
analogue.
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Recovery from inhibition  approximately EC50 ACh concentration was
repeatedly applied at six minute intervals after co-application of the highest
toxin concentration with ACh at VH = -80 mV.
2.3. Data analysis
WinEDR, electrophysiology computer software from the University of
Strathclyde, was used to measure the current amplitude of responses to ACh at
the peak and the decay at the point after one minute application of the
response. In addition, net charge movement, ion exchange, were calculated via
area under curve for the period of a single minute. Also WinWCP from the same
software source was used for estimating time constants. Graphpad prism 6 was
used for data analysis, graph plotting and curve fitting. Concentration-inhibition
and concentration-response curves were used to estimate IC50 and EC50 values
for philanthotoxin analogues and ACh respectively using the following equations:
Where M is the maximum response and nH is the Hill slope.
All plotted points are the mean and standard error of the mean from 3-15
oocytes. IC50s and EC50s were compared using an unpaired t-test.
An adapted version of the Woodhull (1973) equation, that describes the
action of single site ion channel blockers, was used to obtain further knowledge
about PhTX-343 and PhTX-12 binding sites in relation to the nAChR pore. The
IC50 (95% CI) data was plotted against VH and fitted with Eq. 3 to determine the
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SHQHWUDWLRQGLVWDQFHįRIHDFKEORFNLQJFRPSRXQGLQWKHPHPEUDQHHOHFWULFDO
field.
To calculate the time constant (tau) value for the desensitization rate of
wild type nAChR current decay, we used a two exponential equation to calculate
fast (tau-1) and slow (tau-2) time constants for each combination.
Where A1 and A2DUHDPSOLWXGHVRIWKHIDVWDQGVORZFRPSRQHQWVDWW Ĳ1 and
Ĳ2 are the fast and slow time constants, and Ss is the steady state current.
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CHAPTER THREE
ELECTROPHYSIOLOGICAL CHARACTERIZATION OF THE RESPONSE
OF nAChRs TO ACh
Summary
The whole-cell response of eight different combinations of nAChRs
expressed in Xenopus oocytes was extensively characterized. The peak current,
decay current and net charge movement criteria were estimated from 1 minute
ACh applications. It appears from our data that these three criteria are subunit
dependent. For instance, the results from our study show that the peak current
EC50 values of nAChRs calculated from concentration response curves were
PRVWO\GHSHQGHQWRQWKHĮVXEXQLWZLWKDUDQNRUGHUIURPKLJKWRORZRIĮ!
Į ! Į ! Į ,Q DGGLWLRQ WKH UHVSRQVH GHVHQVLWL]DWLRQ UDWH ZDV PRVWO\
GHSHQGHQW RQ WKH ǃVXEXQLW ZLWK UDQN RUGHU IURP IDVWHU WR VORZHU RI QRQǃ
FRQWDLQLQJ!ǃ!ǃ!ǃFRQWDLQLQJUHFHSWRUV$OVRZHVKRZHGWKDWH[FKDQJH
RIDVLQJOHDPLQRDFLGGLIIHUHQFHEHWZHHQWKH0GRPDLQRIǃVXEXQLWDQGǃ
subunit significantly reduced the peak current EC50YDOXHRIĮǃQ$&K5VZKLOH
LWLQFUHDVHGLWIRUĮǃQ$&K5V7KLVOHGXVWRFRQFOXGHWKDWUHSODFLQJYDOLQH
E\ SKHQ\ODODQLQH LQ WKH UDW ǃVXEXQLW LQFUHDVHG VHQVLWLYLW\ WR $&K ZKLOH
VXEVWLWXWLRQVRISKHQ\ODODQLQHE\YDOLQHLQWKHǃVXEXQLWUHGXFHGVHQVLWLYLW\
to ACh.
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3.1. Pharmacological characterization of the ACh response of
mammalian nAChRs expressed in Xenopus oocytes
To confirm that Xenopus oocytes originally did not express any functional
subtype of nAChRs, the highest ACh concentration used in this work, 1mM, was
applied to un-injected clamped (VH = -80 mV) oocytes. This did not cause any
detectable response (data not shown). However, application of 1 mM ACh to
oocytes injected with transcribed mRNA from cDNA encoding subunits of
QHXURQDO  KRPRPHULF Į RU KHWHURPHULF  Į RU   ǃ RU  RU PXVFOH
HPEU\RQLF W\SH ĮǃįǄ VKRZHG VWURQJ UHFHSWRU DFWLYDWLRQ ZKLFK LQGLFDWHV
that Xenopus oocytes express the target receptor and can be used as an
expression system for this group of receptors.
A single injected oocyte was placed in a perfusion chamber (0.5 ml) and
constantly perfused with Xenopus ringer during the recording. The oocytes were
clamped at -80 mV and perfused with a range of increasing ACh concentrations
depending on the sensitivity of expressed combination in oocytes, with 6 minute
intervals between each application. The EC50 values for the peak response, decay
response and net charge transfer were calculated from concentration-response
curves (Figure 3.1.) and presented as mean (95% CI) in Table 3.1. Based on
the peak current EC50 value the sensitivity order of nAChRs to ACh based on their
ĮVXEXQLW IURP ORZHU WR KLJKHU ZDV Į  Į  Į  Į KRPRPHULF Į KDG
URXJKO\ WKHVDPH$&K VHQVLWLYLW\DVKHWHURPHULFĮǃDQGIROGIROG
IROGDQGIROGORZHUWKDQĮǃĮǃįǄ ĮǃDQGĮǃQ$&K5VUHVSHFWLYHO\
On the other hand, the decay current EC50 YDOXHZDVPRVWO\GHSHQGHQWRQWKHǃ
VXEXQLW LQHDFKVXEW\SH)RUH[DPSOHH[SUHVVLRQRIǃZLWKĮRUĮVXEXQLWV
VKRZHG IROG DQG IROG UHGXFWLRQ LQ $&K VHQVLWLYLW\ FRPSDUHG WR ǃ
containing nAChRs, respectively.
The shape of the response generated by 100 µM ACh was considerably
different in desensitization rate and hence net charge movement among
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investigated combinations of nAChRs. The most rapid desensitization was
REVHUYHG IRU UHFHSWRUV FRQWDLQLQJ ĮVXEXQLW DORQH IROORZHG E\ ǃFRQWDLQLQJ
ǃFRQWDLQLQJDQGILQDOO\WKHPXVFOHVXEW\SHQ$&K5V(Figure 3.1. Trace). The
highest EC50 YDOXHEDVHGRQQHW FKDUJHPRYHPHQWZDV UHFRUGHG IRUĮǃDQG
was 76 µM. The data points for the decay response to ACh at concentrations
KLJKHU WKDQ  Ǵ GR QRW ILW WR WKH VLJPRLGDO FXUYH EHFDXVH WKH UHVSRQVHV
became smaller, which suggests an antagonist action for ACh. This inhibition
DFWLYLW\ RI $&K ZDV KLJKHU LQ LQ ǃFRQWDLQLQJ Q$&K5V FRPSDUHG WR RWKHU
subtypes.
To further investigate whether substitution of aromatic phenylalanine at
SRVLWLRQRIǃVXEXQLW0GRPDLQE\DOLSKDWLFYDOLQHRUYLFHYHUVDLQWKHǃ
subunit at position 253 had any effect on signal transduction from receptor
activation to gate opening or not, we compared the EC50 values calculated from
FRQFHQWUDWLRQUHVSRQVH FXUYHV RI Įǃ(V253F) DQG Įǃ(F255V) with wild type
nAChRs. It appears that the peak current EC50 YDOXH RI Įǃ(V253F) was
VLJQLILFDQWO\ ORZHU WKDQ IRUĮǃ S ZKLOH LQ WKH FDVHRI Įǃ(F255V)
the peak current EC50YDOXHZDVVLJQLILFDQWO\KLJKHUWKDQIRUĮǃS
In both cases the decay current EC50 values were not significantly different
between mutant and wild-type.
Also time constants for desensitization of nAChRs (fast, tau 1 and slow,
tau 2) were calculated by using Eq. 4. There was no significant difference
EHWZHHQWDXRUWDXYDOXHVRIZLOGW\SHDQGPXWDWHGĮǃDQGĮǃQ$&K5V
as shown in Table 3.2, which indicates no critical role of this single amino acid
PRGLILFDWLRQRQWKHGHVHQVLWL]DWLRQUDWH,WDSSHDUVWKDWǃFRQWDLQLQJUHFHSWRUV
KDYH KLJKHU WDX YDOXHV WKDQ ǃFRQWDLQLQJ ZKLFK IXUWKHU VXSSRUW WKH VORZ
desensitization rate proposed for UHFHSWRUV FRQWDLQLQJ ǃVXEXQLWV RYHU ǃ
VXEXQLWV2QWKHRWKHUKDQGĮKDVORZHVWWDXYDOXHVDQG0Q$&K5VKDVWKH
highest value.
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Figure 3.1. Characterization of ACh response across six different subunit
combinations of nAChRs. Traces shown are whole-cell current recorded at a
KROGLQJ SRWHQWLDO RI  P9 HOLFLWHG E\ D RQH PLQXWH SXOVH RI  Ǵ $&K LQ
oocytes injected with Įǃ Įǃ Įǃ Įǃ Į ĮǃįǄ Q$&K5V
Concentration-response curves for peak current, decay current and net charge of
each nAChR subtype were constructed. The data points for each curve were
normalized to the maximal response and plotted as mean ± S.E.M. The curves
are fits of Eq. 2. Calculated EC50 for each receptor subtype are shown in Table
3.1.
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Table 3.1. Estimated ACh EC50 (µM) values for peak, decay and net charge
response of oocytes injected with mRNA encoding the UDW Į RU Į VXEXQLWV
HLWKHUZLWKǃRUǃVXEXQLWVPRXVHHPEU\RQLFPXVFOHW\SHQ$&K5VDQGKXPDQ
KRPRPHULFĮDWDKROGLQJSRWHQWLDORIP99DOXHVDUHDYHUDJHRIQQXPEHU
of tested oocytes. 5HFHSWRUV FRQWDLQLQJ Į RU ĮVXEXQLWV VKRZHG D ORZHU
VHQVLWLYLW\WR$&KFRPSDUHGWRWKRVHFRQWDLQLQJĮRUĮVXEXQLWV
nAChRs
n
EC50 µM (95% CI)
Peak Decay Net charge
Įǃ 5 10 (7.4-15) 1.5 (0.8-2.9) 2.7 (1.7-4.2)
Įǃ(V253F) 5 4.8 (3.3-7.0) 1 (0.6-1.7) 1.6 (1.0-2.3)
Įǃ 12 7.2 (5.4-9.5) 5.2 (2.4-11.3) 4.7 (3.0-7.3)
Įǃ 5 25 (17-36) 5.4 (3.2-8.9) 5.8 (4.1-8.1)
Įǃ 8 116 (105-129) 65 (46-91) 76 (53-109)
Įǃ(F255V) 5 209 (183-238) 57 (30-106) 104 (91-120)
Į 6 150 (129-175) 29 (18-46)
ĮǃǄį 6 12 (10-15) 4.5 (1.3-15) 6.5 (4-10)
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Table 3.2. Comparison of current decay tau values of wild-type and mutated N-
Q$&K5VIRUUHVSRQVHVWR0$&KIRUǃFRQWDLQLQJUHFHSWRUVRU0$&K
IRU RWKHU FRPELQDWLRQV %RWK Įǃ(V253F) DQG Įǃ(F255V) did not show any
significant change in their tau 1 and tau 2 values compared to their wild-types.
ǃFRQWDLQLQJ UHFHSWRUV VKRZHG KLJKHU WDX YDOXHV FRPSDUHG WR ǃFRQWDLQLQJ
Q$&K5V7KH ORZHVW WDXYDOXHVZHUH UHFRUGHG IRUĮDQG WKHKLJKHVW IRUĮǃ
(tau 1) or embryonic M-nAChRs (tau 2).
Tau 1 (s)
(S.E.M)
Tau 2 (s)
(S.E.M)
n
Įǃ 3.19
(0.93)
23.14
(2.92)
5
Įǃ(V253F) 2.42
(0.59)
15.12
(1.72)
5
P value 0.2131 0.453
Įǃ 12.63
(5.53)
331.13
(111.71)
5
Įǃ(F255V) 5.84
(1.1)
73.1
(8.7)
4
P value 0.32 0.0815
Įǃ 4.12
(3.48)
44.37
(12.42)
4
Įǃ 2.1
(0.72)
27.42
(8.44)
3
Į 0.79
(0.31)
17.98
(10.1)
5
ĮǃįǄ 1.45
(213)
401.95
(352.54)
2
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Figure 3.2. Combined rat Įǃ, Įǃ(V253F), Įǃ and Įǃ(F255V) N-nAChR
concentration-response curves for peak current, decay current and net charge
transfer at holding potentials of -80 mV. The points are mean ± S.E.M. of n
oocytes normalized data to the maximum ACh response from same cells and fits
are to Eq. 2.
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&XUUHQWYROWDJHFKDUDFWHULVWLFVRIĮǃQ$&K5V
The current-voltage (I-V) characteristics of ACh responses of neuronal
ĮǃQ$&K5VZDVH[DPLQHGE\DSSO\LQJǴ$&KIRUPLQXWHDWVL[PLQXWH
intervals at different holding potentials beginning with +40 mV and changing by
-20 mV gradually for each application up to -140 mV. Whole-cell currents were
normalized to the maximum response (at -140 mV) and mean values are plotted
against voltage in Figure 3.3. The current was inwardly rectifying.
Figure 3.3.&XUUHQWYROWDJHUHODWLRQVKLSRIĮǃ1Q$&K5UHVSRQVHV WRǴ
ACh. Points are mean normalized response ± S.E.M. for 2-6 oocytes plotted
against VH. Some error bars are smaller than the symbol size and are not shown.
5HFRYHU\RIĮǃQ$&K5VIURPGHVHQVLWL]DWLRQE\Ǵ$&K
 7KH UHFRYHU\ UDWH RI Įǃ Q$&K5V IURP $&K GHVHQVLWL]DWLRQ ZDV
investigated by using 10 µM applications separated by variable time periods from
1 to 8 minutes at a holding potential of -80 mV. Each ACh response was
normalized as % of the initial ACh response and plotted against the time period
separating it from the previous response (Figure 3.4.A). Full recovery to the
first ACh peak value was not obtained during the experimental time period but a
time interval between 5 to 7 minutes showed the best recoveries of control
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response. Further investigation showed that 6 minutes is the best time interval
EHWZHHQGLIIHUHQWDSSOLFDWLRQVRI$&KWRHQVXUHDVWDEOHUHVSRQVHWRǋ0$&K
Figure 3.4.B shows the stability of ACh peak current and decay current
responses to a series of 10 µM ACh applications, each separated by 6 minutes.
Therefore, this interval was used as control between each application of ACh
throughout the whole study.
Figure 3.4. 5HFRYHU\ RI ZLOG W\SH UDW Įǃ $&K UHVSRQVHV IURP  Ǵ
desensitization, (A) recovery of peak amplitude currents from desensitization at
different interval time, (B) show recovery percentage of a series of 10 µM ACh
applications separated by constant 6 minute intervals for peak and decay
current, respectively. The data points for tested ACh peak and decay response
current were normalized with control response and plotted against application
interval time as mean ± S.E.M. (n = 7 oocytes).
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CHAPTER FOUR
PHARMACOLOGICAL CHARACTERIZATION OF nAChR INHIBITION
BY PhTX-343
Summary
The pharmacological actions of PhTX-343 on recombinant nAChRs
expressed in Xenopus oocytes after micro-injection with mRNA was investigated
by using TEVC. Concentration-inhibition curves for PhTX-343 were constructed
for each combination of nAChR subunits at -60 mV, -80 mV and -100 mV. ACh
EC50 concentration was used as a control and applied for 1 minute with 6
minutes interval either alone or co-applied with PhTX-343 at various
concentrations ranging between 0.1 nM to 100 µM depending on subtype
sensitivity. A four-parameter logistic equation was used to calculate peak and
decay current IC50 values by plotting PhTX-343 concentration against the mean
RI QRUPDOLVHG FXUUHQW DVRI FRQWURO UHVSRQVH ,W DSSHDUV WKDW WKH ǃVXEXQLW
ZDV PRUH FULWLFDO IRU 3K7; LQKLELWLRQ WKDQ WKH ĮVXEXQLW 3K7; KDG
VHOHFWLYLW\IRUǃFRQWDLQLQJRYHUǃFRQWDLQLQJQ$&K5VǃFRQWDLQLQJUHFHSWRUV
DSSHDUHGWREHPRUHDIIHFWHGE\DOWHUDWLRQRIWKHPHPEUDQHSRWHQWLDOWKDQǃ
containing receptors by comparing the peak current IC50s at -60 mV and -100
P9 DQG WKH DEVHQFH RI D ǃVXEXQLW FKDQJHG 3K7; LQKLELWLRQ WR YROWDJH
independent. The IC50 values were used in an adapted Woodhull equation to
SUHGLFWWKHLQWHUDFWLRQVLWHRI3K7;LQWKHFKDQQHOE\FDOFXODWLQJWKHįYDOXH
PhTX-343 inhibition was non-competitive because it did not shift the ACh EC50
value significantly.
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4.1. Effects of PhTX-343 on ACh-induced responses of wild-type and
mutant nAChRs
The Xenopus oocytes expressing functional homomeric or heteromeric N-
Q$&K5VĮĮǃ Įǃ(V253F)ĮǃĮǃ Įǃ(F255V)ĮǃDQGĮǃįǄZHUH
used to investigate the pharmacological action of PhTX-343 on receptor function.
7KHKLJKHVWFRQFHQWUDWLRQRI3K7;XVHGLQWKLVVWXG\ǴZDVDSSOLHG
alone (at VH = -80 mV) to oocytes expressing nAChRs. This did not produce any
response. In contrast co-application of PhTX-343 with roughly EC50 concentration
of ACh inhibited the peak and decay current of each subtype of nAChRs in a
concentration-dependent manner (Figure 4.1., 4.2. and 4.5.). Stronger
inhibition was observed for the decay current in comparison to the peak current.
At concentrations lower than 10 nM, PhTX-343 slightly potentiated the ACh
FRQWURO UHVSRQVH FXUUHQWV LQGXFHG E\ Įǃ Į DQG ĮǃįǄ The IC50s were
calculated for peak and decay currents from a plot of percentage current
inhibition by PhTX-343 and presented as mean values (95% CI) in Table 4.1.
Figure 4.1. Example trace from two-electrode voltage clamp recording protocol
used in this study and showing amplitude and 1 minute position on the response
used to calculate peak and decay current IC50 values.
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Figure 4.2. Example traces showing the sensitivity of nAChR subtypes to
inhibition by PhTX-343. Approximately EC50$&KFRQFHQWUDWLRQ0IRUĮǃ
ĮǃDQGĮǃįǄ0 IRUĮǃDQG0 IRUĮǃDQGĮQ$&K5V was
perfused to oocytes clamped at -80 mV to generate control (Red). Then,
increasing concentrations of PhTX-343 (other colours) was co-perfused with ACh
at six minute intervals. Stronger current inhibition was observed by PhTX-343 on
WKHǃFRQWDLQLQJQ$&K5VRYHUĮĮǃįǄDQGǃFRQWDLQLQJFRPELQDWLRQV
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First, the inhibitory effect of PhTX-343 was evaluated on the nAChRs with
WKHPDMRUEUDLQĮVXEXQLWĮLQFRPELQDWLRQZLWKHLWKHUǃRUǃDWDKROGLQJ
potential of -80 mV (Table 4.1). The PhTX-343 IC50 value for peak and decay
LQKLELWLRQRIĮǃZDVURXJKO\IROG0DQGIROG0ORZHUWKDQ
FDOFXODWHG IRUĮǃQ$&K5V UHVSHFWLYHO\7KHVH UHVXOWV VXJJHVW WKDW3K7;
SRWHQF\ LQQ$&K5VFRQWDLQLQJĮVXEXQLWVGHSHQGVRQ WKHǃVXEXQLW ,W VHHPV
WKDW 3K7; KDV D UHODWLYHO\ ORZHU DIILQLW\ IRU ELQGLQJ VLWHV RQ Įǃ LQ
FRPSDULVRQWRWKHĮǃFRPELQDWLRQ
Secondly, the pharmacological effects of PhTX-343 were investigated on
WKHPDLQJDQJOLRQLFQ$&K5ĮVXEXQLWĮH[SUHVVHG LQXenopus oocytes either
ZLWKǃRUǃVXEXQLWVDWP9(Table 4.1). IC50 values obtained from peak
DQG GHFD\ FXUUHQW LQKLELWLRQ RI Įǃ E\ 3K7; ZHUH  Q0 DQG  Q0
respectively. The IC50YDOXHIRUǃFRQWDLQLQJUHFHSWRUVZDVFRQVLGHUDEO\KLJKHU
WKDQǃFRQWDLQLQJVXEW\SHVZKHQFRPELQHGZLWKWKHĮVXEXQLW7KHSRWHQF\RI
3K7;RQĮǃQ$&K5VZDV UHGXFHGE\IROGRQSHDN current and 137-
fold on decay current compared to the major ganglionic subtype of nAChRs,
Įǃ7KHVHUHVXOWVIXUWKHUVWURQJO\VXSSRUWWKHSUHYLRXVQRWLRQWKDW3K7;
KDVDKLJKHUDIILQLW\IRUǃFRQWDLQLQJUHFHSWRUVZLWKĮVXEXQLWUDWKHUWKDQǃ
containing.
The data from both previous experiments was further analysed to
LQYHVWLJDWHWKHUROHRIWKHĮVXEXQLW7KH,&50 YDOXHRIǃVXEXQLWLQFRPELQDWLRQ
ZLWK Į ZDV DSSUR[LPDWHO\ WLPHV DQG WLPHV KLJKHU RQ SHDN current and
decay FXUUHQW WKDQ RI Įǃ Q$&K5V ZKHUHDV WKH ,&50 YDOXH RI ǃ H[SUHVVLRQ
ZLWKĮZDVIROGDQGIROGORZHUWKDQWKDWRIĮǃSHDNDQGGHFD\FXUUHQW
UHVSHFWLYHO\ 7KH KLJK DIILQLW\ RI 3K7; WR ĮVXEXQLW LQ ǃFRQWDLQLQJ DQG
ĮVXEXQLWLQǃFRQWDLQJQ$&K5VLVLQDJUHHPHQWZLWKWKHSUHYLRXVVXJJHVWLRQ
WKDW DIILQLW\ RI 3K7; LV GHSHQGHQW PRVWO\ RQ WKH W\SH RI ǃVXEXQLW UDWKHU
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WKDQ WKH ĮVXEXQLW 7KH KLJKHVW ,&50 YDOXHV ZHUH UHFRUGHG IRU ǃFRQWDLQJ
Q$&K5VZKLOHWKHORZHVWZHUHREVHUYHGIRUǃFRQWDLQJQ$&K5V
To further highlight the possible reason behind a high affinity of PhTX-343
IRU ǃFRQWDLQLQJ RYHU ǃFRQWDLQLQJ Q$&K5V ZH FRPSDUHG WKH DPLQR DFLG
VHTXHQFHRI ERWKǃVXEXQLWV ,GHQWLFDOPHPEUDQH WRSRORJ\KDVEHHQSURSRVHG
for all subunits of nAChRs. Comparison of data from the amino acid sequence
DOLJQPHQWVKRZVRYHUVLPLODULW\EHWZHHQǃDQGǃVXEXQLWVZLWKOHVVWKDQ
10% variation in some regions (Figure 4.3). This analysis shows several
changes in various parts of both subunits, particularly in N-terminals with only a
VLQJOH DPLQR DFLG YDULDWLRQ LQ WKH 0 GRPDLQ ǃ(V253), ǃ(F255)). The impact of
WKLVVLQJOHYDULDWLRQDQGVHYHUDOFKLPHULFVXEXQLWVFRQVWUXFWHGIURPǃǃKDV
been investigated previously on the potency of other inhibitors of nAChRs such
as cocaine (Francis et al., 2000) and substance P (Stafford et al., 1998). To
evaluate the role of these single amino acids in this position of the pore, the
HIIHFWV RI 3K7; ZHUH LQYHVWLJDWHG RQ PXWDWHG UHFHSWRUV Įǃ(V253F) and
Įǃ(F255V).
 ,QKLELWLRQ RI Įǃ(V253F) DQG Įǃ(F255V) by PhTX-343 was concentration
dependent (Figure 4.4). The peak current IC50 YDOXHRIĮǃ(F255V) was reduced
by about 3-fold with no noticeable change in the decay current value compared
WR Įǃ Q$&K5V ZKLOH LQ WKH FDVH RI Įǃ(V253F) an approximately 3-fold
reduction was calculated for decay current IC50 with no change for the peak
FXUUHQWYDOXHFRPSDUHGWRĮǃQ$&K5V7KHVHGDWDDOWKRXJKVXJJHVWLQJVRPH
involvement in PhTX-343 interaction, did not support the idea that a single
amino acid difference in the M2 domain is responsible for the high affinity of
3K7;IRUǃFRQWDLQLQJRYHUǃFRQWDLQLQJQ$&K5VZKLFKKDVEHHQSURSRVHG
for other open channel blockers. This mutation is explained in more detail in the
voltage- dependence section.
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 7RIXUWKHUKLJKOLJKWWKHVHFRQIOLFWLQJUHVXOWVREWDLQHGZLWKĮǃ(V253F) and
Įǃ(F255V) combinations of nAChRs with PhTX-343, we decided to substitute the
ĮVXEXQLWEHWZHHQERWKFRPELQDWLRQVDQGJHQHUDWHĮǃ(F255V)DQGĮǃ(V253F) N-
nAChRs (Figure 4.6). IC50 values for PhTX-343 inhibition at -100 mV were 0.5
µM (0.3-0.7 µM) for peak current and 17 nM (10-27 nM) for decay current for
Įǃ(F255V) receptors. These values are not significantly different from that
REWDLQHGIURPZLOGW\SHUDWĮǃQ$&K5V%DVHGRQWKHVHUHVXOWVLWVHHPVWKDW
SKHQ\ODODQLQHDWSRVLWLRQRIǃ LVQRW UHVSRQVLEOH IRU WKHGLIIHUHQFH LQ WKH
3K7;VHQVLWLYLW\2QWKHRWKHUKDQGWKHVHQVLWLYLW\RIĮǃ(V253F) for PhTX-
343 inhibition was increased by 2-fold (IC50 1.5 µM) on the peak current and by
IROG  Q0 RQ WKH GHFD\ FXUUHQW FRPSDUHG ZLWK WKH Įǃ Q$&K5V 7KH
UHVXOWV REWDLQHG IURP WKLV SRLQW PXWDWLRQ LQ WKH ǃVXEXQLW YDOLQH DW SRVLWLRQ
253 by phenylalanine, show a role of this position in PhTX-343 sensitivity but
this might not be through direct contact with the toxin at a binding site but
through changing receptor properties such as desensitization.
Finally, to further improve knowledge on the profile of PhTX-343
across nAChRs and their relationship with auxiliary subunits, their action was
LQYHVWLJDWHG LQ KRPRPHULF Į Q$&K5V ZLWK QR DX[LOLDU\ VXEXQLWV DQG PXVFOH
W\SH Q$&K5V ZKLFK FRQWDLQ PRUH WKDQ RQH VHFRQGDU\ VXEXQLW ĮǃįǄ (Table
4.1). The latter combination showed a roughly 2-fold increase in peak and decay
current IC50 value FRPSDUH WR WKHKRPRPHULFĮ7KHSRWHQF\RI3K7;RQ
decay current of both M-nAChRs and homomeric N-nAChRs was lower compared
to all other tested heteromeric N-nAChRs. These data suggest that the absence
of secondary subunits or having more than one type reduces the activity of
PhTX-343 on nAChRs.
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Uȕ5/$1$((./0''//1.75<11/,53$76664/,6,5/(/6/64/,691(5(4,0776,:/
Kȕ59$1$((./0''//1.75<11/,53$76664/,6,./4/6/$4/,691(5(4,07719:/
Uȕ7'7((5/9(+//'365<1./,53$71*6(/9794/096/$4/,69+(5(4,07719:/
Kȕ7'7((5/9(+//'365<1./,53$71*6(/9794/096/$4/,69+(5(4,07719:/
Uȕ.4(:7'<5/$:166&<(*91,/5,3$.59:/3',9/<11$'*7<(969<719,9561*6,
Kȕ.4(:7'<5/7:1665<(*91,/5,3$.5,:/3',9/<11$'*7<(969<71/,9561*69
Uȕ74(:('<5/7:.3(')'10..95/36.+,:/3'99/<11$'*0<(96)<61$996<'*6,
Kȕ74(:('<5/7:.3(()'10..95/36.+,:/3'99/<11$'*0<(96)<61$996<'*6,
Uȕ4:/33$,<.6$&.,(9.+)3)'441&7/.)56:7<'+7(,'09/.637$,0'')736*(:
Kȕ/:/33$,<.6$&.,(9.<)3)'441&7/.)56:7<'+7(,'09/0737$60'')736*(:
Uȕ):/33$,<.6$&.,(9.+)3)'441&70.)56:7<'57(,'/9/.6'9$6/'')736*(:
Kȕ):/33$,<.6$&.,(9.+)3)'441&70.)56:7<'57(,'/9/.6(9$6/'')736*(:
Uȕ',9$/3*5579134'36<9'97<'),,.5.3/)<7,1/,,3&9/,76/$,/9)</36'&*
Kȕ',9$/3*5579134'36<9'97<'),,.5.3/)<7,1/,,3&9/77//$,/9)</36'&*
Uȕ',,$/3*551(13''67<9',7<'),,55.3/)<7,1/,,3&9/,76/$,/9)</36'&*
Kȕ',9$/3*551(13''67<9',7<'),,55.3/)<7,1/,,3&9/,76/$,/9)</36'&*
Uȕ(.07/&,69//$/7FFLLLISKIVPPTSLDIPLIGKYLLFTMVLVTFSIVTTVCVLNVHH 300
Kȕ(.07/&,69//$/7FFLLLISKIVPPTSLDVPLIGKYLMFTMVLVTFSIVTSVCVLNVHH 300
Uȕ(.07/&,69//$/7VFLLLISKIVPPTSLDVPLVGKYLMFTMVLVTFSIVTSVCVLNVHH 298
Kȕ(.07/&,69//$/7VFLLLISKIVPPTSLDVPLVGKYLMFTMVLVTFSIVTSVCVLNVHH 298
Uȕ56367+70$6:9.(&)/+./37)/)0.53*/(96/9593+364/+/$7$'7$$76$/*37
Kȕ56367+70$3:9.5&)/+./37)/)0.53*3'663$5$)336.6&97.3($7$767
Uȕ56377+70$3:9.99)/(./37//)/4435+5&$545/5/55545(5(*$*$/))5
Kȕ56377+70$3:9.99)/(./3$//)04435++&$545/5/55545(5(*$*$/))5
Uȕ6361/<*660<)91393$$3.6$966+7$*/35'$5/566*5)5('/4($/(*96),$4+
Kȕ6361)<*160<)913$6$$6.63$*6739$,35'):/566*5)54'94($/(*96),$4+
Uȕ(*3$$'3&7&)913$694*/$*$)5$(37$$*3*569*3&6&*/5($9'*95),$'+
Kȕ($3*$'6&7&)915$694*/$*$)*$(3$39$*3*56*(3&*&*/5($9'*95),$'+
Uȕ/(6''5'469,(':.)9$099'5/)/:9)9)9&,/*70*/)/33/)4,+$36.'6
Kȕ0.1''('4699(':.<9$099'5/)/:9)0)9&9/*79*/)/33/)47+$$6(*3<$$45
Uȕ056('''4695(':.<9$09,'5/)/:,)9)9&9)*79*0)/43/)41<7$77)/+3'+6
Kȕ056('''4696(':.<9$09,'5/)/:,)9)9&9)*7,*0)/43/)41<7777)/+6'+6
Uȕ
Kȕ'
Uȕ$366.
Kȕ$366.
Figure 4.3. Multiple sequence alignments of the rat (r) and human (h) neuronal
ǃ DQG ǃ DPLQR DFLG VHTXHQFHV E\ XVLQJ &OXVWDO: VRIWZDUH 7KH IRXU
transmembrane domains are shown in boxes and the single amino acid
difference in the M2 domain and linker region between M2 and M3 are
highlighted in colour.
253
255
M1
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Figure 4.4. Example traces showing the sensitivity of inhibition of mutated
nAChR subtypes to PhTX-343. Approximately EC50 ACh concentration (10 µM for
Įǃ(V253F)DQG0IRUĮǃ(F255)) was perfused over oocytes clamped at -80
mV to generate a control (Red), then increasing concentrations of PhTX-343
(other colours) were co-perfused with ACh at 6 minute intervals.
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Figure 4.5. Screening PhTX-343 inhibitory effects on Peak (A) and decay (B)
current of eight different subunit combinations of nAChRs expressed in Xenopus
oocytes at a holding potential of -80 mV. Graphs are concentration-inhibition
data plotted as mean % control response vs PhTX-343 concentration for peak
current (top) or decay current (bottom) and curve fits are to Equation 1. Decay
FXUUHQWIRUĮ QHWFKDUJH
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Figure 4.6. Combined rat Įǃ, Įǃ(F255V) and Įǃ, Įǃ(V253F) N-nAChRs
concentration-inhibition curves for inhibition of peak and decay of EC50
concentration ACh evoked response by PhTX-343 at holding potential of -100
mV. The points are mean ± S.E.M. of n oocytes normalized data to the control
ACh response from same cells and fits to equation 1. Peak and decay current
IC50 values of Įǃ(F255V) were not significantly different from the wild-type Įǃ
nAChRs, while a significant decrease in IC50 values were recorded for the peak (
p=0.0114) and decay ( p<0.0001) current of Įǃ(V253F) compared to wild-type
Įǃ nAChRs.
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4.2. Voltage-dependent and -independent inhibition of nAChRs by PhTX-
343
Another approach to evaluate the mechanism of action of PhTX-343
across nAChRs is to investigate their binding site positions in relation to the
membrane electric field. These experiments investigated the effect of alterations
in membrane VH RQWKH LQKLELWRU\DFWLRQRI3K7; IRUĮĮǃĮǃ(V253F),
Įǃ Įǃ Įǃ(F255V) Įǃ DQG ĮǃįǄ VXEXQLW FRPELQDWLRQV For each
combination, concentration-inhibition curves for PhTX-343 were constructed at
three different holding potentials, -60 mV, -80 mV and -100 mV. These
combinations were studied to evaluate the contribution of each subunit to the
binding sites and to find the optimum binding sites for PhTX-343 among these
combinations (Table 4.1).
Voltage-dependence was observed for the inhibition of muscle-type,
ĮǃįǄQ$&K5VE\3K7;(Figure 4.7.A), suggesting that PhTX-343 binds
WR D VLWH LQVLGH WKH FKDQQHO SRUH 3K7; DW D FRQFHQWUDWLRQ  Ǵ RU OHVV
showed roughly 10% potentiation of ACh control amplitude in oocytes clamped
at -60 mV, while 100 µM inhibited approximately 90% of peak and decay current
when compared to control. At VH = -80 mV, peak and decay IC50 (95% CI)
values of PhTX-343 were 15 µM (9-23 µM) and 12 µM (8-18 µM) respectively.
These values increased 1.8-fold on the peak and 1.5 fold on the decay current
when the membrane holding potential was increased to -60 mV, whereas shifting
VH to -100 mV reduced both IC50 values roughly 5-times compared to those at -
80 mV.
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Table 4.1. Summary of PhTX-343 Peak P and decay D current IC50 values on
eight different combinations of nAChRs at three different holding potentials, -60
mV, -80 mV and -100 mVµ'¶LQFDVHRIĮ QHWFKDUJH9DOXHVDUHSUHVHQWHG
in µM as mean IC50 (95% CI) and (n) is the number of tested oocytes.
6HQVLWLYLW\ RI ǃFRQWDLQJ Q$&K5V IRU LQKLELWLRQ E\ 3K7; ZDV KLJKHU
FRPSDUHG WR ǃ ǃ DQG QRQǃFRQWDLQLQJ Q$&K5V 9ROWDJHGHSHQGHQFH ZDV
REVHUYHGIRUDOOQ$&K5VXEXQLWFRPELQDWLRQVH[FHSWKRPRPHULFĮ
nAChRs VH= -60 mV VH= -80 mV VH= -100 mV
Įǃ
P 1.9 (1.0-3.5) 0.92 (0.41-2.09) 0.14 (0.09-0.21)
n (7) (7) (7)
D 0.45 (0.28-0.75) 0.3 (0.17-0.45) 0.08 (0.08-0.13)
P 0.6 (0.2-1.2) 0.7 (0.4-1.2) 0.1 (0.06-0.1)
Įǃ
(V253F)
n (14) (10) (8)
D 0.06 (0.04-0.08) 0.1 (0.06-0.23) 0.01 (0.01-0.015)
Įǃ
P 0.97 (0.59-1.58) 0.35 (0.24-0.50) 0.28 (0.17-0.46)
n (9) (9) (6)
D 0.16 (0.12-0.23) 0.06 (0.04-.008) 0.02 (0.01-0.03)
Įǃ
P 84 (8.59-821) 9.2 (5.8-14.5) 3.2 (1.69-6.28)
n (7) (12) (8)
D 1.59 (1.2-2.1) 1.37 (1.1-1.6) 0.36 (0.2-0.4)
Įǃ
P 0.29 (0.21-0.39) 0.08 (0.06-0.10) 0.07 (0.05-0.10)
n (7) (8) (9)
D 0.08 (0.06-0.11) 0.01 (0.009-0.014) 0.007 (0.006-0.009)
Įǃ
(F255V)
P 0.3 (0.23-0.04) 0.03 (0.02-0.04) 0.01 (0.01-0.02)
n (7) (9) (8)
D 0.07 (0.06-0.09) 0.01 (0.010-0.014) 0.005 (0.003-0.006)
Į
P 6.7 (5.3-8.3) 6.4 (5.1-8.2) 8.7 (6.9-11)
n (6) (7) (9)
D 6.5 (5.3-8.1) 5.0 (3.9-6.4) 6.7 (5.4-8.4)
ĮǃǄį
P 27 (19-38) 15 (9-23) 3.2 (2.5-4.1)
n (8) (8) (9)
D 18 (12-25) 12 (8-18) 2.4 (1.5-3.9)
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2QWKHRWKHUKDQG LQKLELWLRQRIKXPDQKRPRPHULFĮQ$&K5VE\3K7;
343 was voltage-independent (Figure 4.7.B.). Similar to muscle type, PhTX-
343 at concentrations lower than 10 nM showed slight potentiation of the ACh
current response at a VH of -80 mV. The IC50 calculated for peak and net charge
IURPDSORWRISHUFHQWDJHFXUUHQWLQKLELWLRQE\3K7;ZDVǴDQGǴ
(n=7) respectively. There was no change observed in IC50 values when the
standard VH of -80 mV was increased or decreased by 20 mV.
To further investigate these divergent inhibition mechanisms by PhTX-343
between heteromeric and homomeric combinations of nAChRs, their action was
FRPSDUHGRQĮǃDQGĮǃQ$&K5V(Figure 4.7.C. and D). At the highest VH
WKH SHDN LQKLELWRU\ SRWHQF\ RI 3K7; RQ Įǃ ZDV  0 DQG WKLV
decreased to 0.28 µM (3.3-fold) at the lowest VHZKLOH RQ Įǃ WKLV FKDQJHG
from 84 µM to 3.2 µM (26-fold). The results from decay current inhibition show
WKDWĮǃSRWHQF\ZDVURXJKO\IROGDQGIROGKLJKHUWKDQĮǃDWP9
and -100 mV, respectively. These data support that inhibition of neuronal
heteromeric nAChRs by PhTX-343 is dependent on the membrane holding
potential but the extent of this depends on the subunits present.
Figure 4.7. (see over) &RPELQHG PRXVH ĮǃįǄ $ KXPDQ Į % UDW
Įǃ&DQGĮǃ'1Q$&K5FRQFHQWUDWLRQLQKLELWLRQFXUYHVIRULQKLELWLRQRI
$&K0IRUĮǃįǄDQGĮǃ0IRUĮǃDQG0IRUĮHYRNHG
peak (left) and decay (right) current by PhTX-343 at holding potentials of -100
mV, -80 mV and -60 mV. The points show mean ± S.E.M. of n oocytes
normalized against control ACh responses from the same oocyte and the curves
ZHUHILWWHGXVLQJHTXDWLRQ)RUĮWKHGHFD\YDOXHLVIRUQHWFKDUJH
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7R XQGHUVWDQG WKH FRQWULEXWLRQ RI ǃ VXEXQLWV LQ WKH SKDUPDFRORJLFDO
DFWLRQ RI 3K7; RQ Q$&K5V ZH UHSODFHG ǃVXEXQLWV ǃ DQG ǃ LQ ERWK
SUHYLRXVFRPELQDWLRQVDQGJHQHUDWHGPDMRU&16ĮǃDQG316ĮǃQ$&K5V
The decay IC50YDOXHRI3K7;RQUHFHSWRUVFRQWDLQLQJǃLQFRPELQDWLRQZLWK
ĮZDV0DWP9DQGWKLVYDOXHZDVIROGKLJKHUFRPSDUHGWRWKH
Įǃ FRPELQDWLRQ $W KROGLQJ SRWHQWLDO  P9 3K7; SRWHQF\ RQ Įǃ
nAChRs was increased 5.6 fold (Figure 4.8). On the other hand, substitution of
YDOLQH  LQ WKH ǃVXEXQLW E\ SKHQ\ODODQLQH JHQHUDWHV WKH FRPELQDWLRQ
Įǃ(V253F) with decay current IC50 value of 0.06 µM, 7.5 times lower than wild
W\SHĮǃDWP9KROGLQJSRWHQWLDO7KLVGHFD\,&50 value was not changed
significantly (p = 0.0934) at -80 mV, while it decreased significantly (p< 0.0001)
by 4.2-fold at -100 mV. Based on these data, PhTX-343 inhibits wild type and
PXWDWHGĮǃQ$&K5VLQDYROWDJHGHSHQGHQWPDQQHU7KLVLPSOLHVDFULWLFDOUROH
RI WKH DPLQR DFLG UHVLGXH LQ WKH SRVLWLRQ  RI ǃVXEXQLW ZKLFK PLJKW
participate in PhTX-343 binding sites or modulating the transduction mechanism
of receptor activation or desensitization rate.
&RH[SUHVVLRQ RI WKH ǃVXEXQLW ZLWK WKH ĮVXEXQLW JHQHUDWHV D
FRPELQDWLRQRIQ$&K5ĮǃZLWKWKHORZHVWGHFD\FXUUHQW,&50 value of all wild
type nAChR for PhTX-343, 7 nM at VH -100 mV (Figure 4.9). This inhibitory
SRWHQF\ZDVIROGKLJKHUFRPSDUHGWRH[SUHVVLRQRIǃZLWKĮVXEXQLW7KLV
LQKLELWLRQ RI Įǃ Q$&K5V E\ 3K7; ZDV GHSHQGHQW RQ PHPEUDQH KROGLQJ
potential; IC50 values at -80 mV and -60 mV were 1.4 and 11.4 fold higher
compared to that at -100 mV. Sensitivity of PhTX-343 following the replacement
RISKHQ\ODODQLQH LQǃE\YDOLQHZDV LQYHVWLJDWHGZKHQFRH[SUHVVHGZLWK
ĮVXEXQLWĮǃ(F255V)7KLVPXWDWLRQLQǃ(F255V) did not produce any noticeable
change in the sensitivity at -60 mV, while significantly (P<0.0001) increased it at
P9DQGP9FRPSDUHGWRZLOGW\SHRIǃVXEXQLWFRH[SUHVVHGZLWKĮ
subunit. Substitution of this residue suggests no critical role for this position in
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voltage-dependent PhTX-343 binding or transduction mechanism of nAChR
activation in this combination.
The IC50 vs voltage relationship curves for both peak and decay current
inhibition by PhTX-343 were constructed based on the Woodhull model to
HVWLPDWHWKHSDUDPHWHUįWKHIUDFWLRQRIWKHPHPEUDQHHOHFWULFILHOGSHQHWUDWHG
by the molecule (Figure 4.11). PhTX-343 carries three positive charges (z = 3)
in the polyamine chain at physiological pH (Stromgaard et al., 1999). The peak
DQG GHFD\ FXUUHQW į YDOXHV FDOFXODWHG IURP ,&50 at three different holding
potentials for each combination are shown in Figure 4.11.C. These values were
quite variable; some were positive and others were negative and in some cases
the decay current value was lower than that for peak current or vice versa. For
H[DPSOH Įǃ Q$&K5V KDG D įYDOXH KLJKHU WKDQ  ZKLFK LQGLFDWHG D
preference for the deep binding site, while in other combinations it was lower
than 0.5, indicating a preference for the shallow site. Therefore, based on the
SUHGLFWHGįYDOXHZHFRQFOXGHGLQJHQHUDOWKDWSHDNDQGGHFD\FXUUHQWLQKLELWLRQ
of all heteromeric nAChR combinations by PhTX-34 was dependent on the
PHPEUDQHSRWHQWLDODQGYLFHYHUVDIRUKRPRPHULFĮQ$&K5V
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Figure 4.8. Combined rat Įǃ and Įǃ(V253F) N-nAChR concentration-inhibition
FXUYHVIRU LQKLELWLRQRIǴ$&KHYRNHGSHDNOHIWDQGGHFD\ULJKWFXUUHQW
by PhTX-343 at holding potentials of -100 mV, -80 mV and -60 mV. The points
show mean ± S.E.M. of n oocytes normalized to the control ACh response from
same cells and curve fits are to equation 1. The IC50 values of Įǃ(V253F) were
significantly lower than Įǃ at all VH for decay current but only at -60 mV for
peak current.
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Figure 4.9. Combined rat Įǃ and Įǃ(F255V) N-nAChR concentration-inhibition
FXUYHVIRULQKLELWLRQRIǴ$&KHYRNHGSHDNOHIWDQGGHFD\ULJKWFXUUHQW
by PhTX-343 at holding potentials of -100 mV, -80 mV and -60 mV. The points
are mean ± S.E.M. of n oocytes normalized to the control ACh response from
same cells and curve fits are to equation 1. The IC50 values of Įǃ(F255V) were
significantly lower than Įǃ at -80 mV and -100 mV for peak current but only
at -100 mV for decay current.
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Figure 4.10. Comparison of PhTX-343 on eight different subunit combinations of
nAChRs. Each bar represents the PhTX-343 IC50 value (95% CI) on the particular
combinations. Red, green and blue bars represent membrane holding potentials
of -100 mV, -80 mV and -60 mV respectively. Peak (top) and decay (bottom)
FXUUHQW LQKLELWLRQ E\ 3K7; 'HFD\ GDWD LQ WKH FDVH RI Į   QHW FKDUJH
Significance of difference between IC50 at -100 mV and -60 mV is indicated by
QVSSSSRUS
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nAChRs
įYDOXH
Įǃ Įǃ(V253F) Įǃ Įǃ Įǃ Įǃ(F255V) Į ĮǃǄį
Peak 0.38 0.17 0.33 0.79 0.39 0.87 -0.06 0.33
Decay 0.26 0.11 0.40 0.20 0.80 0.74 -0.01 0.28
Figure 4.11. Effect of voltage on the action of PhTX-343 across eight different
combinations of nAChRs. IC50YDOXHV&,LQǴIRU3K7;SHDN$DQG
GHFD\ % ZHUH SORWWHG DJDLQVW YROWDJH & HVWLPDWHG į YDOXHV EDVHG RQ
Woodhull equation when z, the number of positive charges on the molecule,
equals 3.
4.3. Recovery from inhibition by PhTX-343
In this class of experiment we investigated the recovery rate of the peak
and decay current of nAChRs expressed in Xenopus oocytes from PhTX-343. In
all experiments we used approximately the ACh EC50 concentration as a control
and followed by co-application of ACh with increasing concentrations of PhTX-
343 (10-10 M to 10-5 M) depending on combination sensitivity, with 6 minute
intervals. Then, after the last co-application of PhTX-343, we continued the
experiment by repeated application of control ACh concentration every 6 minutes
to establish the recovery rate.
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)LUVWWKHUHFRYHU\UDWHRIĮFRQWDLQLQJUHFHSWRUVZDVVWXGLHG,WDSSHDUV
WKDW LQ WKH FDVH RI FRPELQHG DSSOLFDWLRQ RI  Ǵ 3K7; ZLWK WKH (&50
FRQFHQWUDWLRQ RI $&K IRU Įǃ WKH VL]H RI SHDN DQG GHFD\ FXUUHQWV ZHUH
respectively only 3.5% and 0.1% of control. The mean value of recovery for the
peak and decay current after 48 minutes was 88.2% ± 8.4 and 76.7% ± 10.3
UHVSHFWLYHO\RIFRQWUROUHVSRQVH:KLOHĮǃVKRZHGORZHVWVHQVLWLYLW\WRǴ
3K7;DQGORZHUUHFRYHU\FRPSDUHGWRĮǃ&RDSSOLFDWLRQRIǴ3K7;
343 resulted in peak and decay currents of 48.4% and 12.2% of control
UHVSRQVH UHVSHFWLYHO\ IRU Įǃ 7KHLU PHDQ SHDN DQG GHFD\ FXUUHQW UHFRYHU\
values were 56-57% of control response.
6HFRQGO\ ZH LQYHVWLJDWHG WKH UHFRYHU\ UDWH RI ĮFRQWDLQLQJ UHFHSWRUV
IURP WKH LQKLELWLRQ RI  Ǵ 3K7; 7KH SHDN DQG GHFD\ FXUUHQW RI Įǃ
ZKHQ H[SRVHG WR  Ǵ 3K7; ZDV URXJKO\  RI FRQWURO DQG WKH PHDQ
decay current recovery was 69.1%, higher than the peak value of 36.6% after
 PLQXWHV &RDSSOLFDWLRQ RI  Ǵ 3K7; UHVXOWHG LQ SHDN DQG GHFD\
FXUUHQWV RI  DQG  RI FRQWURO UHVSRQVH UHVSHFWLYHO\ IRU Įǃ 7KHLU
mean peak and decay current recovery values were 53.0% and 48.0% of control
response respectively after 48 minutes.
)LQDOO\WKHUHFRYHU\UDWHRIKRPRPHULFĮ1Q$&K5VDQG0Q$&K5VIURP
ǴDQGǴ UHVSHFWLYHO\ZDV LQYHVWLJDWHG ,Q WKH FDVHRIĮ1Q$&K5V
the mean recovery value obtained for the peak current was 108±5.0% and for
net charge movement was 111.0±6.2% after 6 minutes, i.e. it was higher than
the control response. Also, roughly full recovery was observed for the peak
current (99.4±3.2%) of M-nAChRs with slightly lower mean recovery rate for the
decay current (83.8±4.6%).
82
Figure 4.12. 6KRZLQJ UHFRYHU\ RI ĮFRQWDLQLQJ Q$&K5 UHVSRQVHV WR  0
Įǃ 0ĮǃDQGĮǃ(F255V) ACh from inhibition by 10 µM PhTX-343 at
ĮǃĮǃDQG03K7;DWĮǃ(F255V). All applications were at 6 minute
intervals. In between the applications Ringer solution flowed at a rate of 3-6
ml/minute.
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Figure 4.13.6KRZLQJUHFRYHU\RIĮFRQWDLQLQJQ$&K5UHVSRQVHVWR0$&K
IURPLQKLELWLRQE\ǋ03K7;$OODSSOLFDWLRQVZHUHDWPLQXWHLQWHUYDOV
In between the applications Ringer solution flowed at rate of 3-6 ml/minute.
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Figure 4.14.6KRZLQJUHFRYHU\RIĮDQGĮǃįǄQ$&K5UHVSRQVHVWR0
DQG0$&KIURPLQKLELWLRQE\ǋ0ĮRUǋ0ĮǃįǄ3K7;$OO
applications were at 6 minute intervals. In between the applications Ringer
solution flowed at rate of 3-6 ml/minute.
4.4. Competition of PhTX-343 with ACh on nAChRs
To further study the mechanism and mode of action by which PhTX-343
inhibits acetylcholine evoked inward current in oocytes expressing nAChRs, we
analysed the data obtained from the effects of a single PhTX-343 concentration
on inward current induced by different acetylcholine concentrations (Figure
4.15). Co-application of PhTX-343 with different concentrations of acetylcholine
did not show any significant shift in the ACh concentration-response curve to the
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right. The EC50 values in the presence and absence of PhTX-343 were calculated
and are presented in Table 4.2. Thus, the magnitude of inward current
inhibition was independent of the acetylcholine concentration (n = 5-9 oocytes
from different batches).
Table 4.2. The effects of PhTX-343 on nAChRs ACh concentration-response
curve.
EC50 value of nAChRs in µM
 Įǃ Įǃ Įǃ Įǃ Į ĮǃǄį
ACh 14 23 14 74 234 28
+1 µM PhTX-343 22 13 14 89
+10 µM PhTX-343 288
+30 µM PhTX-343 38
P value EC50 0.5278 0.1941 0.9393 0.6381 0.0925 0.0875
P value
1 mM ACh
+PhTX-343
<0.0001 <0.0001 <0.0001 <0.0001 0.09750 <0.0001
Figure 4.15. (see over) PhTX-343 inhibits ACh mediated current responses of
nAChRs in a non-competitive manner. Acetylcholine concentration-response
curves in the absence (blue) or presence (red) of a constant concentration of
PhTX-343 from oocytes clamped at -80 mV. ACh±PhTX-343 was applied for one
minute at 6 minutes intervals. Traces show whole-oocyte current induced by
0ĮǃRUǴĮǃĮǃĮǃ$&Kwith or without 1 µM PhTX-
ZKLOHPXVFOHDQGĮUHVSRQVHVZHUHLQGXFHGE\0DQG0$&K
in the presence or absence of 30 µM and 10 µM PhTX-343, respectively. EC50
values were estimated from plotted data of average current normalized as
percentage of maximum current response against concentration of agonist. The
ACh concentration response curve was shifted downward in the presence of
PhTX-343 without any significant change in EC50 values (Table 4.2).
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CHAPTER FIVE
PHARMACOLOGICAL CHARACTERIZATION OF nAChR INHIBITION
BY PhTX-12
Summary
The pharmacological actions of PhTX-12 on recombinant nAChRs
expressed in Xenopus oocytes after micro-injection with mRNA was investigated
by using TEVC. Concentration-inhibition curves for PhTX-12 were constructed for
each combination of nAChR subunits at -60 mV, -80 mV and -100 mV. ACh EC50
was used as a control and applied for 1 minute with 6 minutes interval either
alone or co-applied with PhTX-12 at various concentrations ranging between 0.1
nM to 100 µM depending on subtype sensitivity. A four-parameter logistic
equation was used to calculate the peak and decay current IC50 values by
plotting PhTX-12 concentration against the mean of normalised current as % of
FRQWURO UHVSRQVH ,W DSSHDUV WKDW ERWK ĮVXEXQLW DQG ǃVXEXQLW DUH FULWLFDO IRU
PhTX-12 inhibition. PhTX-12 did not show any noticeable selectivity among
investigated nAChRs with potency in the micro-molar range. It appears from IC50
values at different holding potential that inhibition of nAChRs by PhTX-12 is
voltage-independent or slightly voltage-dependent. These values were used in an
adapted Woodhull equation to predict interaction site of PhTX-12 in the channel
E\FDOFXODWLQJWKHLUįYDOXHV3K7;LVDQRQFRPSHWLWLYHLQKLELWRUDWĮǃDQG
ĮǃįǄQ$&K5V UHGXFLQJ WKH$&K UHVSRQVHDPSOLWXGHZLWKRXW VKLIWLQJ WKH$&K
EC50 value of significantly.
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5.1. PhTX-12 inhibits the ACh-induced response of wild-type and
mutated nAChRs
PhTX-12 is another synthetic analogue of PhTX-433, where both
secondary amino groups in the polyamine chain were replaced by methylene.
Previous work showed that PhTX-12 was roughly 22-fold more potent on
embryonic M-nAChRs naturally expressed in the TE671 cell line in comparison to
PhTX-343 (Brier et al., 2003) while being much less active at AMPA receptors
(Mellor et al., 2003). Here, we investigated the pharmacological effects of PhTX-
 RQ VHYHUDO 1Q$&K5 VXEXQLW FRPELQDWLRQV Įǃ Įǃ(V253F) Įǃ
Įǃ(F255V)ĮǃĮǃDQGĮDQGHPEU\RQLF0Q$&K5VĮǃįǄH[SUHVVHGLQ
Xenopus oocytes. Concentration-inhibition curves were constructed at a standard
voltage of -80 mV (Figure 5.1, 5.2 and 5.3) and IC50 values calculated for the
peak current and decay current of each combination.
The decay current IC50 YDOXHFDOFXODWHGIRUĮǃįǄQ$&K5VDW9H -80 mV
was 0.10 µM. The decay IC50 YDOXH REWDLQHG IRUĮǃĮǃ(F255V) ĮǃĮǃ
DQG Įǃ(V253F) nAChRs were in the same range (0.10 µM - 0.28 µM) as M-
nAChRs. In contrast, a 25-fold and 49-fold increase in IC50 value was calculated
IRU Įǃ DQG Į Q$&K5V UHVSHFWLYHO\ 7KH UDQNLQJ RUGHU SRWHQF\ RI Q$&K5V
EDVHGRQGHFD\FXUUHQWLQKLELWLRQE\3K7;ZDVĮǃįǄ Įǃ!Įǃ!Įǃ!
Įǃ(V253F)!Įǃ(F255V)!Įǃ!Į
On the other hand, nAChR subunit combinations showed differences in
the peak current IC50 value for PhTX-12. The lowest peak IC50 value, calculated
IRUĮǃQ$&K5VDW9H -80 mV, was 1.64 µM. This value was increased by 3.7-
IROGDQGIROG IRUPXVFOHW\SHDQGKRPRPHULFĮQ$&K5V UHVSHFWLYHO\7KH
peak IC50YDOXHREWDLQHGIRUZLOGW\SHĮǃQ$&K5VZDV0WKLVYDOXHZDV
QRW VLJQLILFDQWO\ S  GLIIHUHQW IURP PXWDWHG Įǃ(F255V) nAChRs. The
peak IC50 YDOXH FDOFXODWHG IRUĮǃZDV 0 WKLV YDOXHGRXEOHG IRUPXWDWHG
Įǃ(V253F) but also was not significantly (p=0.1208) different from wild-type.
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The highest peak IC50YDOXHRI0ZDVUHFRUGHGIRUĮǃQ$&K5V7KHVHGDWD
VXSSRUWWKDWERWKĮDQGǃVXEXQLWLVFULWLFDOIRU3K7;DFWLRQ
200 nA
60 s
2000 nA
60 s
Figure 5.1. Example traces showing nAChR subtype inhibition sensitivity to
PhTX-12. Approximately EC50 $&K FRQFHQWUDWLRQ  0 IRU Įǃ Įǃ DQG
ĮǃįǄ  0 IRU Įǃ DQG  0 IRU Įǃ DQG Į Q$&K5V LQ HDFK
combination was perfused to oocytes clamped at -80 mV to generate control
(Red). Then, PhTX-12 with increasing concentration (other colours) was co-
perfused with ACh at six minute intervals.
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Figure 5.2. Example traces showing mutant nAChR subtype inhibition sensitivity
to PhTX-12. Approximately EC50 $&K FRQFHQWUDWLRQ  0 IRU Įǃ(V253F) and
0IRUĮǃ(F255V)) in each combination was perfused over oocytes clamped
at -80 mV to generate control (Red). Then, increasing concentrations of PhTX-12
(other colours) was co-perfused with ACh at 6 minute intervals.
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Figure 5.3. Screening PhTX-12 inhibitory effects on Peak (top) and decay
(bottom) current of eight different subunit combinations of nAChRs expressed in
Xenopus oocytes at holding potential -80 mV. Graphs are concentration-
inhibition data plotted as mean % control response vs PhTX-12 concentration for
peak current (top) or decay current (bottom) and curve fits are to Equation 1.
'HFD\FXUUHQWRIĮ QHWFKDUJH
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5.2. Voltage effects on the inhibition of nAChRs by PhTX-12
To investigate whether alteration in the membrane holding potential
affects the inhibitory actions of PhTX-12 on nAChRs, concentration-inhibition
FXUYHV IRU3K7;RQĮĮǃĮǃĮǃĮǃ(V253F)ĮǃĮǃ(F255V) and
ĮǃįǄVXEXQLWFRPELQDWLRQVZHUHFRQVWUXFWHGDWWKUHHGLIIHUHQW9H (-60 mV, -
80 mV and -100 mV) and their IC50 (95% CI) values are presented in Table 5.1.
 3K7;VWURQJO\LQKLELWHGĮǃįǄUHFHSWRUVZLWKSHDNDQGGHFD\FXUUHQW
IC50 values of 3.1 µM and 70 nM, at -60 mV (Figure 5.4). Neither of these
values changed significantly by altering VH to -80 mV and -100 mV; they became
6.1 µM and 5.0 µM on the peak current and 100 nM and 70 nM on the decay
current, respectively. Similarly, increasing the VH to -100 mV did not cause any
noticeable change in the calculated IC50 values for the peak current (1.82 µM)
DQGGHFD\FXUUHQWQ0RIĮǃQ$&K5V(Figure 5.4). On the other hand,
WKH KRPRPHULF Į ZDV WKH RQO\ FRPELQDWLRQ WKDW VKRZHG D VLJQLILFDQW S 
0.026) change in the peak current IC50 values calculated at -60 mV (18.7 µM) by
altering membrane potential to -100 mV (Figure 5.7.A).
The decay current IC50YDOXHVRIĮǃĮǃ(V253F)ĮǃĮǃ(F255V), Įǃ
DQGĮQ$&K5VFDOFXODWHGDWP9ZHUHVLJQLILFDQWO\KLJKHUWKDQWKHYDOXHVDW
-100 mV (Figure 5.7.B). The decay current IC50 values recorded at holding
SRWHQWLDOP9IRUĮǃĮǃDQGĮǃ(F255V) were 230 nM, 100 nM and 510
nM, respectively (Figure 5.5 and 5.6). These combinations showed strong
voltage dependence between -60 mV and -100 mV (p < 0.0001 for all
combinations). The least voltage dependent combinations (p < 0.05) were
Įǃ(V253F)DQGĮQ$&K5VE\FRPSDULQJWKHLUGHFD\FXUUHQW,&50 values, 400 nM
and 8900 nM respectively, calculated at VH = -60 mV to that calculated at VH = -
 P9 ,Q DGGLWLRQ Įǃ Q$&K5V ZHUH IRXQG WR EH PRGHUDWHO\ YROWDJH
dependent (p < 0.001) by comparing decay current IC50 calculated at -60 mV
and -100 mV.
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Table 5.1. Summary of PhTX-12 Peak P and decay D current IC50 values on
eight different combinations of nAChRs at three different holding potential, -60
mV, -80 mV and -100 mV. µ'¶LQFDVHRIĮ QHWFKDUJH9DOXHVDUHSUHVHQWHG
in µM as mean IC50 (95% CI) and (n) is the number of tested oocytes. Similarly
sensitivity for PhTX-12 was recorded for six combinations tested and lower
VHQVLWLYLW\ZDVUHFRUGHGIRUĮDQGĮǃEDVHGRQWKHGHFD\FXUUHQW,&50 values
at -80 mV. Voltage-dependence was weak or even absent for peak current
inhibition of some heteromeric combinations.
nAChRs VH= -60 mV VH= -80 mV VH= -100 mV
Įǃ
P 3.8 (1.4-10.1) 2.1 (1.2-3.6) 1.6 (0.7-3.6)
n (8) (9) (11)
D 0.23 (0.14-0.37) 0.27 (0.17-0.44) 0.04 (0.02-0.06)
Įǃ
(V253F)
P 2.2 (1.4-3.4) 4.0 (2.2-7.3) 3.4 (1.3-8.7)
n (4) (5) (9)
D 0.4 (0.27-0.59) 0.29 (0.25-0.34) 0.18 (0.13-0.26)
Įǃ
P 1.51 (0.84-2.72) 1.64 (0.96-2.82) 1.82 (0.81-4.11)
n (9) (12) (9)
D 0.32 (0.21-0.48) 0.28 (0.20-0.40) 0.19 (0.14-0.26)
Įǃ
P 65 (35-118) 60 (21-171) 74 (21-259)
n (9) (12) (10)
D 3.19 (2.39-4.27) 2.57 (2.16-3.06) 1.38 (1.05-1.89)
Įǃ
P 3.08 (2.21-4.47) 2.61 (1.70-4.01) 2.02 (1.22-3.36)
n (7) (8) (8)
D 0.10 (0.07-0.14) 0.10 (0.07-0.14) 0.02 (0.02-0.03)
Įǃ
(F255V)
P 1.6 (0.7-3.6) 2.7 (1.1-6.8) 1.0 (0.5-2.0)
n (5) (5) (5)
D 0.51 (0.29-0.89) 0.35 (0.25-0.49) 0.06 (0.04-0.10)
Į
P 18.7 (14-23) 11.1 (7.2-17) 12.1 (9.0-16)
n (12) (12) (10)
D 8.9 (6.9-11) 4.9 (2.7-8.6) 5.0 (3.0-8.3)
ĮǃǄį
P 3.1 (2.1-4.7) 6.1 (4.0-9.4) 5.0 (2.8-8.8)
n (9) (11) (8)
D 0.07 (0.05-0.09) 0.10 (0.08-0.12) 0.07 (0.05-0.09)
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The IC50 Ǵ  &, YROWDJH UHODWLRQVKLS FXUYHV IRU ERWK SHDN DQG
decay current inhibition by PhTX-12 were constructed based on the Woodhull
PRGHO WRHVWLPDWH WKHSDUDPHWHUį WKH IUDFWLRQRI WKHPHPEUDQHHOHFWULF ILHOG
penetrated by the molecule (Figure 5.8). PhTX-12 carries a single positive
charge (Z = 1) in the polyamine chain at physiological pH compared to three for
3K7; 6WURPJDDUG HW DO  7KH SHDN DQG GHFD\ FXUUHQW į YDOXHV
calculated from IC50 (95% CI) at three different holding potential for each
combination are shown in Figure 5.8.C. These values were quite variable; some
were positive and others were negative and in some cases the decay current
value was lower than that for peak current or vice versa. Therefore, it was
difficult to predict the level of voltage dependence but we predict in general that
peak inhibition of all nAChR combinations by PhTX-12 was weakly dependent on
the membrane potential while decay inhibition was more strongly voltage-
dependent, with few exceptions.
Figure 5.4. (see over)&RPELQHGPRXVHĮǃįǄKXPDQĮUDWĮǃDQG
Įǃ FRQFHQWUDWLRQLQKLELWLRQ FXUYHV IRU LQKLELWLRQ RI  0 IRU ĮǃįǄ DQG
Įǃ 0 IRUĮǃ DQG0 IRUĮ$&KHYRNHGSHDN ULJKW DQGGHFD\
(left) current by PhTX-12 at holding potentials of -100 mV, -80 mV and -60 mV.
The shown points on curves are mean ± S.E.M. of n oocytes normalized to the
control ACh response from the same oocyte and curve fits are to equation 1. For
ĮWKHGHFD\YDOXHLVIRUQHWFKDUJH
95
96
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
Log10 [PhTX-12] (M)
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
Log10 [PhTX-12] (M)
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
Log10 [PhTX-12] (M)
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
Log10 [PhTX-12] (M)
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
Log10 [PhTX-12] (M)
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
Log10 [PhTX-12] (M)
Figure 5.5. Combined rat Įǃ and Įǃ(V253F) concentration-inhibition curves
IRU LQKLELWLRQ RI SHDN ULJKW DQG GHFD\ OHIW FXUUHQW RI  Ǵ  $&K HYRNHG
response by PhTX-12 at holding potentials of -100 mV (bottom), -80 mV
(middle) and -60 mV (top). The shown points on curves are mean ± S.E.M. of n
oocytes normalized to the control ACh response from the same oocyte and curve
fits are to equation 1. The decay current IC50 value of Įǃ(V253F) at -100 mV was
significantly (p<0.0001) higher than that of wild-type Įǃ nAChRs otherwise
there was no difference in PhTX-12 sensitivity between ĮǃDQGĮǃ(V253F).
97
Figure 5.6. Combined rat Įǃ and Įǃ(F255V) concentration-inhibition curves
IRU LQKLELWLRQ RI SHDN ULJKW DQG GHFD\ OHIW FXUUHQW RI  Ǵ  $&K HYRNHG
response by PhTX-12 at holding potentials of -100 mV (bottom), -80 mV
(middle) and -60 mV (top). The shown points on curves are mean ± S.E.M. of n
oocytes normalized to the control ACh response from the same oocyte and curve
fits are to equation 1. Sensitivity of Įǃ(F255V) to PhTX-12 was lower than Įǃ
at all three holding potentials for decay current inhibition (p<0.0001) but there
was no significant difference for peak current inhibition.
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Figure 5.7. Comparison of PhTX-12 potency on eight different combinations of
nAChRs. Each bar represents PhTX-12 IC50 values (95% CI) on the particular
combinations for peak (top) or decay (bottom) current inhibition. Red, green and
blue bars represent membrane holding potentials of -100 mV, -80 mV and -60
mV respectively. Significance of difference between IC50 at -100 mV and -60 mV
LVLQGLFDWHGE\QVSSSSRU
(p<0.0001).
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nAChRs
įYDOXH
Įǃ Įǃ(V253F) Įǃ Įǃ Įǃ Įǃ(F255V) Į ĮǃǄį
Peak 0.60 -0.22 -0.56 0.11 0.26 0.16 0.33 -0.21
Decay 0.51 0.46 0.14 0.46 0.53 0.83 0.38 -0.01
Figure 5.8. Voltage effect on action of PhTX-12 across eight different
combinations of nAChR subunits. IC50YDOXHV&, LQǴIRU3K7;SHDN
(A) and decay (B) current inhibition were plotted against voltage. (C) estimated
įYDOXHVEDVHGRQWKH:RRGKXOOHTXDWLRQZKHQ]QXPEHURISRVLWLYHFKDUJHVRQ
molecule, equals 1.
5.3. Recovery from inhibition by PhTX-12
In this experiment nearly complete recovery of nAChRs expressed in
Xenopus oocytes was observed 6 minutes after the previous co-application of
agonist and PhTX-12 (Figure 5.19, 5.10 and 5.11). In the case of combined
DSSOLFDWLRQRIǴ3K7;ZLWK(&50 ACh concentration the peak amplitude of
WKH FRQWURO UHVSRQVHRI ǃFRQWDLQLQJ UHFHSWRUVZDV UHGXFHGDSSUR[LPDWHO\E\
ZKLOHǃǃDQGQRQǃFRQWDLQLQJUHFHSWRUVE\7KHPHDQ
YDOXHRIUHFRYHU\IRUWKHSHDNFXUUHQWRIĮFRQWLDQLQJZDVURXJKO\
ZKLOHIRUĮĮDQGĮFRQWDLQLQJUHFHSWRUVLWZDV
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Figure 5.9. 5HFRYHU\ RI ĮFRQWDLQLQJ Q$&K5V IURP DQWDJRQLVP E\ 3K7;
Traces in each box show ACh EC50 concentration alone (control, recovery) or
with 10µM PhTX-12. Graphs show mean % control response for peak and decay
current ±S.E.M. before (0 min) during (6 min) and after (12 min) co-application
RIǋ03K7;
101
Figure 5.10. 5HFRYHU\RIĮFRQWDLQLQJQ$&K5V IURPDQWDJRQLVPE\3K7;
Traces in each box show ACh EC50 concentration alone (control, recovery) or
with 10µM PhTX-12. Graphs show mean % control response for peak and decay
current ±S.E.M. before (0 min) during (6 min) and after (12 min) co-application
RIǋ03K7;
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Figure 5.11. 5HFRYHU\RIĮDQGĮǃįǄQ$&K5VIURPDQWDJRQLVPE\3K7;
Traces in each box show ACh EC50 concentration alone (control, recovery) or
with 10µM PhTX-12. Graphs show mean % control response for peak and decay
current ±S.E.M. before (0 min) during (6 min) and after (12 min) co-application
RIǋ03K7;
5.4. Non-competitive action of PhTX-12
To further determine the mechanisms of inhibition by PhTX-12, ACh
FRQFHQWUDWLRQUHVSRQVH FXUYHV ZHUH FRQVWUXFWHG IRU Įǃ DQG ĮǃįǄ LQ WKH
presence and absence of 300 nM PhTX-12 (Figure 5.12). The ACh
concentration-response curves did not shift significantly to the right in the
presence of 300 nM PhTX-12. The EC50 values for peak and decay current and
net charge are presented in Table 5.2 7KXV LQ RRF\WHVH[SUHVVLQJĮǃDQG
ĮǃįǄQ$&K5VFRWUHDWPHQWRIQ0RI3K7;ZLWKYDULRXVFRQFHQWUDWLRQ
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of ACh inhibited the magnitude of ACh inward current but this was independent
on agonist concentration.
Table 5.2. The effects of 300 nM PhTX-12 on nAChR ACh concentration-
response curve. N. not fitted to the equation.
nAChRs EC50 value of nAChRs in µM
Peak Decay Net charge
Įǃ
ACh 101 37 57
+PhTX-12 139 N. 67
P value EC50 0.1605 N. 0.8947
P value
1 mM ACh
+PhTX-12
0.6076 <0.0001 <0.0001
ĮǃǄį
ACh 11 2.1 4.5
+PhTX-12 18 1.7 6.3
P value EC50 0.1591 0.9192 0.7369
P value
1 mM ACh
+PhTX-12
0.4347 <0.0001 0.0002
Figure 5.12. (see over) PhTX-12 inhibits ACh mediated current response of
nAChRs in a non-competitive manner. Increasing ACh concentrations were
applied with or without 300 nM PhTX-12 to oocytes clamped at -80 mV as one
minute application at 6 minutes intervals. Traces show whole-oocyte current
induced by 300 µM ACh with or without 300 nM PhTX-12. The EC50 values were
estimated from plotted data of average current normalized as percentage of
maximum current response in the absence of PhTX-12 against concentration of
agonist. The ACh concentration-response curve was shifted downward in the
presence of PhTX-12 without any significant change in EC50 values (Table 5.2).
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CHAPTER SIX
6758&785($&7,9,7<5(/$7,216+,32)3K7;21Įǃ$1'
Įǃ
Summary
Structure-activity studies of 21 analogues of PhTX-343, were
LQYHVWLJDWHGRQWKHUDWPDMRUEUDLQĮǃDQGJDQJOLRQLFĮǃQ$&K5VWRLPSURYH
selectivity and potency toward particular subtypes. Eleven synthetic analogues
with a single region modification were used to identify the key regions
responsible for toxin activity and selectivity. We showed that the difference in
conformation that the PhTX polyamine tail can adopt (analogues 1, 2 and 10)
might be a new approach for the development of new selective inhibitors of
nAChRs. Also we identified that the presence of the phenyl group in the head
UHJLRQ LV FULWLFDO IRU LPSURYLQJ VHOHFWLYLW\ WRZDUG Įǃ RYHU ĮǃQ$&K5V RU D
cyclohexane group for increasing activity. Analogues having both a cyclohexane
and phenyl group show IC50 values in the pico-molar range and become the most
potent inhibitors that have been investigated so far on nAChRs. Ten analogues
with double region modification in the head region were used to investigate the
role of the hydrophobicity and the bulky size. Overall, analogues show a better
selectivity toward ganglion type nAChRs over the brain type with few exceptions
such as analogue 7, which lost selectivity.
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6.1. Structure activity relationship (SAR)
A library of philanthotoxin analogues was developed based on the
structure of PhTX-343 to identify the key regions of the toxin responsible for the
LQKLELWRU\ DFWLYLW\ DQG VHOHFWLYHO\ RQ Įǃ DQG Įǃ Q$&K5V H[SUHVVHG LQ
Xenopus oocytes. The structure of the PhTX-343 molecule is shown in Figure
6.1 divided in to four regions (I, II, III and IV) to obtain systematic replacement
in different regions. The IC50 values for each analogue were calculated from
concentration-inhibition curves and compared to the potency of analogue 1
(PhTX-343) at a holding potential of -100 mV. The parent analogue (1) had peak
and decay current IC50VRIQ0DQGQ0UHVSHFWLYHO\IRUĮǃDQGQ0
DQG  Q0 UHVSHFWLYHO\ IRU Įǃ DQG KHQFH IROG VHOHFWLYLW\ RQ WKH GHFD\
FXUUHQWRIĮǃRYHUĮǃQ$&K5V3KLODQWKRWR[LQGHULYDWLYHVZHUHGLYLGHGLQWR
two categories: single region and double region modification.
Figure 6.1. Chemical structure of PhTX-343 divided into four regions. (Red)
region I= terminal ammonium group, (blue) region II= spermine, (green) region
III= butyryl and (brown) region IV= tyrosine.
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6.1.1. Single region modification (SRM)
The first category consisted of analogues with a single region
modification. Firstly, we started to evaluate the key role of tail regions (I and II)
of PhTX-343 in toxin potency by two synthetic analogues 2, which has less
positive charge in region II, and 3, which has a more bulky group in region I,
compared to analogue 1 (Figure 6.2. and Table 6.1). The potency of analogue
3, where the terminal amino group (Region I) was replaced by a guanidinium
JURXSRQĮǃQ$&K5VZDVUHGXFHGDSSUR[LPDWHO\IROGRQSHDNDQGIROG
on the decay current compared to analogue 1. Substitution of both secondary
amino groups in the polyamine chain (region II) with methylene develops
analogue 2 (PhTX-12; this has been extensively described in chapter 5), which
ORVW WKHVHOHFWLYLW\EHWZHHQĮǃDQGĮǃVKRZQE\1. This analogue showed
reduced potency compared to the parental analogue 1 by roughly 26-fold on
SHDN DQG IROG RQ GHFD\ FXUUHQW RI Įǃ OLNHZLVH IROG UHGXFWLRQ ZDV
REVHUYHGRQSHDNFXUUHQWRIĮǃQ$&K5VEXWDIROGLQFUHDVHLQSRWHQF\ZDV
observed on decay current.
Secondly, the pharmacological action of three analogues (4, 5 and 6)
with hydrophobic head region (III and IV) modification was investigated. These
DQDORJXHV GUDVWLFDOO\ LQFUHDVHG SRWHQF\ DQG VHOHFWLYLW\ IRU Įǃ RYHU Įǃ
nAChRs. Extending the aliphatic chain in the region III from four carbon atoms to
ten produced analogue 4. The IC50YDOXHVRQWKHSHDNDQGGHFD\FXUUHQWRIĮǃ
were 656 nM and 3 nM, respectively. These values were reduced 11.5 fold on
SHDN FXUUHQW DQG LQFUHDVHG IROG RQ GHFD\ FXUUHQW ZKHQ WHVWHG RQ Įǃ
nAChRs. Removing the phenolic hydroxyl group from the aromatic nucleus of
region IV of PhTX-343 produced analogue 5 with peak and decay IC50 value of
 Q0 DQG  Q0 UHVSHFWLYHO\ RQ Įǃ. This analogue showed considerable
VHOHFWLYLW\ IROGRQSHDNDQGIROGRQGHFD\ IRU ĮǃRYHUĮǃQ$&K5V
(Figure 6.3.), compared to 1.8-fold and 11.4-fold for 1. Analogue 6 which has a
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similar chemical structure to analogue 5, with the phenylalanyl group extended
by only one methylene group, showed a decrease in peak (131 nM) and decay
(20 nM) IC50YDOXHRQĮǃFRPSDUHGWRDQDORJXH5 and caused a reduction in
selectivity by 3-fold on peak and 1.5-fold on decay compared to analogue 5.
These data suggest that modifications in head groups are important for
increasing PhTX-343 potency and selectivity.
1 2 3 4 5 6
0.1
1
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10000
Analogues
1 2 3 4 5 6
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1
10
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10000
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Figure 6.2. Comparison of peak (Blue bars) and decay (Red bars) current
SRWHQF\ RI 3K7; DQDORJXHVZLWK D VLQJOH UHJLRQPRGLILFDWLRQ RQĮǃ DQG
ĮǃDWP9(DFKEDU UHSUHVHQWVWKHDQDORJXH¶V ,&50 value (±95% CI) in
nM.
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Figure 6.3. Sample traces (top) obtained by co-application of 5 with 100 µM
DQG0$&KDWP9IRURRF\WHVH[SUHVVLQJĮǃRUĮǃUHVSHFWLYHO\
and their corresponding concentration-inhibition curves (bottom) compared with
parental analogue 1. Analogue 5 KDV VWURQJ VHOHFWLYLW\ IRU Įǃ RYHU Įǃ
receptor as shown in example traces and concentration inhibition curves.
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Table 6.1. Comparison of PhTX-analouge IC50 values (nM) with single region
modification on the major CNS and PNS hetromeric N-nAChRs
PhTX-analouges Įǃ Įǃ
1.
P 143 (94-218) 1 77 (58-102) 1 1.8
n (7) (9)
D 80 (48-132) 1 7 (6-9) 1 11.4
2.
P 1641 (734 - 3665) 0.08 2025 (1219-3360) 0.03 0.8
n (11) (8)
D 43 (29-64) 1.8 26 (21-33) 0.26 1.6
3.
P 1131 (480-2661) 0.12
n (7)
D 3051 (1736-5362) 0.02
4.
P 57 (31-103) 2.5 656 (136-3159) 0.1 0.08
n (8) (8)
D 97 (56-168) 0.8 3 (1-6) 2.3 32
5.
P 220 (118-411) 0.6 13 (6-28) 5.9 16.9
n (6) (6)
D 27 (19-39) 2.9 0.9 (0.6-1.4) 7.7 30
6.
P 131 (84-205) 1.0 25 (1-41) 3 5.2
n (6) (6)
D 20 (14-29) 4.0 1 (1-2) 7 20
Peak and decay current are represented as P and D respectively. IC50 (95%
CI) are presented in nM and (n) = number of tested oocytes. Red values indicate
analogues potency relative to PhTX-343 on the same receptor combination. Blue
YDOXHVUHSUHVHQWDQDORJXHVHOHFWLYLW\IRUĮǃRYHUĮǃQ$&K5V
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Finally, the effect of cyclic groups on the pharmacological action of PhTX-
343 was studied. It has been shown previously that substitution of the tyrosine
structure with cyclohexylalanine generates the most potent and selective
analogue, 7, of PhTX-343 to have been tested on M-nAChRs expressed in TE671
cells with an IC50 value of 60 nM at -100 mV (Olsen et al., 2006). This analogue
shows roughly similar IC50IRUSHDNLQKLELWLRQRIĮǃDQGIROGORZHURQĮǃ
receptors, while in the case of decay current the value was in the range of 1 to 2
nM on both combinations (Figure 6.5). On the other hand, replacing the butyryl
group by cyclohexanoyl produced analogue, 8, one of the most potent and
selective inhibitors that has ever been investigated on N-nAChRs (Figure 6.6).
The calculated IC50YDOXHVRQWKHSHDNDQGGHFD\FXUUHQWRIĮǃUHFHSWRUVZHUH
2 nM and 400 pM respectively, which are 76-fold and 90-fold lower compared to
ĮǃUHFHSWRUV,QDGGLWLRQWRWKDWDQDORJXH9 which has cyclopentanoyl in the
position of the butyryl group shows roughly 2-fold increase on peak and
GHFUHDVHRQGHFD\FXUUHQWVHOHFWLYLW\IRUĮǃRYHUĮǃUHFHSWRUVFRPSDUHGWR
analogue 8. Adding cyclopropane with two different orientations, trans and cis,
in the polyamine moiety (region II) generated analogues 10 and 11. These two
analogues also show 30 to 40-fold selectivity for major ganglionic type nAChRs
over brain type when comparing decay current inhibition.
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Figure 6.4. Comparison of peak (Blue bars) and decay (Red bars) current
potency of PhTX-343 analogues with single region modifications incorporating
F\FORDONDQH JURXSV RQ Įǃ DQG Įǃ DW  P9 (DFK EDU UHSUHVHQWV WKH
analogues IC50 value (±95% CI) in nM.
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Figure 6.5. Sample traces (top) obtained by co-application of 7 with 100 µM
DQG0$&KDWP9IRURRF\WHVH[SUHVVLQJĮǃRUĮǃUHVSHFWLYHO\
and their corresponding concentration-inhibition curves (bottom) compared with
parental analogue 1. Analogue 7 KDVVWURQJDFWLYLW\RQĮǃDQGĮǃUHFHSWRU
but poor selectivity.
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Table 6.2. Comparison of PhTX-analouges IC50 values (nM) with single region
modification to cyclic alkanes on the major CNS and PNS hetromeric N-nAChRs
PhTX-analouges Įǃ Įǃ
1.
P 143 (94-218) 1 77 (58-102) 1 1.8
n (7) (9)
D 80 (48-132) 1 7 (6-9) 1 11.4
7.
P 51 (29-90) 2.8 31 (21-47) 2.4 1.6
n (5) (6)
D 1 (0.8-4) 80 2 (1-4) 3.5 0.5
8.
P 153 ( 98-238) 0.93 2 (1-2) 38 76.5
n (6) (9)
D 36 (28-41) 2.2 0.4 (0.3-0.6) 17.5 90
9.
P 704 (469-1057) 0.2 4 (2-7) 19.2 176
n (8) (6)
D 22 (17-29) 3.6 0.5 (0.4-0.7) 14 44
10.
P 320 (215-474) 0.4 26.5 (12.5-56.2) 2.9 12
n (6) (6)
D 47 (40-56) 1.7 1.44 (0.98-2.10) 4.8 32.6
11.
P 243 (154-382) 0.5 16.3 (6.1-43.4) 4.7 14.9
n (6) (8)
D 44 (36-54) 1.8 0.92 (0.68-1.23) 7.6 47.8
Peak and decay current are represented as P and D respectively. IC50 (95%
CI) are presented in nM and (n) = number of tested oocytes. Red values indicate
analogue potency relative to PhTX-343 on the same receptor combination. Blue
YDOXHVUHSUHVHQWDQDORJXHVHOHFWLYLW\IRUĮǃRYHUĮǃQ$&K5V
115
Analogue 1
Analogue 8
3 4
3 4
4 2
4 2
Figure 6.6. Sample traces (top) obtained by co-application of 8 with 100 µM
DQG0$&KDWP9IRURRF\WHVH[SUHVVLQJĮǃRUĮǃUHVSHFWLYHO\
and their corresponding concentration-inhibition curves (bottom) compared with
parental analogue 1. Analogue 8KDVVWURQJDFWLYLW\DQGVHOHFWLYLW\RQĮǃRYHU
ĮǃUHFHSWRU.
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6.1.2. Double region modification (DRM)
The second category include analogues with double region modifications
to try and further increase the activity and selectivity of PhTX-343 toward a
particular subtype of receptors. Firstly, the role of cyclic group substitution in
head regions (III and IV) was investigated. A range of synthetic analogues with
double region modification were developed based on the structure of the highly
potent compound with a single region modification, analogue 7. Region IV
substitution, tyrosine to cyclohexylalanine, was the same for all analogues 12-17
and the other cyclic group replacement was in region III (Figure 6.7 and Table
6.3). Substitution of the butyryl group by cyclopropanoyl produces analogue 12,
which showed 2.6 fold higher decay current activity compared to analogue 1 on
ĮǃDQGIROGVHOHFWLYLW\RYHUĮǃQ$&K5V7KLVVXEW\SHVHOHFWLYLW\UHGXFHG
to 20, 8.3, 15.5 and 27.7-fold when region III was replaced by cyclobutanoyl 13,
cyclopentanoyl 14, cyclohexanoyl 15 and norbornanylacetyl 17, respectively.
However, this selectivity was increased in analogue 16 which has
cyclooctylacetyl in the position of the butyryl group.
Then several analogues (18-21) were synthesised based on the single
region modification structure of the highly potent (7) and highly selective (5)
analogues. These four analogues have fixed cyclohexylalanyl at region IV and
variable aromatic groups in region III. Analogue 19 was the most potent and
selective analogue of PhTX-343 ever tested. This analogue has a naphthalene
group in place of the aliphatic chain. The peak and decay current IC50 values on
ĮǃQ$&K5VZHUHQ0DQGS0UHVSHFWLYHO\DQGWKH\ZHUHIROGDQG
IROG ORZHU FRPSDUHG WR Įǃ $SSUR[LPDWHO\ WKH VDPH SRWHQF\ DQG
selectivity was determined for analogue 18 with a single phenyl group in region
III. On the other hand, a cinamoyl group in region III, generating analogue 20,
had a 19-fold increase in peak IC50 value compared to analogue 19. Similarly,
analogue 21 which has a biphenyl group caused a 55-fold and 17.5-fold
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UHGXFWLRQLQSHDNDQGGHFD\FXUUHQWSRWHQF\RQĮǃQ$&K5V&RQVHTXHQWO\WKH
ODWWHUWZRDQDORJXHVORVWVHOHFWLYLW\IRUĮǃRYHUĮǃEHFDXVHDQDORJXHV18-
21VKRZHGURXJKO\WKHVDPHOHYHORIDFWLYLW\RQĮǃ
Figure 6.7. Comparison of peak (Blue bars) and decay (Red bars) current
SRWHQF\ RI 3K7; DQDORJXHV ZLWK GRXEOH UHJLRQ PRGLILFDWLRQV RQ Įǃ DQG
ĮǃDWP9(DFKEDUUHSUHVHQWVWKHDQDORJXH¶V,&50 values (±95% CI) in
nM.
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Table 6.3. Comparison of PhTX-analouge IC50 values (nM) with double region
modification on the major CNS and PNS hetromeric N-nAChRs
PhTX-analouges Įǃ Įǃ
1.
P 143 (94-218) 1 77 (58-102) 1 1.8
n (7) (9)
D 80 (48-132) 1 7 (6-9) 1 11.4
12.
P 106 (68-164) 1.3 31 (24-40) 2.4 3.4
n (8) (5)
D 112 (80-154) 0.7 2.6 (2.1-3.2) 2.6 43
13.
P 34 (17-66) 4.2 5 (3-8) 15.4 6.8
n (5) (7)
D 20 (9-47) 4 1 (0.7-1.4) 7 20
14.
P 23 (11-48) 6.2 14 (9-22) 5.5 1.6
n (5) (6)
D 5 (2-9) 16 0.6 (0.4-1.0) 11.6 8.3
15.
P 174 (92-330) 0.8 29 (18-48) 2.6 6
n (7) (6)
D 31 (20-48) 2.5 2 (1-3) 3.5 15.5
16.
P 112 (50-249) 1.2 4.5 (2.7-7.3) 17.1 24.8
n (7) (7)
D 28 (19-41) 2.8 0.5 (0.4-0.6) 14 56
17.
P 100 (53-190) 1.4 14 (10-21) 5.5 7.1
n (8) (6)
D 25 (16-39) 3.2 0.9 (0.6-1.3) 7.7 27.7
Peak and decay current are represented as P and D respectively. IC50 (95%
CI) are presented in nM and (n) is the number of tested oocytes. Red values are
indicating analogues potency relative to PhTX-343 on the same receptor
combination. Blue YDOXHV UHSUHVHQW DQDORJXH VHOHFWLYLW\ IRU Įǃ RYHU Įǃ
nAChRs.
119
1 18 19 20 21
1 18 19 20 21
Figure 6.4. Comparison of peak (Blue bars) and decay (Red bars) current
SRWHQF\ RI 3K7; DQDORJXHV ZLWK GRXEOH UHJLRQ PRGLILFDWLRQV RQ Įǃ DQG
ĮǃDWP9(DFKEDUUHSUHVHQWVWKHDQDORJXH¶V,&50 values (±95% CI) in
nM.
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Table 6.4. Comparison of PhTX-analouge IC50 values (nM) with double region
modifications on the major CNS and PNS hetromeric N-nAChRs
PhTX-analouges Įǃ Įǃ
1.
P 143 (94-218) 1 77 (58-102) 1 1.8
n (7) (9)
D 80 (48-132) 1 7 (6-9) 1 11.4
18.
P 163 (73-363) 0.8 1.6 (0.9-2.9) 48 101
n (6) (5)
D 21 (14-32) 3.8 0.3 (0.2-0.6) 23.3 70
19.
P 108 (64-180) 1.3 1.0 (0.6-1.5) 77 108
n (5) (7)
D 14 (10-19) 5.7 0.16 (0.11-0.22) 43.7 87.5
20.
P 104 (74-146) 1.3 19 (10-35) 4 5.4
n (5) (6)
D 12 (8-17) 6.6 0.34 (0.27-0.43) 20.5 35.2
21.
P 171 (105-277) 0.8 52 (20-134) 1.4 3.2
n (8) (4)
D 25 (17-38) 3.2 2.8 (1.5-5.3) 2.5 8.9
Peak and decay current are represented as P and D respectively. IC50 (95%
CI) are presented in nM and (n) = number of tested oocytes. Red values are
indicating analogues potency relative to PhTX-343 on the same receptor
combination. Blue YDOXHV UHSUHVHQW DQDORJXH VHOHFWLYLW\ IRU Įǃ RYHU Įǃ
nAChRs.
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Figure 6.5. Summary of the peak and decay IC50 values of the 21-PhTX
analogues investigated in this project. Comparison between the peak and
decay current IC50 YDOXHV RQ WKH VDPH FRPELQDWLRQ $ Įǃ DQG %
Įǃ &6KRZLQJVHOHFWLYLW\RI WKLVJURXSRIDQDORJXHVEHWZHHQĮǃ
DQGĮǃ
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6.3. Comparison of PhTX-343 potency with two LGIC antagonists
This experiment compared the difference in potency of PhTX-343 with
synthetic argiotoxin-636 (ArgTX-636), a natural product from Argiope lobata
spider (Poulsen et al., 2013) and ketamine (Yamakura et al., 2000b) on rat N-
Q$&K5V7RLQYHVWLJDWHWKHUROHRIDURPDWLFJURXSLQWKHVHOHFWLYLW\EHWZHHQǃ
DQG ǃFRQWDLQJ UHFHSWRUV +HUH ZH VKRZ $UJ7; DQG NHWDPLQH (Figure
6.6) LQKLELW ǃFRQWDLQLQJ Q$&K5V ZLWK KLJKHU SRWHQF\ WKDQ ǃFRQWDLQLQJ
based on decay current IC50 value (Figure 6.7. and Table 6.5).
The peak current IC50YDOXHFDOFXODWHGIRU$UJ7;RQĮǃDQGĮǃ
was 50 nM, roughly the same as peak current IC50YDOXHRI3K7;RQĮǃ
 Q0 EXW IROG ORZHU WKDQ Įǃ UHFHSWRUV 7KH GHFD\ FXUUHQW ,&50 value
ZDV  Q0 RQ Įǃ DQG IROG ORZHU RQ Įǃ DW 9H = -100 mV. This high
VHOHFWLYLW\RI$UJ7;IROGIRUǃRYHUǃVXEXQLWVFRPSDUHGWRIROG
for PhTX-343 suggests that ArgTX-636 could serve as a lead compound for
highly selective inhibitors of N-nAChRs which has been reported previously for
other ionotropic receptors such as NMDAR and AMPAR (Poulsen et al., 2014;
2013).
.HWDPLQH LQKLELWHG SHDN DQG GHFD\ FXUUHQWV RI Įǃ Q$&K5V ZLWK ,&50
values of 36.8 µM and 19.8 µM, respectively with roughly 10-fold lower values
RQĮǃUHFHSWRUV7KLVGDWDVKRZVWKDWWKHSRWHQF\RINHWDPLQHZDVORZHUE\
55 and 263-fold on the peak current and 271 and 240-fold on decay current of
ĮǃDQGĮǃQ$&K5VUHVSHFWLYHO\FRPSDUHGWR3K7;7KHLQKLELWLRQGDWD
obtained from ArgTX-636 and ketamine further support that channel blockers
FRQWDLQLQJ DURPDWLF JURXSV EORFN ǃFRQWDLQJ UHFHSWRUV PRUH HIIHFWLYHO\ WKDQ
ǃFRQWDLQLQJ
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Figure 6.6. Structures of PhTX-343, ArgTX-636 and Ketamine.
Table 6.5. Comparison of PhTX-343 IC50 values (µM) with two LGIC inhibitors
Įǃ Įǃ
PhTX-343
P 0.14 (0.09-0.21) 1 0.07 (0.05-0.10) 1 2
n (7) (9)
D 0.08 (0.08-0.13) 1 0.007 (0.006-0.009) 1 11.4
ArgTX-636 P 0.05 (0.002-0.12) 2.8 0.05 (0.01-0.27) 1.4 1
n (6) (4)
D 0.08 (0.03-0.18) 1 0.002 (0.001-0.003) 3.5 40
Ketamine
P 36.8 (18.5-73.4) 0.003 3.4 (1.5-7.8) 0.02 10.8
n (5) (5)
D 19.2 (10.1-36.5) 0.004 1.9 (0.63-5.9) 0.003 10.1
Peak and decay current are represented as P and D respectively. IC50 (95%
CI) are presented in µM and (n) = number of tested oocytes. Red values are
indicating analogues potency relative to PhTX-343 on the same receptor
combination. Blue YDOXHV UHSUHVHQW DQDORJXH VHOHFWLYLW\ IRU Įǃ RYHU Įǃ
nAChRs.
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Figure 6.7. Comparison of peak (Blue bars) and decay (Red bars) current
SRWHQF\RI3K7;ZLWKWZRRWKHULRQRWURSLFUHFHSWRULQKLELWRUVRQĮǃWRS
DQG Įǃ ERWWRP DW  P9 (DFK EDU UHSUHVHQWV WKH WR[LQ¶V ,&50 values
(±95% CI).
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CHAPTER SEVEN
GENERAL DISCUSSION
Summary
This chapter will summarise the main findings of the study and discuss
them in more detail. Firstly, we discuss why mammalian nAChRs are different in
their sensitivity to ACh and desensitisation rate. We propose a model based on
the size and chemical properties of different amino acids in the agonist binding
site loops E and F which might explain the difference in desensitisation rate
among mammalian nAChRs. Secondly, we discuss why the inhibition potency of
3K7;RQPDPPDOLDQQ$&K5VLVVWURQJO\GHSHQGHQWRQWKHǃVXEXQLWUDWKHU
WKDQWKHĮVXEXQLWDQGZK\WKHLUSRWHQF\RQǃFRQWDLQLQJUHFHSWRUV LVKLJKHU
FRPSDUHG WRǃǃDQGQRQǃFRQWDLQLQJ UHFHSWRUV ,QFRQWUDVW WKH LQKLELWLRQ
SRWHQF\ RI 3K7; LV PRVWO\ GHSHQGHQW RQ ERWK WKH Į DQG ǃVXEXQLWV :H
propose a hypothesis based on the distribution of charged residues at the
entrance, channel pore and exit of the channel. This hypothesis theoretically
explains the reason behind the higher potency of PhTX-343 on N-nAChRs over
M-nAChRs, but it does not explain the reason behind subunit-specificity among
N-nAChRs. Also, it explains the basis of voltage-independence of PhTX-12 on M-
nAChRs and slightly higher voltage-dependence on N-nAChRs. Finally, we
discuss in more detail, the structure-activity relationship of PhTX analogues and
the possible reasons behind the changes in activity and selectivity for the tested
DQDORJXHVRQWKHPDMRUEUDLQĮǃDQGJDQJOLRQLFĮǃ1Q$&K5V
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7.1. Characterization of the ACh response of the nAChRs expressed in
Xenopus oocytes
In common with previous reported studies in the literature on Xenopus
oocytes expressing various subtypes of nAChRs (Chavez-Noriega et al., 1997;
Luetje and Patrick, 1991) the whole-cell ACh response shows a fast peak current
(ms) after application of ACh followed by a decaying current under prolonged
exposure to the agonist with the rate depending on subunit combination. Results
from our studies are in agreement with previously reported data showing that
ACh at concentrations of 1 mM or higher can act as a channel blocker and reduce
the maximum response and affect the desensitization rate and hence net charge
movement (Luetje and Patrick, 1991; Maconochie and Knight, 1992). It appears
WKDWLQKLELWLRQRIǃFRQWDLQLQJUHFHSWRUVLVKLJKHUWKDQWKDWIRUǃǃDQGQRQ
ǃFRQWDLQLQJUHFHSWRUV5HFHSWRUEORFNLQJWKHRU\E\DKLJKDJRQLVWFRQFHQWUDWLRQ
is not distinctive to nAChRs but also found in other members of the LGIC family
(Jones and Westbrook, 1996).
Differences in the agonist selectivity and sensitivity profile have been
reported for rat nAChRs and their human homologues (Chavez-Noriega et al.,
1997). Francis et al (2000) reported an EC50 value of 53 µM for ACh peak current
RIKXPDQĮǃZLWKURXJKO\IROGORZHUYDOXHRQĮǃ1Q$&K5VDW9H = -50
mV. Other studies calculated an EC50YDOXHRI0IRUKXPDQĮǃDQG
IROG ORZHU YDOXH IRU Įǃ Q$&K5V DW 9H = -70 mV (Yamakura et al., 2000b).
Here, we reported EC50YDOXHVRI0DQG0IRUUDWĮǃDQGĮǃDW9H
= -80 mV. The peak current EC50 values obtained previously from oocytes
H[SUHVVLQJUDWĮǃQ$&K5VZDVǴDWP9DQGIROG ORZHUWKDQIRUUDW
ĮǃQ$&K5V<DPDNXUDDQG+DUULV2QWKHRWKHUKDQGWKHSHDNFXUUHQW
EC50YDOXHRIUDWĮǃZDVǴDQGĮǃZDVǴLQWKLVVWXG\URXJKO\
WKH VDPH $&K VHQVLWLYLW\ YDULDWLRQ KDV EHHQ UHSRUWHG EHWZHHQ ERWK Į
contanining nAChRs but with different potency (Yamakura et al., 2000b). EC50
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YDOXHVRIǴDQGǴKDYHEHHQUHSRUWHGIRUKXPDQĮ*LQLDWXOOLQHWDO
2005) and embryonic M-nAChRs respectively. These values are in a close
agreement with the EC50 YDOXHV FDOFXODWH LQ WKLV SURMHFWZKLFKDUHǴ IRU
KXPDQĮDQGǴIRUHPEU\RQLF0Q$&K5V
The rank order of decay current and net charge EC50 value based on the
ĮVXEXQLWZDVĮĮĮĮFRQWDLQLQJUHFHSWRUV:KLOHEDVHGRQWKHǃ
VXEXQLWWKHGHVHQVLWL]DWLRQUDWHRUGHUZHUHQRQǃFRQWDLQLQJ!ǃ!ǃDQGǃ
containing. We proposed a model based on the loops A-F that participate in the
ACh binding pocket. This model might explain the reason behind the difference
in the desensitization rate between nAChR combinations used in this study. We
identified from the sequence alignment the main amino acids participating in
loop A-C of the principle subunit based on the Torpedo marmorata ĮVXEXQLW
DQGORRS')IURPWKHFRPSOHPHQWDU\VXEXQLWEDVHGRQWKHįDQGǄVXEXQLWVRI
Torpedo californica.
The model is based on the size, number and properties of the key
residues that participate in the ACh binding pocket. It appears from our model
that the amino acids participating in loops A-C are identical in all principle
VXEXQLWVĮĮĮDQGĮXVHGLQWKLVVWXG\6LPLODUO\$&KELQGLQJUHVLGXHV
in loop D of the auxiliary subunits were identical, while the main differences were
observed in loops E and F. The presence of five small neutral asparagine
UHVLGXHV LQ ORRS ( RI WKH Į VXEXQLWPLJKW EH WKHPDLQ UHDVRQ EHKLQG LWV IDVW
desensitization rate. In addition, reducing the number of these small neutral
UHVLGXHV LQ KHWHURPHULF ǃFRQWDLQLQJ Q$&K5V WR WZR RU WKUHH QHXWUDO VHULQH
UHVLGXHVPLJKW H[SODLQ WKHLU VORZHUGHVHQVLWL]DWLRQ FRPSDUHG WRKRPRPHULFĮ
receptors. On the other hand, the lowest desensitization rate between N-nAChRs
ZDVREVHUYHGIRUǃFRQWDLQLQJQ$&K5VWKLVPLJKWEHGXHWRWKHSUHVHQFHRID
large and positively charged arginine in their loop E. We have shown that M-
nAChRs have the lowest desensitization rate between all types of nAChRs and
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this might be due to the complex interaction due to the presence of aromatic
W\URVLQH LQ ORRS ( RI WKH įVXEXQLW DQG QHXWUDO K\GURSKLOLF VHULQH LQ WKH Ǆ
subunit. The presence of loop F in M-nAChRs and their absence in N-nAChRs
might be the other reason that explains the low desensitization rate of M-
nAChRs.
Although there is no evidence in the literature to support the idea that
desensitization rates are governed by the ligand binding pocket residues, it has
EHHQVKRZQSUHYLRXVO\WKDWWKHGHVHQVLWL]DWLRQUDWHRIĮQ$&K5V LVGHFUHDVHG
by substitution of threonine in ring 5 of Table 7.1 by serine without modifying
any other functional properties of the receptor (Placzek et al., 2005). Therefore,
it will be worth investigating this model in the future and see if there is any
relationship between agonist binding site residues and desensitization rate.
Figure 7.1. Model illustrating the key amino acids that participate in the ACh
binding pocket based on the identified residues in the loops of the principle and
complementary subunits of Torpedo species.
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7.2. Screening PhTX-343 and PhTX-12 for nAChR subtype selectivity
The results presented in this investigation show that the mechanism of
inhibition and recovery of vertebrate nAChRs in response to PhTX-343 is strongly
LQIOXHQFHGE\ WKHLU VXEXQLW FRPELQDWLRQ7KHǃVXEXQLWZDVPRUH LQIOXHQWLDORQ
WKHLQKLELWLRQSRWHQF\RI3K7;WKDQWKHĮVXEXQLWV2QWKHRWKHUKDQGWKHLU
inhibition and recovery by PhTX-12 did not depend strongly on any particular
subunit-types. Previous work by Brier et al (2003) showed 22-fold higher activity
for PhTX-12 on embryonic muscle-type nicotinic acetylcholine receptors (M-
nAChR) naturally expressed in the TE671 cell line in comparison to PhTX-343. In
the present study, PhTX-12 also shows higher potency over PhTX-343 on M-
nAChRs expressed in Xenopus oocytes but does not show any considerable
VHOHFWLYLW\RYHU1Q$&K5V2QWKHRWKHUKDQG3K7;LQKLELWVKRPRPHULFĮ
nAChRs with lowest potency between all investigated N-nAChRs combinations.
+HWHURPHULFǃFRQWDLQLQJQ$&K5VZHUHPRUHVHQVLWLYH WR3K7;FRPSDUHG
WRǃFRQWDLQLQJ UHFHSWRUV 7KH LGHD RI ǃVXEXQLWVKDYLQJDKLJKHU VHQVLWLYLW\
WKDQ ǃVXEXQLWV KDV EHHQ LQYHVWLJDWHG SUHYLRXVO\ IRU RWKHU RSHQ FKDQQHO
blockers of nAChRs such as substance P (Stafford et al., 1998) and cocaine
(Francis et al., 2000). However, the contrary of this idea has been confirmed for
other compounds such as hexanol, pentobarbital and gaseous inhibitors such as
nitric oxide (Yamakura et al., 2000a; Yamakura and Harris, 2000).
PhTX-343 tail region (I and II) amino groups become fully protonated at
physiological pH (Stromgaard et al., 1999). Inhibition of ACh-induced current in
nAChRs expressed in Xenopus oocytes by PhTX-343 was time-, subunit- and
concentration-dependent. Results from our current inhibition experiments show
that inhibition of peak current by PhTX-343 is less effective than on decay
current and it was in agreement with Liu et al (1997). This variation in potency
indicates that to interact with their binding sites and inhibit nAChRs, PhTX-343
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requires time for channels to open as a consequence of signal transduction
between receptor activation and gate opening (Brier et al., 2003).
Evidence from this investigation shows that PhTX-343 at a concentration
of 1 nM potentiated the ACh response by ~ 6% of a few nAChR combinations
VXFK DV Į DQG Įǃ UHFHSWRUV 7KH UHVSRQVH SRWHQWLDWLRQ PLJKW EH YLD 3K7;
binding to the agonist site and might be via binding to an allosteric site which
has been suggested previously for NMDA receptors (Anis et al., 1990). This
finding of potentiation of the nAChR response by concentrations of 1 nM and less
is in agreement with Brackley et al (1990) who found it in Xenopus oocytes
expressing chicken N-nAChRs and Shao (1997) found it in the TE671 cell line
naturally expressing M-nAChRs. Stromgaard et al (2002) reported potentiation of
M-nAChRs in TE671 cells by PhTX-10. Furthermore, Shao et al (1998) observed
the same phenomenon with spermine.
2XU VWXGLHV VKRZ WKDW Q$&K5V FRQWDLQLQJ ǃVXEXQLWV KDG WKH KLJKHVW
affinity binding sites for PhTX-343 with the lowest IC50 values of all nAChRs
investigated. The decay IC50 value for Įǃ FXUUHQW LQKLELWLRQ E\ 3K7;
calculated in this work was 80 nM at VH = -60 mV and this was approximately
GRXEOH IRU Įǃ Q$&K5V 7KHVH YDOXHV ZHUH LQ WKH VDPH ,&50 value range
reported previously by a patch-clamp study of the PC12 cell line, 100 nM (Liu et
al., 1997). It has been shown that PC12 cells might express more than a single
SRSXODWLRQ RI 1Q$&K5V EXW Įǃ FRPELQDWLRQV are dominant (Rogers et al.,
 3K7; SRWHQF\ UHGXFHG IROG DQG IROG RQ Įǃ DQG Įǃ
UHFHSWRUV UHVSHFWLYHO\ FRPSDUHG WRĮǃQ$&K5V'XH WR WKHXQLTXH UHJLRQDO
GLVWULEXWLRQRIǃDQGǃVXEXQLWVLQWKH&16DQG316=ROLHWDODQGWKH
selectivity of PhTX-343, this compound could be considered as a candidate for
drug development.
It has been shown by molecular modelling and photolabile cross-linking
studies that PhTX-343 enters inside the channel of nAChR (Bixel et al., 2000;
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7LNKRQRYHWDO7KHUHIRUHWKLVYDULDWLRQLQVHQVLWLYLW\EHWZHHQǃDQGǃ
subunit containing nAChRs might be due to a single amino acid difference
EHWZHHQ WKH 0GRPDLQ RI ǃ(V253) DQG ǃ(F255), which is supposed to face the
channel pore (Imoto et al., 1986; Oiki et al., 1988) or variation in other parts of
the subunit such as the N-terminals (Stafford et al., 1998). Higher potency of
3K7; LQ ǃFRQWDLQLQJ Q$&K5V PLJKW EH GXH WR VWDELOL]DWLRQ RI WKHLU
SURWRQDWHG DPPRQLXP JURXS ZLWK ȺHOHFWURQV RI WKH DURPDWLF SKHQ\ODODQLQH
which have been proposed previously for substance P (Stafford et al., 1998) or
DQ DURPDWLF VWDFNLQJ LQWHUDFWLRQ ȺȺ HOHFWURQV LQWHUDFWLRQ RI WKH W\URVLQH
PRLHW\ ZLWK SKHQ\ODODQLQH ,QKLELWLRQ RI Įǃ SHDN S  DQG GHFD\
(p=0.3273) currents were not changed significantly by phenylalanine
VXEVWLWXWLRQLQǃVXEXQLWVE\YDOLQHDW9H = -60 mV. However, replacing valine
LQ WKHǃVXEXQLWE\SKHQ\ODODQLQHVLJQLILFDQWO\ UHGXFHGWKHGHFD\FXUUHQW ,&50
YDOXHRIĮǃWRWKHOHYHORIĮǃSDQGLWZDVVLJQLILFDQWO\IROGORZHU
RQ WKH SHDN FXUUHQW S  6LPLODUO\ H[SUHVVLQJ ǃ(F255V) ZLWK WKH Į
subunit did not produce any significant change in peak (p=0.082) and decay
(p=0.1210) IC50 value at VH = -100 mV compared to wild-type, whereas,
Įǃ(V253F) significantly increased peak (p=0.0114) and decay (p<0.001) current
SRWHQF\ FRPSDUHG WR Įǃ Q$&K5V 7KHUHIRUH WKLV VLQJOH DPLQR DFLG UHVLGXH
GLIIHUHQFHLQWKH0GRPDLQEHWZHHQǃVXEXQLW9DQGǃVXEXQLW)
LVFULWLFDOIRUWKH3K7;SRWHQF\RQǃEXWQRWIRUǃFRQWDLQLQJQ$&K5V7KLV
SRLQW PXWDWLRQ LQ WKH 0 GRPDLQ RI WKH ǃVXEXQLW KDV EHHQ VKRZQ WR FKDQJH
sensitivity, at least partially, of other nAChRs to blockers such as cocaine
(Francis et al., 2000), substance P (Stafford et al., 1998) and nitric oxide
(Yamakura et al., 2000a).
The highest PhTX-343 decay IC50 value calculated for N-nAChRs was 6.5
0IRUKRPRPHULFĮUHFHSWRUVDW9H = -60 mV; 81-WLPHVKLJKHUWKDQIRUĮǃ
As expected, M-nAChRs showed the lowest sensitivity to PhTX-343 compared to
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all N-nAChRs. This difference in the sensitivity of nAChRs to PhTX-343 might be
due to the difference in the distribution pattern of charged amino acid rings that
guard the entrance and exit of the channel pore, as shown in Table 7.1 (Dani
and Bertrand, 2007). We suggested a hypothesis based on the positions of
positive and negative amino acids in the channel entrance and exit and their
relationship with positive charges on PhTX-343. Theoretically, this hypothesis
explains the reason behind low potency of PhTX-343 on M-nAChRs compared to
KHWHURPHULF 1Q$&K5V EXW QRW KRPRPHULF ĮQ$&K5V ZKLFK KDV XQLTXH
SKDUPDFRORJLFDO SURSHUWLHV GXH WR WKH DEVHQFH RI D ǃVXEXQLW 3UDFWLFDOO\ LW
requires further investigation by site directed mutagenesis to confirm the role of
residues supposed to have a role in this hypothesis.
The hypothesis has several steps. Firstly, it is well known that nAChRs are
cation selective ion channels having negatively charged residues in the loop
between the M2 and M3 domains which surround the outer mouth parts of the
channel to attract positively charged ions to the channel pore entrance (Dani and
Bertrand, 2007; Galzi et al., 1992). In neuronal subunits negatively charged
DVSDUWDWHLQSUHVHQWLQWKHORRSEHWZHHQ0DQG0GRPDLQRIǃD292ǃD311 and
ĮD288ZKLOH LQPXVFOHVXEXQLWVDJOXWDPDWH LV IRXQG LQǃE300ǄE245DQGİE296.
The position and numbers of these negatively charged amino acids might be
responsible for the high sensitivity of N-nAChRs for PhTX-343 over M-nAChRs. It
KDVEHHQVKRZQWKDW LQMHFWLRQRIRRF\WHVZLWKDGLIIHUHQWQHXURQDOĮǃVXEXQLW
ratio can generate various populations of receptors that are pharmacologically
GLIIHUHQW7KHUHIRUHDQLQMHFWLRQUDWLRRIPLJKWJHQHUDWHDPL[WXUHRIĮǃ
RU Įǃ =ZDUW DQG 9LMYHUEHUJ  +HWHURPHULF 1Q$&K5V FRQVLVWLQJ RI
ǃ RU  VXEXQLWV ZLOO KDYH WKUHH QHJDWLYHO\ FKDUJHG DVSDUWDWH FRPSDUHG WR
WZRJOXWDPDWH LQǃDQGǄVXEXQLWVRI0Q$&K5V7KLVPLJKWFRQFOXGH WKDW0
nAChRs has lower probability than heteromeric N-nAChRs to attract a positively
charged molecule like PhTX-343. This hypothesis could be further tested by
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investigating the actions of PhTX-343 on the ACh-gated chloride channels. These
receptors might belong to the Cys-loop LGIC superfamily because they are
functionally identical to nAChRs but selective for chloride ions. They have been
identified so far only in invertebrates such as the snail Lymnaea (van Nierop et
al., 2005).
Table 7.1. Amino acid sequence of the M1-M2 loop, the M2-domain and the M2-
M3 loop from the subunits used in this study from three different species r (rat),
m (mouse) and h (human). Positively charged amino acids are coloured green,
negatively charged orange. Blue and red amino acids are the single difference
EHWZHHQ0GRPDLQVRIǃDQGǃVXEXQLWV7KHQXPEHUVUHIHUWRrings of
amino acids that line the pore from extracellular to intracellular (outer charged
glutamate, leucine, valine, equatorial leucine, serine, threonine, intermediate
glutamate and internal aspartate ring, respectively).
8 7 6 5 4 3 2 1
UĮ DCG-EKVTLCISVLLSLTVFLLVITETIPSTSLVIPLIG 299
UĮ ECG-EKVTLCISVLLSLTVFLLLITEIIPSTSLVIPLIG 309
Uǃ DCG-EKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVG 297
Uǃ DCG-EKMTLCISVLLALTFFLLLISKIVPPTSLDIPLIG 316
PĮ DSG-EKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIG 295
Pǃ DAG-EKMGLSIFALLTLTVFLLLLADKVPETSLAVPIII 309
Pį DCG-EKTSVAISVLLAQSVFLLLISKRLPATSMAIPLVG 313
PǄ KAGGQKCTVATNVLLAQTVFLFLVAKKVPETSQAVPLIS 254
Pİ KAGGQKCTVSINVLLAQTVFLFLIAQKIPETSLSVPLLG 305
KĮ DSG-EKMTLSISVLLSLTVFLLVIVELIPSTSSAVPLIG 320
KĮ DSG-EKISLGITVLLSLTVFMLLVAEIMPATSDSVPLIA 294
Kǃ DAG-EKMGLSIFALLTLTVFLLLLADKVPETSLSVPIII 309
Kį DSG-EKTSVAISVLLAQSVFLLLISKRLPATSMAIPLIG 310
KǄ KAGGQKCTVAINVLLAQTVFLFLVAKKVPETSQAVPLIS 306
Kİ QAGGQKCTVSINVLLAQTVFLFLIAQKIPETSLSVPLLG 305
KĮ NEG-EKICLCTSVLVSLTVFLLVIEEIIPSSSKVIPLIG 314
KĮ ASG-EKVSLGVTILLAMTVFQLMVAEIMPA-SENVPLIG 300
KĮ DSG-EKVSLGVTVLLALTVFQLLLAESMPP-AESVPLIG 229
KĮ DCG-EKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIG 329
KĮ DCG-EKVTLCISVLLSLTVFLLVITETIPSTSLVIPLIG 305
KĮ ECG-EKITLCISVLLSLTVFLLLITEIIPSTSLVIPLIG 309
KĮ DCG-EKVTLCISVLLSLTVFLLVITETIPSTSLVVPLVG 304
Kǃ DCG-EKMTLCISVLLALTVFLLLISKIVPPTSLDVPLVG 298
Kǃ DCG-EKMTLCISVLLALTFFLLLISKIVPPTSLDVPLIG 296
Kǃ DEG-EKLSLSTSVLVSLTVFLLVIEEIIPSSSKVIPLIG 297
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Secondly, the outer glutamate ring (1) is the first barrier that PhTX-343
faces to enter the channel from the extracellular side. The distribution ratio of
positive to negatively charged residues near to the pore entrance may drastically
affect the potency of PhTX-343. Heteromeric N-nAChRs will have two or
maximum three positively charged amino acids in the ring 1 area depending on
WKHQXPEHURIǃVXEXQLWVFRQWDLQLQJDO\VLQHZKLOHLQWKHFDVHRI0Q$&K5VILYH
SRVLWLYHO\FKDUJHGUHVLGXHVDUHSUHVHQWLQWKLVUHJLRQO\VLQHIURPǃO\VLQH
IURPǄDQGO\VLQHDUJLQLQHIURPįVXEXQLWVDQGQRQHLQĮUHFHSWRUV7KH
presence of this large number of positive charges at the external entrance of the
pore in M-nAChRs compared to N-nAChRs might be the main reason that reduce
the chance of fully protonated PhTX-343 polyamine tail to enter their channel
(Brier et al., 2003).
Finally, there are several other charged residues further down in the
channel pore which might affect the action of PhTX-343. For example ring 7,
ZKLFK LVDQHJDWLYHO\ FKDUJHGJOXWDPDWH LQDOO VXEXQLWVH[FHSWPXVFOHǄDQGİ
subunits, where it is a neutral glutamine. The latter two muscle subunits also
have a positively charged lysine residue in ring 8 which is conversely negatively
charged in all other subunits. In addition, the presence of conserved polar
residues (serine, threonine or asparigine) in rings 5 and 6 of all nAChRs used in
WKLV VWXG\ H[FHSW WKH PXVFOH ǃVXEXQLW ZKLFK FRQWDLQV SKHQ\ODODQLQH DQG
glycine respectively, might also be responsible for the low activity of PhTX-343
on M-nAChRs. This hypothesis might explain the low sensitivity of M-nAChRs to
PhTX-343 compared to N-nAChRs, but does not clarify the reason behind the
subunit-specific selectivity between N-nAChRs.
This hypothesis arises from an explanation of the differences in the
inward rectification phenomena and Ca2+ permeability among subtypes of
AMPARs. Previous studies (Hollmann et al., 1991; Hume et al., 1991; Mellor,
2010; Verdoorn et al., 1991) reported that the Q/R site from M2 which is located
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at the narrowest part of the AMPAR channel pore is critical for inward
rectification and Ca2+ permeability properties. These studies showed a strong
inward rectification for AMAPRs containing GluA1, 3 and 4 subunits due to
blocking by intracellular spermine permitted by the presence of only glutamine
residues at the Q/R site. However, AMPARs containing a GluA2 subunit lack
inward rectification due to the presence of positively charged arginine in the Q/R
site which prevents entrance of spermine from the cytoplasmic side of the
channel. In addition, the presence of GluA2 subunits in AMPARs drastically
reduces their Ca2+ permeability for the same reason.
In addition to that, a difference in the pharmacological properties of
GluA2-containing and lacking AMPARs has been reported particularly with regard
to inhibition by extracellular application of polyamine-containing compounds of
synthetic origin (Magazanik et al., 1997) or from wasps and spiders (Mellor and
Usherwood, 2004; Washburn and Dingledine, 1996). It has been reported earlier
that a few of these natural polyamine toxins act as antagonists on native non-
NMDARs of insect (Bruce et al., 1990; Kerry et al., 1988) and rats (Ashe et al.,
1989). It has been shown that Arg-TX-636 (Brackley et al., 1993) and joro
spider toxin (Blaschke et al., 1993) act as strong inhibitors of recombinant
GluR2-lacking AMPARs and act as a weak antagonists on AMPARs containg-
GluA2. These data further support our proposed hypothesis for the inhibition of
nAChRs by PhTXs.
This hypothesis might also explain other properties such as inward rectification
and high Ca2+ permeability in N-nAChRs compared to M-nAChRs (Figure 7.2)
(Arneric and Brioni, 1998; Francis and Papke, 1996; Vernino et al., 1994).
Previous investigations have demonstrated that the rectification of N-nAChRs
might be due to positively charged intracellular molecules such as spermine and
Mg2+ blocking the channel pore when there is a force pushing the outward
passage of cations (Haghighi and Cooper, 1998; Neuhaus and Cachelin, 1990).
These findings further support our hypothesis due to the fact that the presence
of negatively charged residues in rings 7 and 8 of all N-nAChR subunits will
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attract positively charged intracellular molecules and block outward cation
FXUUHQW :KHUHDV LQ WKH FDVH RI HPEU\RQLF 0Q$&K5V WKH ǄVXEXQLW KDV
positively charged lysine in ring 8 which acts as the main barrier preventing
molecules carying positive charge from blocking the pore and causing inward
rectification. Also a neutral glutamine residue from the same subunit in ring 7
instead of glutamate might have a similar effect. In addition to that, it is
LPSRUWDQW WR LQYHVWLJDWH ZKHWKHU PDPPDOLDQ KRPRPHULF Į RU KHWHURPHULF
ĮĮ1Q$&K5VZLOOJHQHUDWHLQZDUGUHFWLILFDWLRQRUQRWEHFDXVHLQWKHFDVHRI
WKHĮVXEXQLWULQJKDVDQHXWUDODODQLQHLQVWHDGRIDFKDUJHGUHVLGXHLQRWKHU
ĮVXEXQLWV7KLVPLJKWVXJJHVWWKDW1Q$&K5FRPELQDWLRQVFRQWDLQLQJĮZLOOQRW
cause inward rectification similar to M-nAChRs. It has been reported previously
that nAChRs in PC12 cells appear to be less affected by changes to external Mg2+
concentration than to internal changes (Neuhaus and Cachelin, 1990). This data
further support the critical role of ring 7 and 8 in inward rectification.
Figure 7.2. (see over) Illustrating the inward rectification and Ca2+
permeability properties of nAChRs and AMPAR in relation to charged residues
around the pore. Pink circles represent glutamine. Green and red circles are
representing positive and negative charged residue respectively. Yellow dotted
circles indicate ring position in the channel. A. highlights the rings 7 and 8, and
C. ring 1 of nAChRs in Table 7.1. B. shows the Q/R site in AMPAR. AMPAR idea
modified from Mellor(2010).
137
138
0RUHRYHULWKDVEHHQSURSRVHGWKDWKRPRPHULFĮQ$&K5VKDVDKLJKHVW
Ca2+ permeability contributing to about 10% of the whole inward current
compared to 5% for heteromeric and 2% for M-nAChRs (Vernino et al., 1992;
7KHSRVVLEOHUHDVRQEHKLQGWKHKLJKSHUPHDELOLW\RIĮWR&D2+ ions might
be due to the absence of positively charged amino acids in ring 1 near to the
external pore mouth. While in case of heteromeric N-nAChRs the presence of 2
to 3 positively charged amino acids in the same ring will reduce Ca2+
permeability and 5 positive residues in case of M-nAChRs will drastically diminish
Ca2+SHUPHDELOLW\,QFRUSRUDWLRQRIDQRUSKDQVXEXQLWLQWRWKHKHWHURPHULFĮǃ
N-nAChRs modifies its properties (Groot-Kormelink et al., 1998). For example,
LQVHUWLRQ RI WKH ĮVXEXQLW LQWR HLWKHU Įǃ RU Įǃ ZLOO LQFUHDVH &D2+
SHUPHDELOLW\ FRPSDUHG WR WKH FRPELQDWLRQV ODFNLQJ WKH ĮVXEXQLW 5DPLUH]
/DWRUUHHWDO/LNHO\WKLVZLOODOVRKDSSHQE\LQVHUWLRQRIWKHǃVXEXQLW
The presence of two negatively charged glutamic acid residues at the ring 1 area
might be the possible reason behind increasing Ca2+ permeability of N-nAChRs
by insertion of these orphan-subunits, although, it has been shown that
UHSODFLQJ QHJDWLYHO\ FKDUJHG JOXWDPLF DFLG LQ ULQJ  RI KRPRPHULF Į ZLOO
eliminate their permeability to Ca2+ without showing any effect on monovalent
Na+ and K+ ions (Bertrand et al., 1993).
The importance of multiple positive charges on the polyamine tail of
PhTX-343 for potency has been investigated previously on mammalian NMDAR,
AMPAR and M-nAChRs (Mellor et al., 2003). The data from that study showed
that fully protonated PhTX-343 has lower potency on M-nAChRs compared to
NMDAR and AMPAR. It also showed that removing the amino group near to the
head region (PhTX-83) generated a selective analogue for AMPAR, while
removing both secondary ammonium groups (PhTX-12) produced a selective M-
nAChR analogue. Tikhonov et al. (2004) proposed two binding modes for the
middle ammonium group in the polyamine tail of PhTX-343 interacting with polar
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rings inside the M-nAChR pore. The deeper binding mode shows interaction of
both secondary ammonium groups with the conserved serine residue in ring 5 of
DOOVXEXQLWVXVHGLQWKLVVWXG\H[FHSWQHXURQDOĮDQGPXVFOHǃDQGǄVXEXQLWV
which contain polar threonine, nonpolar phenylalanine and polar asparagine,
respectively. The other model suggests their binding with threonine and serine
UHVLGXHV LQULQJ$OOĮVXEXQLWVKDYHDSRODUVHULQHUHVLGXH LQWKLVULQJZKLOH
RWKHUDX[LOLDU\VXEXQLWVKDYHQRQSRODUDODQLQHH[FHSWPXVFOHǃZKLFKKDVSRODU
WKUHRQLQH7KHVHWZRPRGHVDUHLQDJUHHPHQWZLWKWKHHVWLPDWHGįYDOXHVRI
IRU Įǃ VXSSRUWLQJ WKH GHHSHU VLWH DQG  IRU Įǃ ZKLFK VXSSRUWV WKH
shallower binding site. This amino acid difference in rings 4 and 5 based on both
binding modes of PhTX-343 might further clarify the reason behind greater N-
nAChR inhibition compared to M-nAChRs.
It appears from our data that the presence of the secondary ammonium
groups in PhTX-343 polyamine moieties are important for subtype selectivity
among the investigated mammalian nAChRs expressed in Xenopus oocytes.
However, previous research shows that the presence of this positively charge
group hinders inhibition of M-nAChRs naturally expressed in TE671 cells (Brier,
2001). Other studies show their presence in the polyamine tail of natural PhTX-
433 is critical for their inhibition but the molecule will lose selectivity between
ionotropic glutamate and nAChRs (Stromgaard et al., 2000B). Mellor and his
collaborators (2003) reported 236-fold selectivity for PhTX-83 (secondary
ammonium group near to head region replaced by methylene), at AMPAR
expressed in oocytes over M-nAChRs in TE671 cells. Here we show that
substitution of both secondary ammonium groups by methylene to generate
PhTX-12 (with decay IC50 value of 0.07 µM gives 34-fold selectivity over PhTX-
343 on mouse M-nAChRs at VH = -100 mV. Previous study on human M-nAChRs
in TE671 cells recorded an 11-fold lower PhTX-12 potency and 22-fold selectivity
over PhTX-343 (Brier et al., 2003). It is likely the difference in PhTX-12 activity
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between the two studies is due to the recording technique and expression
system. We used TEVC and mouse M-nAChRs expressed in oocytes while the
other study used patch clamp of TE671 cell line naturally expressing human M-
nAChRs.
PhTX-12 showed mostly the same potency level on the nAChRs
investigated in this study without any noticeable subtype selectivity among them
H[FHSW Į DQG Įǃ UHFHSWRUV ZKLFK VKRZHG D ORZHU VHQVLWLYLW\ WR 3K7;
Their IC50 values were in the low micro-molar range (1-6 µM) for peak current
inhibition and in the sub-micro-molar range (0.10-0.35 µM) for decay current
DFURVVDOOZLOGW\SHDQGPXWDWHGQ$&K5VVWXGLHGH[FHSWĮDQGĮǃUHFHSWRUV
which were higher at VH = -80 mV. Our data on PhTX-12 are in agreement with
previous investigations that absences of secondary amino groups give a folded
structure to philanthotoxin as a result of chemical interaction between the
terminal amino group and the head region. Consequently, they suggest a binding
site at the outer part of the pore for PhTX-12 and enhancing desensitisation rate
%ULHU HW DO  7LNKRQRY HW DO 0XWDWLRQ RI ǃ(F255V)-subunit shows
increase in IC50 YDOXH RI 3K7; ZKLOH ǃ(V253F)-subunit did not, i.e. the
opposite of PhTX-343 activity. This might be due to the changes in
desensitization rate. The high amino acid similarity in the proposed region for
PhTX-12 binding (outer pore) might be the reason behind a lack of selectivity
among nAChRs at VH = -80 mV.
In the present work, the percentage of recovery from inhibition by PhTX-
343 and PhTX-12 was also time and subunit dependent. Most heteromeric N-
nAChRs showed only 30-70% recovery from inhibition by 10 µM PhTX-343 after
WRPLQXWHV7KHRQO\H[FHSWLRQZDVĮǃUHFHSWRUVZKLFKVKRZHG
recovery, possibly because the PhTX-343 molecule can pass to the inside of the
FHOOPRUHHDVLO\ LQ WKLVFRPELQDWLRQ ,QFRQWUDVW0Q$&K5VDQGKRPRPHULFĮ
receptors show roughly full recovery after 6 minutes; this might be due to a poor
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interaction between positive charges on PhTX-343 and negative residues of
channel compared to the strong interaction for other combinations, which require
long time for recovery. On the other hand recovery from inhibition by PhTX-12
ZDV RYHU  IRU ĮFRQWDLQLQJ Q$&K5V ZKLOH  IRU Į Į DQG Į
containing nAChRs. The peak current recovery of mouse M-nAChRs from PhTX-
343 inhibition was lower than from PhTX-12 inhibition at -80 mV and was in
accordance with previous data on M-nAChRs in TE671 cells (Brier et al., 2003).
From the present and previous studies, the exact mechanism of PhTX
analogue block of nAChR inward current is still not fully clarified. One likely mode
of action is that they act as open channel blockers of nAChRs. PhTX-343 induced
inhibition in heteromeric nAChRs was dependent on the membrane holding
potential and use dependent, which suggested an open channel blocker
PHFKDQLVPRIDFWLRQ+RZHYHUYROWDJHLQGHSHQGHQWLQKLELWLRQLQKRPRPHULFĮ
did not support the open channel blocker action. It is likely that any effects of
membrane voltage on the inhibition potency of PhTX-343 are related mainly with
ELQGLQJ VLWH RQ ǃVXEXQLWV EHFDXVH ODFN RI WKLV VXEXQLW LQ KRPRPHULF Į
receptors caused PhTX-343 inhibition to become independent on the membrane
holding potential. As shown in Figure 7.3 based on the peak current inhibition,
ǃFRQWDLQLQJQ$&K5VDUHPRUHDIIHFWHGE\DOWHUDWLRQRIWKHPHPEUDQHKROGLQJ
SRWHQWLDO WKDQ ǃFRQWDLQLQJ UHFHSWRUV 7KH LGHD RI VXEXQLWVSHFLILF DVVRFLDWLRQ
with holding potential has been reported earlier also for cocaine (Francis et al.,
2000). The voltage-dependent and independent inhibition of hetero- and homo-
meric nAChRs, respectively by PhTX-343 might be due the two distinct
PHFKDQLVPV RI DFWLRQ 7KHVH GDWD VXJJHVW WKDW 3K7; RQ Į ELQGV WR WKH
same site at the outer part of the channel proposed for PhTX-12 in muscle type
while in heteromeric receptors it interacts with a deeper site in the channel. It
has been proposed previously that PhTX-343 has the ability to inhibit open and
closed conformation of mouse M-nAChRs in BC3H1 cells (Jayaraman et al.,
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1999). This finding is not unique to PhTX-343 inhibition of nAChRs. Slater and
co-workers (2002) demonstrated that the mechanism of human M-nAChR
inhibition by the plant alkaloid tetrandrine is voltage-dependent while in N-
nAChRs it is voltage-independent. Another study shows rat M-nAChR inhibition
by strychnine is voltage-independent while it is voltage-dependent in N-nAChRs
(Garcia-Colunga and Miledi, 1999).
It is well documented that the positive charges carried by molecules
acting as open channel blockers, such as hexamethonium and local aesthetics,
are mainly responsible for their strong voltage-dependent inhibition (Arias,
1996; Sine and Taylor, 1982). This is in agreement with strong voltage-
dependent inhibition observed for wild-type and mutated heteromeric nAChRs by
PhTX-343 (Figure 7.3). Therefore, a PhTX-343 molecule carrying three positive
charges at -100 mV will have a better chance to enter the channel faster and
penetrate it to reach the narrowest part of channel and consequently will
strongly block the pathways of ion movement. This voltage-dependent property
of PhTX-343 is in agreement with the outcomes of Liu et al (1997), who reported
a strong voltage-dependent inhibition of N-nAChRs naturally expressed in the
PC12 cell line. In addition, Rozental et al (1989) also reported voltage-dependent
inhibition for frog end-plate current by PhTX-433.
However, PhTX-12 inhibits wild-type and mutated nAChRs in a voltage-
independent or weakly-dependent manner, probably due to the presence of only
a single positive charge on the tail region and fully folded conformation. These
properties probably will reduce their chance to entre or deeply penetrate the
membrane electric field. In M-nAChRs, voltage-independent block by PhTX-12
might be due to a shield of positive charge around ring 1 and prevent further
penetration by changing membrane to a more negative voltage, while a slightly
higher voltage-dependence observed in N-nAChRs might be due to less positive
charges present at the same ring of the channel. The M-nAChRs voltage
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dependence data is in accordance with the results of Brier et al (2003), who
demonstrated weakly voltage dependent inhibition of M-nAChRs by PhTX-12 in
TE671 cells. It has been proposed previously that increasing the hydrophobicity
of PhTX analogues would increase their affinity toward the voltage-independent
binding site in M-nAChRs of TE671 cells (Brier, 2001).
Figure 7.3. Shows peak and decay current inhibition difference between -60 mV
and -100 mV of nAChRs by PhTX-343 and PhTX-12. Difference is expressed as
IC50(-60 mV)/IC50(-100 mV).
Another possibility is that PhTX analogues might be competitive inhibitors
of nAChR inward current through their agonist binding site. It appears from the
data obtained that ACh concentration-response curves of all investigated nAChR
combinations in the presence of a single concentration of PhTX-343 or PhTX-12
did not show any significant change in ACh EC50 value. This non-competitive
mode of inhibition by philanthotoxin has been observed previously by Bixel et al
ZKR VKRZHG WKDWĮ%*7KDVQRHIIHFW RQ WKHELQGLQJDIILQLW\ RIN3-Ph-
PhTX-343-Lys to nAChRs of Torpedo californica while a slight improvement was
QRWLFHGZLWKFDUEDP\OFKROLQH$OVR WKH\VKRZHG  WKDWQHLWKHUĮ%*7QRU
carbamylcholine has any effect on the binding affinity of 125I-MR44, a related
polyamine-containing nAChR inhibitor.
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,WDSSHDUVIURPGHFD\FXUUHQWįYDOXHVREWDLQHGIRU3K7;DQG3K7;
12 (Figure 7.4) that both analogues have different binding sites in different
combinations based on desensitization rate. PhTX-343 showed a preference for
GHHSHUELQGLQJLQUHFHSWRUVKDYLQJORZHUGHVHQVLWL]DWLRQUDWHVOLNHǃFRQWDLQLQJ
and M-nAChRs, while a shallower site for those with higher desensitization rates
OLNH ǃFRQWDLQLQJ DQG KRPRPHULF Į Q$&K5V ,Q FRQWUDVW 3K7; VKRZHG D
preference for deeper sites in receptors having higher desensitization rates like
ǃFRQWDLQLQJDQGKRPRPHULFĮQ$&K5VDQG IRUVKDOORZVLWHV LQFRPELQDWLRQV
ZLWK ORZHU GHVHQVLWL]DWLRQ UDWH OLNH 0Q$&K5V DQG Įǃ ZKLOH LQ ZLOGW\SH
PXWDWLRQRIĮǃUHFHSWRUV3K7;VKRZHGDSUHIHUHQFH IRU WKHGHHSELQGLQJ
site.
Figure 7.4. Schematic representation of the nAChR pore divided into ten similar
VL]HGVHFWLRQV7KHQXPEHUVUHSUHVHQWWKHSHQHWUDWLRQGLVWDQFHįYDOXH
of PhTX-343 and PhTX-12 inside channel based on the decay IC50 values in
adapted Woodhull equation.
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We determined whether the predicted distance across the membrane
HOHFWULFILHOGįYDOXHIRU3K7;VKRZHGDQ\FRUUHODWLRQZLWKSRWHQF\DQGRU
UHFRYHU\%DVHGRQGHFD\FXUUHQWįYDOXHVZHFODVVLILHGWKH blocking of nAChRs
by PhTX-343 into three categories.
7KH ILUVW FDWHJRU\ZDVQ$&K5FRPELQDWLRQVZLWKDįYDOXHJUHDWHU WKDQ
0.5 and these show considerable but not complete recovery from 1 µM or 10 µM
3K7; ZLWKLQ  PLQXWHV 7KLV JURXS LQFOXGH ZLOGW\SH DQG PXWDWHG Įǃ
UHFHSWRUV ZKLFK KDYH į YDOXHV RI  DQG  UHVSHFWLYHO\ 3K7; VKRZHG
KLJKHVWSRWHQF\RQWKHVHFRPELQDWLRQVZLWKKLJKįYDOXHV
 7KHVHFRQGFDWHJRU\FRQVLVWHGRIQ$&K5FRPELQDWLRQVZLWKįYDOXHORZHU
than 0.5 and also comparably lower recovery from 10 µM PhTX-343 than those
LQWKHILUVWFDWHJRU\7KHVHZHUHĮǃĮǃDQGĮǃZLOGW\SHDQGPXWDQW
ZKLFKKDYHįYDOXHVRIDQGUHVSHFWLYHO\3K7;VKRZHG
intermediate potency on these combinations.
 7KH ILQDOFDWHJRU\FRQVLVWHGRIQ$&K5FRPELQDWLRQVZLWKįYDOXHV ORZHU
than 0.5 but can be differentiated from the second group by their high rate of
UHFRYHU\ VKRZLQJ FRPSOHWH UHFRYHU\ ZLWKLQ  PLQXWHV LQ WKH FDVH RI Į DQG
near complete recovery for M-nAChR. 7KLV JURXS LQFOXGHV Į DQG 0Q$&K5
ZKLFKKDYHįYDOXHVRIDQGUHVSHFWLYHO\3K7;VKRZHGWKHORZHVW
potency on these receptors.
7.4. Structure-Activity Study
The results from this and previous SAR studies confirm that four regions
of the philanthotoxin molecule are critical for their antagonism action (Anis et
al., 1990; Nakanishi et al., 1997). A significant finding from SAR of PhTX-343
analogues in the present work was that adding a bulky group to the terminal
ammonium group drastically reduced the potency, while to the head region it
significantly increased the potency. Also, it appears that the presence of a
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phenyl group at region III or IV is important for nAChR subtype selectivity while
cyclohexane is important for activity. Therefore, the analogues that have both
JURXSVLQWKHLUKHDGUHJLRQKDYHDKLJKHUDFWLYLW\DQGVWURQJVHOHFWLYLW\IRUĮǃ
RYHUĮǃQ$&K5V
Modifications in the terminal ammonium group (region I) of PhTX-343
and PhTX-433 have been shown to strongly affect their antagonist potency, for
example acetylation abolished activity (Benson et al., 1993) while extension
increased it (Nakanishi et al., 1997). This was supported by our data that
exchanging the terminal amine group of PhTX-343 for a guanidinium group
(analogue 3) caused an 8-fold and 38-fold loss of potency on peak and decay
FXUUHQWVRIĮǃQ$&K5V UHVSHFWLYHO\$UJ7;ZKLFKKDVHORQJDWLRQ LQ WKLV
UHJLRQ VKRZHG URXJKO\ D IROG LQFUHDVH LQ GHFD\ FXUUHQW LQKLELWLRQ RQ Įǃ
compared to PhTX-343. The reason behind this increase in potency by tail
extension in ArgTX-636 might be due to their ability to make stabilized H-bonds
with ring 6, threonine (Nakanishi et al., 1997).
Alterations in region II, the polyamine moiety, of analogue 1 have been
connected strongly with conformation and selectivity of PhTX-343 analogues
across cation selective ion channels (Figure 7.5). A straight conformation has
been proposed for the region II of analogue 1 due to the presence of three
protonated amine groups, while the absence of the two secondary amine groups
(analogue 2) causes a fully-folded conformation (Tikhonov et al., 2004).
Recently, Franzyk et al (2014) showed that incorporating a cis cyclopropane
structure to this region of analogue 1 will cause a semi-folded conformation and
this increased their activity on rat GluA1 flop subtype of AMPARs whereas the
trans isomer remains linear and shows higher activity than cis. Tested here on
N-nAChRs (analogues 10 and 11), ERWKDQDORJXHVKDGDKLJKVHOHFWLYLW\IRUǃ
RYHUǃFRQWDLQLQJUHFHSWRUVWKLVPLJKWEHGXHWRWKHSUREDELOLW\RIWKHWHUPLQDO
amino groups or inserted cyclopropane group interacting with the single amino
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DFLGGLIIHUHQFHEHWZHHQ0GRPDLQVRIWKHWZRǃVXEXQLWVDVDFRQVHTXHQFHRI
their semi-folded conformation. This idea might become a new approach for
developing selective compounds for nAChR subtypes due to the various semi-
folded conformations that the PhTX molecule can adopt and consequently their
interaction with different amino acids that participate in the channel pore.
Figure 7.5. Schematic illustration of different conformations that PhTX
analogues may adopt inside the channel pore based on molecular modeling data
from previous studies.
It has been proposed previously that substitution in the tyrosine moiety
(region IV) reduces the affinity of PhTX-343 molecules on NMDAR, while region
III, butyric acid, modification increases affinity (Anis et al., 1990). It appears
from the data reported here that modifications to either regions III or IV
generally increase the activity and selectivity of PhTX-343 compounds to the
PDMRU JDQJOLRQLF Įǃ UHFHSWRUV RYHU EUDLQ Įǃ 1Q$&K5 FRPELQDWLRQV )RU
example, previous research shows that elongation in region III enhances activity
on qGluR, while shortening the chain length drastically reduced the potency
(Bruce et al., 1990). Analogue 4 which has a ten carbon chain in region III,
here showed a slight increase in the peak current activity compared to PhTX-343
RQ Įǃ EXW LW ZDV IROG UHGXFHG RQ Įǃ Q$&K5V2Q WKH RWKHU KDQG WKH
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GHFD\DFWLYLW\LQFUHDVHGURXJKO\E\IROGRQĮǃFRPSDUHGWRDQDORJXH1 and
UHGXFHGVOLJKWO\RQĮǃ7KLVYDULDQFHLQSRWHQF\PLJKWEHGXHWRWKHGLIIHUHQFH
in the channel diameter of both combinations and time required to reach their
binding sites.
In addition, omission of the hydroxyl group in region IV (analogues 5
and 6) did not cause any considerable change on the peak current activity of
3K7; RQ Įǃ UHFHSWRUV ZKLOH WKH DFWLYLW\ LQFUHDVHG GUDVWLFDOO\ RQ Įǃ
receptors. This finding suggests that the presence of a benzyl group at region IV
might be critical for subtype selectivity among nAChR combinations. It also has
been shown in previous studies that analogues that have hydroxyl omission
show better activity on nAChRs than qGluRs (Nakanishi et al., 1994) and
NMDARs (Anis et al., 1990). In insect, hydroxyl omission in PhTX-433 slightly
reduced activity on neuromuscular synaptic transmission while considerably
increased it on neuronal somata of Locusta (Benson et al., 1993; 1992).
Studies focusing on the critical roles of introduced cyclic-groups in PhTX
analogues are restricted and limited to Olsen et al (2006) and more recently
Franzyk et al (2014) studies. Here we have further expanded our knowledge
about the profile of the different cyclic-groups in various regions of the PhTX
molecule by investigating their action on N-nAChRs. These analogues show a
UHPDUNDEOH VHOHFWLYLW\ WRZDUG Įǃ RYHU ĮǃQ$&K5VZLWK D IHZ H[FHSWLRQV
For instance, Olsen et al (2006) showed that the inhibitory potency of PhTX-343
was increased by 276-fold when the tyrosyl group was replaced by a
cyclohexylalanine (analogue 7). This analogue, with nano-molar IC50 value is the
most potent known antagonist of M-nAChRs, with some similar attributes to
PhTX-12, showing inhibition at +50 mV, as well as PhTX-343, showing strong
voltage dependence. This demonstrates the role of cyclohexylalanine in potency
and proposed their possibility to bind either to sites outside or deep inside the
channel pore. This modified PhTX-343 analogue shows roughly the same activity
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WR0Q$&K5VQ0DVZHIRXQGRQĮǃQ0ZLWKIROGORZHUDFWLYLW\RQ
WKH SHDN FXUUHQW RI Įǃ Q$&K5V 7KH ORVV RI VXEW\SH VHOHFWLYLW\ EHWZHHQ
nAChRs by analogue 7 and the inhibition pattern is in contrast to our proposed
hypothesis that charge distribution inside and near to the mouth of the channel
pore increases their likelihood to interact with the same extracellular binding site
as PhTX-12 at the entrance of the pore, rather than the deep PhTX-343 binding
site. Antagonists which bind at the PhTX-12 binding site do not show selectivity
because of the high amino-acid homology of all subunits in this area. The binding
site of PhTX-343 shows low homology between subunits and allows for selective
inhibition by different molecules.
The critical role of hydrophobicity in the head regions (III and IV) of
PhTX-343 on inhibitory potency has been investigated previously. Nakanishi et al
(1990) suggested that hydrophobicity is the major factor determining the
inhibition potency of PhTX-343, demonstrating a critical role for the bulky group
in region III. Other studies show that the potency of PhTX-343 is mainly
dependent on the size of the hydrophobic head group rather than
hydrophobicity; increasing the size of region III and IV leads to a marked
increase in potency of PhTX-343 (Benson et al., 1992; Bixel et al., 2000). By
incorporating a fixed cyclohexylalanine in region IV and increasing the size of
other cyclo-substitutes in region III, cyclopropane, cyclobutane and
F\FORSHQWDQH WKH SRWHQF\ RI 3K7; DV H[SHFWHG LQFUHDVHG RQ Įǃ DQG
Įǃ Q$&K5V )XUWKHU LQFUHDVLQJ WKH K\GURSKRELFLW\ DQG VL]H RI 3K7; E\
having cyclohexyl groups in both regions III and IV caused a slight reduction in
SRWHQF\RQĮǃDQGLQFUHDVHRQĮǃ7KLVYDULDWLRQLQSRWHQF\PLJKWEHGXHWR
DGLIIHUHQFHLQFKDQQHOGLDPHWHUEHWZHHQĮǃDQGĮǃDVZHVXJJHVWHGHDUOLHU
ZKHQPROHFXOHVKDYHDQHORQJDWHGFKDLQ LQ UHJLRQ,,, ,WPLJKWEHĮǃKDVD
QDUURZHUFKDQQHOFRPSDUHGWRĮǃEHFDXVHWKHDGGLWLRQRIDQHQRUPRXVKHDG
JURXS WR 3K7; UHGXFHV WKH SRWHQF\ RQ Įǃ SUREDEO\ YLD SUHYHQWLQJ WKH
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polyamine tail regions (I and II) penetrating the channel pore and interacting
with the deep binding site (Tikhonov et al., 2004). The head group size was
found to be a major factor in determining selectivity with several analogues of
the cyclohexylalanyl (region IV) compound showing considerable selectivity for
ĮǃRYHUĮǃZKLOHRWKHUVGLGQRW
Nakanishi and his co-workers (1994) proposed that adding a bulky group
with modest hydrophobicity to the head regions (III and IV) of the PhTX-343
seems to be critical for the potency. By incorporating substitutions we suggested
to be responsible for selectivity, phenyl group in region III, and activity,
cyclohexylalanine in region IV, analogue 18 or vice versa with adding hydroxyl
to phenolic group, analogue 8, this would moderate the head region
hydrophobicity. As expected, this drastically increased the potency (IC50 0.3 to 2
Q0DQGVHOHFWLYLW\WRIROGRQĮǃRYHUĮǃQ$&K5V0RGLILFDWLRQLQ
analogue 8 confirmed the outcome of previous studies which show an increase in
activity of PhTX-343 by 2.4-fold on locust muscle twitch contraction and 6.5-fold
on Torpedo compared to parental analogue 1 with roughly 82-fold selectivity on
NMDARs (Anis et al., 1990; Bruce et al., 1990; Nakanishi et al., 1994). Further
increasing the size of the bulky group in region III of analogue 18 by replacing
the phenyl group with naphthalene, lead to the most potent open channel
blocker (analogue 19) identified so far on nAChRs, with a considerable selectivity
IRU Įǃ RYHU Įǃ UHFHSWRUV %DVHG RQ WKH GDWD UHSRUWHG KHUH ZH FRQFOXGHG
that the presence of a cyclohexyl and a phenyl group at the head regions, III
and IV, of PhTX-343 give the molecule a most appropriate shape to fit inside
WKHLU ELQGLQJ VLWH LQ Įǃ Q$&K5V ZLWK XQSUHFHGHQWHG DFWLYLW\ DQG JUHDW
selectivity. Modifying analogue 18 by extending the chain carrying the phenyl
group in region III as in analogue 20 and 21 reduced the activity, but it was still
higher than analogue 1. This might be due to the same reason we mentioned
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for earlier analogues such as compound 4 where the polyamine tail did not reach
the deep binding site.
Ketamine is a synthetic anesthetic used widely in animal studies and
PHGLFDO SUDFWLFH 3UHYLRXV UHVHDUFK VKRZV WKDW NHWDPLQH LQKLELWV KXPDQ ǃ
FRQWDLQLQJ UHFHSWRUV ZLWK KLJKHU SRWHQF\ FRPSDUHG WR ǃFRQWDLQLQJ UHFHSWRUV
(Yamakura et al., 2000b). This was in agreement with what we found, with
VOLJKWO\KLJKHUDFWLYLW\RQUDWĮǃ,&50 0DQGĮǃ,&50 = 36.8 µM)
compared to human nAChRs. This finding further supports the previous notion
we proposed that the presence of a cyclohexyl and phenyl group in the structure
RI WKH PROHFXOH LQFUHDVHV WKHLU DIILQLW\ WRZDUG Įǃ RYHU Įǃ UHFHSWRUV ,Q
addition, the potency of ketamine was roughly 49-fold and 263-fold lower
FRPSDUHGWR3K7;RQĮǃDQGĮǃUHFHSWRUVUHVSHFWLYHO\7KLVPLJKWEH
due to the absence of the polyamine tail that is present in PhTX-343.
Figure 7.6. Schematic representation illustrates the channel diameter difference
EHWZHHQĮǃDQGĮǃQ$&K5V
152
Figure 7.7. The relationship between the head group size and length in PhTX-
DQDORJXHVZLWKWKHLUSRWHQF\RQĮǃDQGĮǃQ$&K5V7KHQXPEHUVRQ[
axis refer to the analogue number. In all analogues there was a fixed
cyclohexylalanyl group in region IV and the modification was in region III. (A)
Shows increasing size of cyclic alkane group in region III from cyclopropane (12)
to cyclohexane (15). (B) Shows increasing length and size of phenyl-containing
groups. The points in the graphs are mean IC50 values at VH= -100 mV.
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CONCLUSIONS
PhTX-343 inhibited nAChRs in a subunit-, time- and concentration-
GHSHQGHQWPDQQHUDQGZLWK WKHH[FHSWLRQRIKRPRPHULFĮUHFHSWRUVVKRZHG
quite strong voltage dependence. Overall, PhTX-343 demonstrated strongest
LQKLELWLRQDJDLQVWǃFRQWDLQLQJUHFHSWRUVDWPRUHQHJDWLYH9H after one minute
of application. This inhibition was non-competitive and proposed to be mainly
due to open channels block.
On the other hand the inhibition of nAChRs by PhTX-12 was less subunit-
and voltage-dependent as for PhTX-343 but like PhTX-343 it was time- and
FRQFHQWUDWLRQGHSHQGHQW,WDSSHDUVWKDWERWKĮDQGǃVXEXQLWVDUHFULWLFDOIRU
the potency of PhTX-12. In strong contrast to PhTX-343 it showed a slight
VHOHFWLYLW\ WRZDUG ĮǃįǄ ,QKLELWLRQ E\ 3K7; OLNH 3K7; ZDV QRQ
competitive and thought to involve block of the pore but possibly via a shallower
site than PhTX-343.
The structure-activity studies showed that adding a bulky group to the
terminal ammonium drastically increased the IC50 value while in the head region
it decreased the IC50 value. In addition, we identified the key head region
substitutions responsible for increasing PhTX activity (cyclohexylalanine) and
selectivity (phenyl group). Analogues having cyclohexylalanine and aromatic
groups in the head region showed IC50 values in the low nano-molar and pico-
molar (160-400 pM) range. These data suggest that PhTXs could serve as lead
compounds for highly potent and selective inhibitors of N-nAChRs.
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APPENDIX
Parts of this work have been published separately as abstracts in
conference proceedings and journals as detailed below:
*British Pharmacological Society annual meeting, London, 18th to 20th
December 2012.
7KHDFWLRQVRISKLODQWKRWR[LQRQUDWĮǃQHXURQDOQLFRWLQLF
acetylcholine receptors
It is useful to understand the pharmacological and functional properties of
the major hetero-oligomeric neuronal nicotinic acetylcholine receptor (N-nAChR),
ĮǃLQWKHPDPPDOLDQFHQWUDOQHUYRXVV\VWHP+HUHZHVWXGLHGWKHDFWLRQVRI
philanthotoxin-343 (PhTX-343), a synthetic analogue of philanthotoxin-433, the
active component of the Egyptian solitary digger wasp, Philanthus triangulum,
YHQRPRQUDWĮǃ1Q$&K5H[SUHVVHGLQ;HQRSXVRRF\WHV:KROHFHOOFXUUHQW
elicited by application of ACh was measured electrophysiologically by using two-
electrode voltage clamp at three different holding potentials (VH = -60 mV, -80
mV and -100 mV). PhTX-343 concentration-inhibition curves were constructed
and IC50 values estimated for each holding potential. The IC50 value for PhTX-343
LQKLELWLRQ RI SHDN Įǃ FXUUHQW DW P9ZDV  ǴDQG WKLV VLJQLILFDQWO\
LQFUHDVHGWRǴSDQGǴSDWP9DQG
mV, respectively. It is important to note that toxin potency was augmented by
holding the cell at more negative VH indicating its voltage-dependent manner of
action. This property supports the open channel blocker mechanism of N-nAChRs
by PhTX-343 that requires gate opening first and then inhibition of ion flow
through the nAChR channel. The IC50s were significantly lower than those
obtained previously for muscle type nAChR. We conclude that PhTX-343 works
DVDSRWHQWRSHQFKDQQHOEORFNHURIWKHĮǃPDPPDOLDQ1Q$&K5
167
* The RSC/SCI Symposium on Ion Channels as Therapeutic Targets,
Cambridge, 18th to 19thMarch 2013
*The First International Scientific Conference for Kurdistan Students,
Nottingham, 16th September, 2013
3RWHQW,QKLELWLRQRIĮǃDQGĮǃ1HXURQDO1LFRWLQLF$FHW\OFKROLQH
Receptors by Philanthotoxin-343
Philanthotoxin-343 (PhTX-343) is a synthetic analogue of philanthotoxin-
433, the active component of the Egyptian solitary digger wasp, Philanthus
triangulum, venom. Previous research has shown that this toxin is an open
channel blocker of muscle-type nicotinic acetylcholine receptors (M-nAChR) with
moderate potency. In this study, we investigate the pharmacological action of
PhTX-343 on the major mammalian hetero-oligomeric neuronal nicotinic
DFHW\OFKROLQH UHFHSWRUV 1Q$&K5 Įǃ DQG Įǃ H[SUHVVHG LQ ;HQRSXV
oocytes. Whole-cell currents in response to application of acetylcholine alone or
co-applied with PhTX-343 were studied electrophysiologically using two-electrode
voltage-clamp at three different membrane holding potentials (VH = -60 mV, -80
mV and -100 mV). PhTX-343 concentration-inhibition curves were constructed
and IC50 values estimated for each holding potential. The IC50 value for PhTX-
LQKLELWLRQRISHDNFXUUHQWDWP9ZDVQǴDQGQǴIRUĮǃDQG
Įǃ UHVSHFWLYHO\ 7KH WR[LQ SRWHQF\ ZDV DXJPHQWHG E\ KROGLQJ WKH FHOO DW
more negative VH indicating its voltage-dependent manner of action. It is
important to note that PhTX-343 activity is not influenced by increasing the ACh
concentration which indicates non-competitive antagonist action. These
properties support the open channel blocker mechanism of N-nAChRs by PhTX-
343 that requires gate opening first. The IC50s were significantly lower than
those obtained previously for muscle type nAChR. This variation in potency may
EHUHODWHGWRDPLQRDFLGV IURPWKHǃVXEXQLW OLQLQJWKH LRQFKDQQHO7KHUHIRUH
we conclude that PhTX-343 works as a potent open channel blocker of the major
heteromeric mammalian N-nAChR.
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*British Pharmacological Society annual meeting, London, 17th to 19th
December 2013
Inhibition of Neuronal Nicotinic Acetylcholine Receptors by
Philanthotoxins is Strongly Influenced by Subunit Composition
Philanthotoxin-343 (PhTX-343) and Philanthotoxin-12 (PhTX-12) are
synthetic analogues of philanthotoxin-433, the active component of the Egyptian
solitary digger wasp, Philanthus triangulum, venom. They have shown a different
inhibitory mode of action on embryonic muscle-type nicotinic acetylcholine
receptors (M-nAChR) naturally expressed in the TE671 cell line with moderate
potency. To try and confirm predictions of potential binding sites from this earlier
work, we investigated the pharmacological action of both analogues on different
mammalian hetero-oligomeric neuronal nicotinic acetylcholine receptor (N-
nAChR) subunit combinations expressed in Xenopus oocytes. Whole-cell currents
in response to application of acetylcholine alone or co-applied with PhTX-
analogue were studied electrophysiologically using two-electrode voltage-clamp
at three different membrane holding potentials (VH = -60 mV, -80 mV and -100
mV). Concentration-inhibition curves were constructed and IC50 values estimated
for each holding potential. The IC50YDOXHVIRU3K7;LQKLELWLRQRIĮǃĮǃ
DQGĮǃSHDNFXUUHQWVDWP9ZHUHǴQ ǴQ DQG
Ǵ Q  UHVSHFWLYHO\ IRU 3K7; WKH\ZHUHǴ Q Ǵ
Q DQGǴQ UHVSHFWLYHO\7KHSRWHQF\RI3K7;ZDVVWURQJO\
augmented by holding the cell at more negative VH while this was not the case
for PhTX-12 where weak voltage-dependence was observed. Inhibition by PhTX-
343 was not influenced by increasing the ACh concentration which indicates a
non-competitive antagonist action. These properties support the open channel
block mechanism of N-nAChRs by PhTX-343 that requires gate opening first. The
YDULDWLRQLQSRWHQF\LVPRVWOLNHO\GXHWRDVLQJOHDPLQRDFLGFKDQJHLQWKHǃ
subunit pore lining region. Therefore, we strengthen our conclusion that PhTX-
343 works as a potent open channel blocker of the mammalian heteromeric N-
nAChR and has binding site deep in the channel while the PhTX-12 site is near to
the outside of channel. These distinct binding sites in the nAChR pore could be
exploited to develop subtype selective therapeutics.
169
*American Biophysics Society 58th annual meeting, San Francisco,
California, 15th-19th February 2014
Subunit-Dependent Inhibition of Neuronal Nicotinic Acetylcholine
Receptors by Philanthotoxins
Philanthotoxin-433 (PhTX-433) is the active component of the Egyptian
solitary digger wasp, Philanthus triangulum, venom which non-selectively inhibits
several excitatory ion channels. To improve selectivity two synthetic analogues,
Philanthotoxin-343 (PhTX-343) and Philanthotoxin-12 (PhTX-12), were
developed. Previous work showed a 22-fold selectivity for PhTX-12 on embryonic
muscle-type nicotinic acetylcholine receptors (M-nAChR) naturally expressed in
the TE671 cell line in comparison to PhTX-343. In this study, we investigated the
pharmacological action of both analogues on different mammalian hetero-
oligomeric neuronal nicotinic acetylcholine receptor (N-nAChR) subunit
combinations expressed in Xenopus oocytes. Whole-cell currents in response to
application of acetylcholine alone or co-applied with PhTX-analogue were studied
electrophysiologically using two-electrode voltage-clamp at three different
membrane holding potentials (VH = -60 mV, -80 mV and -100 mV).
Concentration-inhibition curves were constructed and IC50 values estimated for
each holding potential. The IC50 YDOXHV IRU 3K7; LQKLELWLRQ RI Įǃ Įǃ
Įǃ DQG Įǃ SHDN FXUUHQWV DW  P9 ZHUH  Ǵ0 Q   Ǵ0
Q   Ǵ0 Q  DQG Ǵ0 Q  UHVSHFWLYHO\ IRU 3K7; WKH\
ZHUH  Ǵ0 Q   Ǵ0 Q   Ǵ0 Q  DQG  Ǵ0
(n=9) respectively; i.e. in contrast to M-nAChR, PhTX-343 was more potent than
PhTX-12 in all cases. The potency of PhTX-343 was strongly augmented by
holding the cell at more negative VH while this was not the case for PhTX-12
where weak voltage-dependence was observed. The variation in potency is most
OLNHO\GXHWRDVLQJOHDPLQRDFLGFKDQJHLQWKHǃVXEXQLWSRUHOLQLQJUHJLRQ
Therefore, we conclude that PhTX-343 works as a potent open channel blocker of
the mammalian heteromeric N-nAChR and has binding site deep in the channel
while the PhTX-12 site is near to the outside of channel.
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*Nicotinic Acetylcholine Receptors, 23-26 July 2014, Churchill College,
Cambridge, UK.
*American Society for Neuroscience annual meeting, Washington DC,
15th to 19th November 2014.
Inhibition of nicotinic acetylcholine receptors by philanthotoxins is
strongly influenced by subunit composition
Philanthotoxin-433 (PhTX-433) is active component of the Egyptian
solitary digger wasp, Philanthus triangulum, venom which non-selectively inhibits
several excitatory ion channels. To improve selectivity two synthetic analogues,
Philanthotoxin-343 (PhTX-343) and Philanthotoxin-12 (PhTX-12), were
developed. Previous work by Brier et al. (2003) showed a 22-fold better
selectivity for PhTX-12 on embryonic muscle-type nicotinic acetylcholine
receptors (M-nAChR) naturally expressed in the TE671 cell line in comparison to
PhTX-343. In this study, we investigated the pharmacological action of both
analogues on mammalian hetero- and homooligomeric neuronal nicotinic
acetylcholine receptor (N-nAChR) subunit combinations expressed in Xenopus
oocytes. Whole-cell currents in response to application of acetylcholine alone or
co-applied with PhTX-analogue were studied electrophysiologically using two-
electrode voltage-clamp at three different membrane holding potentials (VH = -
60 mV, -80 mV and -100 mV). Concentration-inhibition curves were constructed
and IC50 values estimated for each holding potential. The IC50 values for PhTX-
LQKLELWLRQRIĮǃĮǃĮǃĮǃDQGĮSHDNFXUUHQWVDWP9ZHUH
ǴQ ǴQ ǴQ ǴQ DQGǴQ
 UHVSHFWLYHO\IRU3K7;WKH\ZHUHǴQ ǴQ 
ǴQ ǴQ DQGǴQ UHVSHFWLYHO\LHLQFRQWUDVWWR0
nAChR, PhTX-343 was more potent than PhTX-12 in all cases. The variation in
SRWHQF\LVPRVWOLNHO\GXHWRDVLQJOHDPLQRDFLGFKDQJHLQWKHǃVXEXQLWSRUH
lining region. For inhibition of heteromeric N-nAChRs, the potency of PhTX-343
was strongly augmented by holding the cell at more negative VH while this was
not the case for PhTX-12 where only weak voltage-dependence was observed.
7KH LQKLELWLRQ RI KRPRPHULF Į UHFHSWRUV E\ ERWK WR[LQV ZDV YROWDJH
independent. Therefore, we conclude that PhTX-343 works as a potent open
channel blocker of the mammalian heteromeric N-nAChR and has binding site
deep in the channel while the PhTX-12 site is near to the outside of channel. In
FRQWUDVWLQKLELWLRQRIKRPRPHULFĮUHFHSWRUVPD\EHWKURXJKLQWHUDFWLRQDWDQ
alternative site outside the channel pore.
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3KDUPDFRORJLFDODFWLRQVRISKLODQWKRWR[LQDQDORJXHVRQĮǃDQGĮǃ
nicotinic acetylcholine receptors
Neuronal nicotinic acetylcholine receptors (nAChRs) are excitatory ion
channels, which have wide subtype diversity due to the many possible subunit
combinations, some heteromeric, others homomeric. Each subunit is composed
of a large N-terminal segment containing the ACh binding site and four
membrane-spanning segments named M1-M4. The pore lumen is lined mainly by
the second of these membrane segments, M2. nAChRs play a critical role in
many physiological and pathophysiological processes, thus, neuronal nAChRs
have become targets for drug discovery and research.
The venom of the Egyptian digger wasp contains a toxin, philanthotoxin-
433 (PhTX-433), that works as a strong non-competitive inhibitor of ionotropic
glutamate receptors and nAChRs in their target prey. PhTX-433 has a polyamine
tail and aromatic head group. The main obstacle facing the use of the natural
toxin (PhTX-433) as a candidate for drug development and understanding
pharmacological characteristics of ionotropic receptors is the lack of subtype
selectivity. The present study aims to investigate the activity and selectivity of
WZHQW\ RQH V\QWKHWLF DQDORJXHV RQ UDW QHXURQDO Įǃ DQG Įǃ Q$&K5V :H
showed that the presence of positive charge in the polyamine tail of PhTX
compounds is essential for nAChR subtype selectivity and their removal makes
the molecule lose its selectivity. Also, it appears that adding a bulky group to the
terminal ammonium drastically reduced the activity while in the head region it
increased their potency. In addition, we identified the key regions and
substitutions responsible for increasing PhTX activity, cyclohexylalanine, and
selectivity, phenolic group. Analogues having cyclohexylalanine and a phenolic
group in the head region showed IC50 values in the low nano-molar and pico-
molar (160-400 pM) range. These data suggest that PhTXs could serve as lead
compounds for highly potent and selective inhibitors of N-nAChRs.
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Ismailia, Egypt 15th to 16th December 2014
MODIFICATION OF THE POLYAMINE MOIETY OF PHILANTHOTOXIN
ALTERS INHIBITION OF INOTROPIC GLUTAMATE AND NICOTINIC
ACETYLCHOLINE RECEPTORS AND THEIR SUBTYPES
Philanthotoxin-433 (PhTX) derived from the venom of the solitary wasp
Philanthus triangulum, and its synthetic derivative PhTX-343, is a potent
inhibitor of ionotropic glutamate and nicotinic acetylcholine receptors (nAChR).
PhTX is formed of a modular butyryl-tyrosyl-thermospermine structure which
forms a head-tail type configuration. We performed a series of structural
modifications to the tail region of PhTX looking to increase potency at, and
selectivity between, the aforementioned ionotropic receptors and their subtypes.
These properties were assessed by two electrode voltage clamp assays of
;HQRSXV RRF\WHV H[SUHVVLQJ *OX$ IORS ĮDPLQRK\GUR[\PHWK\O
LVR[D]ROHSURSLRQLFDFLGUHFHSWRUV$03$5RUĮǃRUĮǃQ$&K5V$GGLWLRQRI
a cyclopropane moiety to the polyamine tail of PhTX-343 increased the potency
DWĮǃDQGĮǃQ$&K5VDQG$03$5VUHODWLYHWR3K7;$WQ$&K5VERWKFLV
and trans-cyclopropyl-PhTX-343 show half maximal inhibitory concentration
(IC50) values in the low nanomolar range, with 32.6- and 47.8-fold selectivity
IRU Įǃ RYHU Įǃ UHVSHFWLYHO\ 7KH VDPH FRPSRXQGV ZHUH OHVV SRWHQW DW
GluA1 flop AMPARs, than nAChRs, with IC50 values of 1.79 µM and 240 nM for
cis and trans-cyclopropyl-PhTX-343, respectively. These data suggest that PhTX
and its analogues are useful/interesting compounds that are not only selective
for nAChRs but also for sub-types within the nAChR population.
